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SUMMARY OF THESIS  
 
Introduction: Prostate cancer is a leading cause of cancer deathin men. Death is usually 
a consequence of castration resistant tumour progression. Some metalloproteinases are 
implicated in the process of cancer progression. ADAMTS proteinases (A Disintegrin 
And Metalloproteinase with ThromboSpondin motifs) are metalloproteinases that play 
diverse roles in tissues. Prostate cancer cells express ADAMTS-1 and -15 but the role 
played by these proteinases in prostate cancer progession is unknown. This study was 
designed to determine the role of ADAMTS-1 and 15 in prostate cancer progression. 
Materials & Methods: Prostate cancer and stromal cell tumour spheroids were grown in 
3-dimensional culture in ECM gel containing a quenched-fluorescent substrate. The 
tumour spheroids were observed for evidence of proteolytic activity. Prostate cancer 
cells were treated with DHT and TNF. Changes in expr ssion of ADAMTS-1 and -15 
were analysed. ADAMTS-1 and -15 expression was knoced-down in PC3 prostate 
cancer cells and the effect of knock-down on proliferation, migration and invasion was 
analysed. 
 Results: Tumour spheroids emitted fluorescence after approximately 24 hours in 
culture, indicating proteolytic activity. DHT and TNF down-regulated ADAMTS-15 
expression in LNCaP cells and stromal cells respectively. The validated anti-ADAMTS-
15 antibody detected 50kDa bands, suggesting a novel cleavage site within the 
disintegrin-like domain of ADAMTS-15. ADAMTS-1 and 15 knock-down had no 
effect on proliferation, migration or invasion of PC3 prostate cancer cells. 
Conclusions: Prostate cancer and stromal cells degrade components of the surrounding 
ECM. ADAMTS-15 but not ADAMTS-1 expression is androgen and TNF-regulated.  
ADAMTS-1 and 15 expression do not affect the proliferation, migration or invasive 
 7 
potential of PC3 cells in vitro. Cleavage of ADAMTS-15 in the disintegrin-like domain 
results in the release of a C-terminal fragment with potential anti-angiogenic properties. 
Down-regulation by DHT in prostate cancer cells suggests that ADAMTS-15 could be 
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“Mankind's three most implacable enemies are Heart Disease, Pneumonia, 
Cancer. And the most baffling of these is Cancer, which is rapidly 
overtaking the other two for the rank of World's Worst Disease. Mankind's 
war of defense on Cancer has only recently begun.” 
Time Magazine Editorial, January 12, 1931 
 
“History shows that the progress of the past 50 years has resulted mainly 
from the slow painstaking attack by pathologists and clinicians, on the 
problems as presented in the cancer patient, and experience indicates that 
future progress will be along the same tedious paths.”  
James Ewing, 1937 
 
“What it is that makes apparently normal tissue begin to grow abnormally 
and extend beyond its normal boundaries is, as yet, incompletely 
understood.”  
Anonymous, circa 1959 
 
“Between 1950 and 2000, science has lowered the death rate from heart 
attacks and strokes. We’re making great progress but not in cancer. We 
have a problem.” 



























CHAPTER 1:  
INTRODUCTION 
Prostate cancer is a disease of the prostate gland in which the epithelial cells lining the 
acini of the glandular tissue undergo malignant transformation. The reason for this 
transformation is not clearly understood. Prostate c ncer is the most common cancer in 
men in the western world, and third leading cause of cancer mortality in men, surpassed 
by lung and colorectal cancer (Jemal 2011). Approximately 30% of men diagnosed with 
prostate cancer will die of the disease (Aus 2005), usually as a result of metastases 
(Khafagy 2007). The importance of prostate cancer to public health warrants further 
study into the mechanisms of pathogenesis and disease progression. 
 
1.1 Epidemiology of Prostate Cancer 
Prostate cancer affects men worldwide. Data from 2004 shows an incidence of 
approximately 90 per 100,000 and a mortality of 26 per 100,000 for the UK (Collin 
2008). Comparative figures from the USA show an incidence of 160 per 100,000 and 
mortality of 19 per 100,000. Incidence and mortality varies in different populations 
around the globe, with the highest mortality reported in the West Indies, and the lowest 
in the Far East (Jemal 2011). Within the USA, African American men have the highest 
incidence of prostate cancer, and Asian men the least (Williams 2009). A similar pattern 
of variation in incidence between ethnic groups exists n the UK (Chinegwundoh 2006; 
Ben-Shlomo 2008). The incidence of prostate cancer increases with age. A study 
involving 8887 men with prostate cancer in an unscreened population found that the 
median age at diagnosis was 75 years (range 40-96) (Aus 2005). 12% were aged < 65 
years, 37% aged 65-74 years and 51% aged ≥ 75 years. In populations where serum 
PSA testing is  used for screening, prostate cancer is detected earlier, with an average 
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age of 63 years at the time of diagnosis (Hugosson 2004). Comparing data from the 
USA (screened population) with the UK (unscreened population), peak incidence was 
between ages of 55-64 for USA and age over 85 for UK (Collin 2008), though there is 
ongoing concern about over-diagnosis and overtreatmnt of prostate cancer in screened 
populations. Autopsy studies of men dying from other causes have shown the presence 
of latent prostate cancer as early as the third decade in men living in USA and Spain 
(Haas 2008). Regardless of geographical location, the prevalence of latent prostate 
cancer rises with age, with up to 80% of men older than 80 years having foci of cancer 
in the prostate at autopsy (Breslow 1977). 
 
1.2 Aetiology and Predisposing Factors 
A number of causes have been postulated and investigated including hereditary factors, 
diet and obesity. The relative risk of developing prostate cancer is two-fold if one 
brother is affected at age >70 or father <70, 2.5 if one brother is affected at age <70 
years, and three-fold if two relatives are affected at age >70 years (Bratt 2007). The risk 
is even higher for men with two or more affected relatives aged <70 (relative risk of 
four), and men with three or more affected relatives aged <70 (relative risk of five) 
(Bratt 2007). A number of susceptibility genes have be n identified and investigated in 
hereditary prostate cancer, including HPC1 on chromosome 1q24-25, PCaP on 
chromosome 1q42-43, HPCX on chromosome Xq27-28, CAPB on chromosome 1p36, 
HPC2/ELAC2 on chromosome 17p12, and HPC20 on chromos e 20q13 (Bratt 2002). 
In addition, a higher frequency of somatic mutations i  a number of genes have been 
identified in prostate cancer patients. The length of the CAG (Cytosine-Adenosine-
Guanine) repeat of the AR gene is inversely related to the risk of developing prostate 
cancer (Bott 2005). Other somatic mutations identified are losses in chromosome 
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regions 3p, 6q, 7q, 8p, 9p, 10q, 13q, 16q, 17q and 18q and gains in 7p, 7q, 8q and Xq 
(Bott 2005). A combined genome-wide linkage scan of 1,233 families with a high 
incidence of prostate cancer by Xu et al identified chromosomes 5q12, 8p21, 15q11, 
17q21 and 22q12 as regions harbouring putative susceptibility genes (Xu 2005). 
Genome-wide association studies by Eeles et al haverec ntly identified a number of 
single nucleotide polymorphisms (SNPs) associated with hereditary and early onset 
prostate cancer from 3,268 patients, and have proposed some candidate affected genes 
(in parenthesis). SNPs were identified on chromosome 3 (CHMP2B, POU1F1), 
chromosome 6 (SLC22A3, SLC22A2, LPAL2, LPA), chromosome 7 (LMTK2, 
BHLHB8), chromosome 10 (MSMB), chromosome 11, chromosome 19 (KLK2, KLK3) 
and the X chromosome (NUDT10, NUDT11, GSPT2, MAGED1/4B/4, CTD-
2267G17.3, XAGE2/1C/1D/5/3, SSX8/7/2/2B, SPANXN5, TMEM29B/29) (Eeles 
2008). Further analyses identified seven more SNPs at chromosomes 2p21 (THADA), 
2q31 (ITGA6), 4q22 (PDLIM5) 4q24 (TET2) 8p21 (NKX3.1) 11p15 (IGF2, IGF2AS, 
INS, TH), and 22q13 (TTLL1, BIK, MCAT, PACSIN2) (Eeles 2009). 
A diet high in animal fat and red meat has been associated with an increased risk of 
prostate cancer (Meyer 1999). High dietary calcium ntake has also been implicated as 
conferring increased risk (Giovannucci 2006). The anti-oxidant lycopene, contained in 
tomatoes has been shown to have a protective effect (Etminan 2004), as has cruciferous 
vegetables (Cohen 2000). The effect of sexual activity, previous vasectomy, alcohol 
consumption, exposure to ultraviolet radiation and occupation on risk of developing 
prostate cancer have been investigated, but no conclusive evidence supports a role for 
these (Kolonel 2004). Dietary selenium, previously thought to have a protective effect 
from prostate cancer (Clark 1998), has been shown in larger studies to have no effect on 
prostate cancer risk (Lippman 2009). The role of prostatic inflammation as an 
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aetiological factor is still under investigation (De Marzo 2007), but epidemiological 
studies have shown a decreased incidence of prostate cancer in long-term non-steroidal 
drug (NSAID) users (Garcia Rodriguez 2004; Jacobs 2005; Platz 2005).  
 
1.3 The Prostate Gland 
1.3.1 Anatomy 
The prostate gland is a walnut-sized exocrine gland that is part of the male uro-genital 
tract. In Caucasian men, the prostate measures approximately 20g in weight with a 
volume of 21 cc and increases in size with age (Berry 1984; Rhodes 1999). On average 
the gland is smaller in men of Eastern extraction (Ganpule 2004; Gupta 2005; Kehinde 
2005).  Some aspects of prostate anatomy and physiology are worth noting, as it helps 
in understanding the pathophysiology of prostate cancer and the various management 
strategies.  
The anatomy of the prostate has been recently review d by Brooks (Brooks 2007). 
Figure 1.1 shows the anatomic relationships of the prostate. The apex of the prostate lies 
inferiorly and the base lies superiorly. Superior to the prostate is the bladder and inferior 
is the urogenital diaphragm made up of fibres of the levator ani muscle and its fascia. 
The urethra passes from the bladder through the prostate gland before entering the penis 
to open externally. The prostate is bound laterally by the lateral venous plexus, 
neurovascular bundles, and the endopelvic fascia. Special effort is made to preserve the 
neuro-vascular bundles during a radical prostatectomy in order to maintain potency 
(Walsh 1983). Superior-posterior to the prostate on either side are the seminal vesicles 
and vas deferens. These merge to form the ejaculatory ducts that enter the prostate at the 
base, coursing through the substance of the prostate and opening into the distal prostatic 
urethra. The prostate is attached to the pubic bone ant riorly by the pubo-prostatic 
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ligaments. Blood supply to the prostate is from the inf rior vesical artery, which divides 
into urethral and capsular branches. Venous drainage occurs via the periprostatic plexus 
of veins into the hypogastric vein. Lymphatic vessel  from the prostate drain into the 
obturator and internal iliac lymph nodes on either side and into the para-aortic lymph 
nodes. These lymph nodes become enlarged when they become infiltrated with cancer 
cells (Long 1999). The prostate is innervated by the cavernous nerves which supplies 
sympathetic and parasympathetic innervation. Sympathetic nerve fibres supply the 
smooth muscle and stroma, while parasympathetic nerve fibres supply the acini. 
 
Figure 1.1: Anatomy of the male genito-urinary system. Front and side views show the 
anatomic relationship between the prostate gland an surrounding organs. (Image 
obtained from the National Cancer Institute website, www.cancer.gov, and used with 
the permission of the copyright holder). 
The prostate gland is bound externally by a fibrous capsule made up of collagen and 
smooth muscle. Extension of tumour beyond the capsule reduces the chance of 
complete tumour resection at prostatectomy (Ayala 1989). Continuous with the capsule 
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is the fibromuscular stroma. The stroma encircles and invests the glandular components 
of the prostate.  
The prostate gland can be divided into four zones. The transitional zone, which 
surrounds the prostatic urethra, the central zone, through which the ejaculatory ducts 
traverse, the peripheral zone, which is the largest zone and forms the posterior and 
lateral parts of the gland, and the anterior fibromuscular stroma (Figure 1.2) (McNeal 
1972; McNeal 1981). 
 
Figure 1.2: Zonal anatomy of the prostate gland as described by J.E. McNeal. 
Schematic representation of the zones of the prostate howing the anatomic relationship 
of the zones to the urethra (U), and seminal vesicl (S). The drawings were  modified 
and  used with permission from Wolters Kluwer Health Publishing. 
About 30% of the prostate is stromal tissue and 70% is glandular tissue (McNeal 1988). 
The prostatic glands have a tubulo-alvoelar structue lined with simple cuboidal or 
columnar epithelium. The glandular acini are surrounded by a thin layer of stromal 
smooth muscle and connective tissue. The prostatic secretions drain into the prostatic 





1.3.2 Prostate Cells 
At the microscopic level, prostate tissue is comprised of epithelial and stromal 
compartments, separated by the basement membrane (Figure 1.3). Each compartment 
contains distinct cell types, surrounded by ECM. 
 
Figure 1.3: Cells of the prostate gland. Schematic representation of the cellular 
environment of the prostate showing cells of the epith lial and stromal compartments. 
1.3.2.1 Epithelial Cells 
Prostate epithelial cells are of three types, secretory epithelial cells, basal cells and 
neuroendocrine cells. The secretory epithelial cells are the most abundant (Peehl 2005). 
These cells are tall columnar epithelial cells that are terminally differentiated. They 
originate from the basal cells and become differentiated, expressing cytokeratin 8 and 
18, unlike the basal cells which express cytokeratins 5 and 14 (Brawer 1985). They 
contain abundant granules of secretory vacuoles containi g PSA, acid phosphatase and 
aminopeptidases. The apical cell membrane at the lum n possesses microvilli and form 
the lining of the acinus. The secretory granules migrate to the apex of the cells where 
 32 
they are secreted into the lumen of the acini which drain into the prostatic ducts, ending 
up in the urethra. The cells are attached to the bas ment membrane and adjacent cells by 
integrin receptors. Secretory cells express AR and are normally androgen-dependent for 
growth and survival (Leav 1996). Androgen ablation leads to a 90% decrease in the 
number of these cells and the remaining cells are shrunken in size (Tetu 1991). 
The basal cells are small cells that rest on the basement membrane, wedged between 
adjacent columnar secretory cells. They proliferate nd replenish the epithelial cells 
(McNeal 1995; Kyprianou 1996). Basal cells express AR mRNA but little or no protein 
(Iwamura 1994; Leav 1996). Prostate stem cells have been reported to lie in the basal 
layer (Schalken 2003). Evidence for the existence of pr static stem cells is supported by 
the presence of cells highly expressing α2β1 integrins (Collins 2001) and telomerase 
(Soda 2000). Prostatic stem cells have the potential to differentiate into mature 
epithelial cells, and are thought to be the origin of malignant clones of cells that develop 
into cancerous lesions (Collins 2006). 
Neuroendocrine cells make up a small percentage of the epithelial component 
(Bonkhoff 1998). They release neuropeptides and cytokines that regulate the growth and 
differentiation of the surrounding epithelial cells in a paracrine fashion (Abrahamsson 
1999). 
1.3.2.2 Stromal Cells 
The stromal component of the prostate surrounds the glandular acini and composed of 
different cell types including smooth muscle cells, fibroblasts, endothelial cells, and 
inflammatory cells. Smooth muscle cells make up about 50% of the mass of the stroma 
(Bartsch 1979), and contract under sympathetic adrenergic stimulation during 
ejaculation to expel prostatic fluid from the acini and ducts into the urethra (Furuya 
1982). Fibroblasts produce numerous growth factors including fibroblast growth factor 
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(FGF), epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α) and -
beta (TGF-β) (Hellawell 2002). These growth factors act in a pracrine fashion to 
regulate growth and development of normal and neoplastic prostate epithelium (Steiner 
1993). Epithelial-stromal interactions are required for normal development of both the 
stromal and epithelial components of the prostate (Cunha 2004).  
1.3.3 Extracellular Matrix of the Prostate 
The ECM is the acellular, complex network of proteins, glycoproteins and 
proteoglycans that form the basement membrane on which epithelial cells lie and 
surrounds the cells in the stromal component. The known components of the ECM 
include collagens, chondroitin sulphate proteoglycans like aggrecan and versican, 
heparan sulphate proteoglycans, glycoproteins like elastin, laminin, fibronectin and 
thrombospondin (Kalluri 2003; Rowe 2009). The ECM components form a structural 
scaffold for the cells and confers tensile strength and compressive resistance to tissue 
(Heinegard 2009). In addition to structural functions, the ECM molecules also have 
several other functional roles. Some of these molecules possess peptide domains that 
regulate cell functions, and growth factors sequester d by ECM molecules are released 
during ECM proteolysis (Ruoslahti 1991; Schultz 2009).  
The ratio of these ECM components varies between different tissue types. In the human 
prostate, CSPGs of different sizes have been identified (Goulas 2000).  
Immunohistochemical staining of prostate tissue hasidentified CSPGs, type IV 
collagen, perlecan and laminin distributed evenly i the stromal component, however 
there was increased peri-acinar staining of CSPGs, suggesting that CSPGs could be 
playing a role in basement membrane structure and fu ction (Cardoso 2004). Syndecan-
1, a HSPG, is expressed by epithelial basal and secretory cells, and is associated with a 
higher risk of disease progression (Chen 2004; Shariat 2008). Versican and decorin are 
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secreted by human prostate fibroblasts (Sakko 2003). Versican has been identified as 
the major component of prostate ECM (Ricciardelli 1998; Ricciardelli 1999). Versican 
modulates the attachment of prostate cancer cells to ECM components, and promotes 
cell migration, possibly by binding to the RGD peptide in ECM molecules like 
fibronectin to which cellular integrins attach (Sakko 2003). Versican is also reported to 
protect cells from oxidative stress and apoptosis (Wu 2005). Versican expression in 
prostate fibroblasts is up-regulated by TGF-β (Sakko 2001). Interestingly, TGF-β down-
regulates the expression of the proteoglycanases ADAMTS-1 and -15 in prostate 
fibroblasts and up-regulates the expression and activity of the metalloproteinase 
inhibitor, TIMP-3 (Cross 2005), suggesting that versican accumulation may be 
dependent on depletion of ADAMTS-1 and -15 in the ECM.    
1.3.4 Prostatic Secretions 
Prostatic secretions make up approximately 0.5ml of the human ejaculate (Tauber 
1975). Just over 1000 distinct proteins have been dtected in 2-dimensional 
electrophoresis of prostatic fluid (Guevara 1985). The three main proteins contained in 
prostatic fluid are prostatic acid phosphatase (PAP), prostate specific antigen (PSA) and 
beta-microseminoprotein (β-MSP) (Lilja 1988). Human PAP is a non-specific 
phosphomonoesterase secreted as a dimer of molecular mass of 100kDa (Ostrowski 
1994). PSA (human kallikrein 3) is a serine proteinase that is secreted as a 34kDa 
glycoprotein that keeps liquefies semen post-ejaculation by cleaving seminogelins to 
facilitate sperm motility (Balk 2003). Beta-microseminoprotein is a 94kDa protein that 
binds human immunoglobulin-gamma and protects sperm fro  being destroyed in the 
female reproductive tract (Kamada 1998). Other proteins that have been isolated from 
the prostate include the spermadhesins AQN 2 and AWN, PSP I and PSP II (Manaskova 
2002). Citric acid, lactate dehydrogenase and zinc are also present in prostatic fluid 
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(Grayhack 1965). The pH of prostatic fluid ranges from 6.2 – 8, and is regulated by the 
concentration of citric acid (Kavanagh 1985). 
1.3.5 Androgen Regulation of the Prostate 
The prostate depends on androgens for normal developm nt and function (Sandberg 
1980; Nef 2000). Eunuchs, castrated at an early age do not have fully developed glands, 
and withdrawal of androgens leads to atrophy of the prostate (Wu 1991; Civantos 
1995). Androgens regulate the secretory function of pr state epithelial cells. Growth 
and proliferation is mediated by the prostatic stromal cells, which secrete growth factors 
in response to androgen stimulation (Steiner 1993; Hellawell 2002). The most abundant 
androgen in humans is testosterone, with the testes producing up to 95% of circulating 
androgen, with the remaining 5% from the adrenal (Tplin 2001). Androgen production 
and secretion is regulated by the hypothalamus and pituitary gland by a negative 
feedback system (Figure 1.4). The hypothalamus releas s lutenising hormone releasing 
hormone (LHRH), which stimulates the anterior pituitary gland to release luteinizing 
hormone (LH). LH stimulates the Leydig cells of the testes to secrete testosterone. The 
hypothalamus also secretes corticotrophin releasing hormone (CRH), which stimulates 
the anterior pituitary to release adenocorticotropic hormone (ACTH). ACTH stimulates 
the release of androstenedione and dihydroepiandrosterone from the adrenal cortex 
(Cunha 2004). Testosterone from the circulation is converted in the prostate by 5-α-
reductase to DHT, the androgen which is most active in prostate tissue (Steers 2001; 
Zhu 2003). Serum level of DHT in men diminishes following prostatectomy (Miller 
1998; Olsson 2010), suggesting that prostate tissue is the major contributor of DHT to 
serum. Serum levels of FSH and LH are increased following prostatectomy, indicating 




Figure 1.4: Production and regulation of androgens. The hypothalamus produces 
LHRH which stimulates the anterior pituitary gland to secrete LH. LH stimulates the 
testes to produce testosterone. The hypothalamus also produces CRH which stimulates 
the anterior pituitary gland to produce ACTH. ACTH stimulation causes the adrenal 
glands to secrete androstenedione and dihydroepiandrosterone. The system is regulated 
by negative feedback loops to maintain homeostasis.  
 
1.4 Pathology of Prostate Cancer 
1.4.1 Pathogenesis of Prostate Cancer 
Prostate cancer develops from the epithelial component of the gland. It is not certain 
what the initiating events may be, but the transformation to malignancy is likely to be 
multifactorial, involving several steps. Prostatic intraepithelial neoplasia (PIN) is 
proposed to be the precursor lesion of prostate cancer (Graham 1992). As with prostate 
cancer, the incidence of PIN increases with age (Sakr 1993). The frequency of PIN is 
higher in prostates with cancer, and the peripheral zone, where most cancers occur 



















markers of secretory differentiation, hyperplasia, increase in nuclear size, prominent 
nucleoli, hyperchromatism, changes in ploidy, and progressive disruption of the basal 
cell layer with an intact basement membrane (Bostwick 1987; Montironi 1990; Amin 
1993; Crissman 1993). There is a progression from low grade to high grade PIN, then to 
carcinoma in-situ (Bostwick 1987; Montironi 1990). The malignant cells in CIS foci 
degrade the basement membrane and invade the stroma, f r ing a localised tumour. 
Cancer cells from localised tumours invade surrounding tissues and eventually 
metastasize via vascular and lymphatic channels (Ware 1987; Arya 2006). 
 
 
Figure 1.5: Progression of prostate cancer. Proposed quence of changes from normal 
epithelium and ending with metastatic cancer cells at distant sites. 
 
1.4.2 Grading of Prostate Cancer 
The Gleason grading system was described by Gleason in 1966 (Gleason 1966), and is 
accepted as the standard for describing the degree of differentiation of prostate 
adenocarcinoma (Murphy 1994). The system classifies th  histopathologic features 
from 1 to 5, with 1 being well differentiated and 5 poorly differentiated (Bailar 1966) 
(Bailar 1966) (Figure 1.6). The Gleason score is a derivation of the Gleason grade and is 
a sum of the two most predominant grades. Thus, the Gleason score could range from 2 
to 10. Grades 2 to 5 are classified as low grade, 6 to 7 medium grade and 8 to 10 high 
grade prostate cancer (Epstein 1996). The Gleason sc re remains the best prognostic 
indicator in clinical use (Albertsen 1998; Buhmeida 2006). 
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CIS   Localised 
  Tumour 
     Metastasis  
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Figure 1.6: The Gleason grading system. On the left is the schematic template devised 
by D.F. Gleason showing changes in glandular morphology and tissue architecture 
from well differentiated Grade 1 progressing through to poorly differentiated Grade 5. 
On the right is a Haematoxylin/Eosin stained histological slide at x 300 magnification. 
The top half of the slide is moderately differentiated grade 3 and the bottom half is 
poorly differentiated grade 4. (Image on left was adapted from the original drawing by 
D.F. Gleason and used with permission from Blackwell Publishing Inc. Image on right 
was used courtesy of Otis Brawley and obtained from the National Cancer Institute 
website, www.cancer.gov).  
 
1.4.3 Staging of Prostate Cancer 
Prostate cancer is staged according to the universal TNM (Tumour, Node, Metastases) 
staging system of the International Union Against Cancer (Sobin 1988; Schroder 1992). 
This system takes into account the extent of local spread of the tumour (T) the presence 
of lymph node infiltration (N) and the presence of metastases to distant organs (M) 
(Table 1.1). Localised tumours are confined within t e capsule of the gland (Figure 1.7). 




the pubic bone anteriorly, the bladder superiorly, the seminal vesicles supero-
posteriorly, or the rectum posteriorly. Local growth can also obstruct the distal ureters 
or cause compression of the urethra as it passes throug  the prostate causing bladder 
outflow obstruction (Mazur 1991; Paul 1994). Lymph node infiltration usually occurs in 
stepwise fashion, first involving the iliac lymph node chain, progressing to the para-
aortic nodes and mediastinal nodes, and in advanced disease, inguinal, axillary and 
cervical nodes could be involved (Long 1999). Prostate cancer has a predilection to 
metastasize to bone (Figure 1.9). Bone is the most c mmon site of metastasis and 
occurs in up to 95% of prostate cancer patients (Bubendorf 2000). Bone metastases 
cause severe morbidity in prostate cancer patients due to pain, pathological fractures 
and spinal cord compression (Osborn 1995; Khafagy 2007).  
 
Tx Primary tumour can not be assessed 
T0 No evidence of primary tumour 
T1 Tumour clinically inapparent, not palpable, not visible by imaging 
T2 Tumour confined to prostate, palpable or visible on imaging 
T3 Locally advanced tumour 
Tumour 
T4 Tumour fixed or invades adjacent structures i.e. bladder, rectum or pelvic wall 
Nx Regional lymph nodes can not be assessed 
N0 No regional lymph node metastases 
Nodes 
N1 Regional lymph node metastases 
Mx Presence of distant metastases can not be assessed 
M0 No distant metastases 
Metastasis  
M1 Distant metastases present in non-regional lymph nodes, bones or other sites 
 





Figure 1.7: Magnetic resonance imaging (MRI) of the p lvis of a prostate cancer 
patient. Image shows a localised tumour the prostate gland (Jones, H.E.). MRI can be 
used to detect extra-capsular extension of tumour or pelvic lymph node invasion. 
 
Figure 1.8:  Local progression of prostate cancer. The tumour can progress from a T1 
tumour in A to a T2 tumour in B, invasion of the seminal vesicles (T3) in C, and 
eventually invasion of the rectum, pubic bone, and pelvic lymph nodes (T4, N1) in D. 
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(Image obtained from the National Cancer Institute w bsite, www.cancer.gov, adapted 
and used with the permission of the copyright holder). 
 
 
Figure 1.9: Radio-nuclide bone scintigraph of a prostate cancer patient. The disease 
has progressed, showing evidence of multiple bone metastases. There are multiple ‘hot 
spots’ in the skull, right humeral head, ribs, vertebrae, pelvis, right femoral head and 
left femoral mid-shaft. 
 
1.4.4 Role of the Androgen Receptor in Prostate Cancer 
Androgen-regulated gene expression is mediated via the action of nuclear receptors 
(Lee, D.K. 2003). The AR is classified as an N3C4 nuclear receptor (Robinson-Rechavi 
2003; Robinson-Rechavi 2003). The AR gene is located on the long arm of the X 
chromosome at Xq11-12 (Lubahn 1988). The protein has approximately 900 a.a. 
residues (Trapman 1997), and has a relative mass of 99-110kDa depending on the 
degree of phosphorylation (Trapman 1988). There are four domains, the amino-terminal 
domain (NTD), which interacts with co-regulator proteins, the DNA binding domain 
(DBD), which binds to DNA after activation, a hinge r gion (HR), and the ligand 
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binding domain (LBD), which binds to androgens and AR antagonists (Jenster 1992). 
The NTD has a polymorphic CAG repeat segment, the length of which is thought to 
inversely correlate with the risk of prostate cancer (Bott 2005). The AR could have up 
to 930 a.a. residues depending on the length of the CAG repeat segment (Trapman 
1997).  
Activation of the AR causes a conformational change i  the receptor, dissociation from 
heat shock proteins (HSPs) and translocation of the rec ptor from the cytoplasm to the 
nucleus (Lee, D.K. 2003). The activated AR binds to AREs located in proximity to 
androgen-regulated genes (Brinkmann 1999; Claessens 2004) and influences gene 
transcription either by up-regulation or down-regulation of the target gene. AREs are 
15-base pair (bp) DNA sequences comprising two six-bp half sites separated by a three-
bp spacer. The sequence 5’-GGA/TACAnnnTGTTCT-3’ has been described as the 
consensus ARE (Roche 1992). 
In addition to growth stimulation via the action ofgrowth factors (Steiner 1993), 
androgens protect prostate cancer cells from apoptosis (Coffey 2002), induce invasion 
by prostate cancer cells (Chuan 2006), and also favur angiogenesis within the prostate 
stroma (Stewart 2001; Colombel 2005). Androgen deprivation therapy (ADT) in the 
form of surgical or medical castration is used in the management of locally advanced, 
metastatic, or relapsing disease (Soloway 1991). Androgen deprivation leads to 
reduction in the size of prostate tumours, and the siz  and number of metastatic deposits 
(Huggins 1942). ADT reduces serum androgen concentrations to undetectable levels 
(Seidenfeld 2000; Anderson 2008), and slows the progression of prostate cancer. High 
expression levels of AR in cancerous prostates is associated with more aggressive 
disease (Li 2004). Mutations of the AR are seen in as many as 50% of advanced 
prostate cancers (Taplin 1995; Marcelli 2000).  
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Translocation of the androgen-regulated TMPRSS2 (Transmembrane protease serine 2 
or epitheliasin) promoter to ETS (E twenty-six) transcription factor genes, more 
commonly ERG (ETS related gene), has been identified in up to 79 % of prostate cancer 
specimens (Tomlins 2005) and has been associated with aggressive disease (Wang 
2006). The TMPRSS/ERG fusion leads to androgen regulated over-expression of the 
ETS oncoproteins, favouring tumour initiation and progression (Narod 2008; Tomlins 
2009). 
Androgens have been reported to down-regulate the expression of E-cadherin and up-
regulate N-cadherin in prostate cancer cells (Zhu 2010), changes which are 
characteristic of epithelial-mesenchymal transition (EMT).  EMT is a process by which 
differentiated epithelial cells de-differentiate and assume a mesenchymal phenotype. 
Markers of epithelial cells for example E-cadherin a d β-catenin are lost, and 
mesenchymal cell markers for example N-cadherin and vimentin are expressed (Thiery 
2003). This change is similar to a process seen during embryonic development which 
allows endodermal cells to migrate during organ formation. EMT is is frequently found 
in cells at the invasive front of solid tumours and i  metastatic deposits and has 
therefore been implicated in increased cancer cell motility, tumour progression and 
metatstasis (Yilmaz 2010). The expression level of the androgen receptor in prostate 
cancer cells appears to be critical in androgen-induce  EMT. Paradoxically, cells 
expressing low levels of AR were more susceptible to EMT than cells expressing high 
levels of AR (Zhu 2010).   
AR signalling is evident in hormone-resistant prostate cancer (HRPC), despite castrate 
levels of serum testosterone (Mohler 2004), and AR signalling in HRPC promotes 
cancer cell proliferation (Zegarra-Moro 2002). These findings implicate the AR in the 
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pathogenesis and progression of prostate cancer. Th exact mechanism of AR signalling 
in HRPC progression is not fully understood (Schrode  2008; Yuan 2009). 
 
1.5 Management of Prostate Cancer 
Management options for prostate cancer are guided by the stage and grade of the 
disease. In clinical practice, the extent of disease could be categorised at the time of 
diagnosis as localised (T1-T2, N0, M0), locally advnced (T3-T4, any N, M0) or 
metastatic (any T, any N, M1) disease. The choice of whether to treat and what 
treatment is best has to be made with the patient, taking into account the best clinical 
evidence available at the time (Patel 2003). Current co sensus guidelines for prostate 
cancer management have been published by the European Association of Urology 
(EAU) (Heidenreich 2008) and the National Comprehensive Cancer Network (NCCN) 
in North America (Mohler 2010). The treatment options currently recommended are 
summarised in Table 1.2.   
Stage Management Options 
Localised disease  
(T1-T2, N0, M0) 
Active surveillance, Radical radiotherapy, Radical 
prostatectomy 
Locally advanced disease  
(T3-T4, any N, M0) 
Radical prostatectomy (selected T3, N0), Radical radiotherapy 
(T3, N0), Androgen deprivation therapy 
Metastatic disease  
(Any T, any N, M1) Androgen deprivation therapy, Palliative radiotherapy 
Hormone-refractory disease 
(Any T, any N, M1) Chemotherapy 
 
Table 1.2: Established management options for patients with prostate cancer. 
 
1.6 The Role of Proteinases in Prostate Cancer Tumourigenesis, Progression and 
Management 
Proteinases (or peptidases) are a group of over 600 enzymes in humans whose action is 
to cleave peptide bonds in proteins. The genes that code for proteinases or their 
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homologues in humans account for approximately 2% of the human genome (Rawlings 
2006). The International Union of Biochemistry and Molecular Biology has divided 
proteinases into 2 groups; Endopeptidases (or proteinas s), which cleave peptide bonds 
at specific points within the protein and exopeptidases which remove amino acids 
sequentially from either the N terminus (aminopeptidases) or C terminus 
(carboxypeptidases) of the protein. The MEROPS classification 
(www.merops.sanger.ac.uk), divides the proteinases into families according to their 
structure and evolutionary relationships (Rawlings 2006). Another useful classification 
system is to group the proteinases according to the residue or moiety at the centre of the 
active catalytic site e.g. cysteine proteinases, serine proteinases, aspartic proteinases, 
metalloproteinases etc. (Table 1.3). 





















Table 1.3: Classification of selected proteinases according to the nucleophylic amino 
acid residue at the catalytic site.  
 
In humans, proteinases serve various roles and are involved in numerous biological 
processes including digestion, coagulation, immunity, endocrine function, blood 
pressure regulation and maintenance of tissue architecture. Their activity is regulated at 
the levels of transcription and translation and by the activity of proteinase inhibitors, 
over 100 of which are encoded in the human genome (Rawlings 2006).  
Proteinases are involved in complex activation pathw ys and cascades. The most 
extensively characterised of these is the blood coagulation cascade. Timely blood 
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coagulation is essential for maintaining intravascular fluid volume. The successful 
formation of a fibrin clot is dependent on sequential activation of clotting factors, most 
of which are serine proteinases, from the inactive pro-enzyme by other proteinases 
(Davie 2003). Other proteinase activating cascades ar  the complement system for 
maintaining innate immunity, which comprises mainly serine proteinases (Forneris 
2012), and the apoptosis pathway, which involves serial activation of caspases to 
achieve programmed cell death (Wang, Z.B. 2005).  
The activity of proteinases in the ECM makes them good candidates for research into 
tumourigenesis, tumour progression and tumour metastasis. Riddick et al have 
compared the expression of degradome components in benign and malignant prostate 
tissue and analysed the correlation with Gleason score (Riddick 2005). The results 
showed that some proteinases are dysregulated in prostate cancer and correlate 
positively or negatively with Gleason grade (Table 1.4). This suggests that these 
proteinases may be playing a role in tumour progression. 
Up-regulated 
(Correlation with Gleason Score) 
Down-regulated 
(Correlation with Gleason Score) 
MMP10(+), MMP15(+), MMP24(+), 
MMP25(=), MMP26(+), Hepsin(+), MTSP1(+), 
uPA(=), uPAR(+), PAI1(+) 
MMP2(-), MMP23(-), Maspin(-), TIMP3(-), 
TIMP4(-), RECK(-), PAI2(=) 
 
Table 1.4: Expression of proteinases, their receptors and inhibitors in prostate cancer 
and correlation with Gleason score. MTSP1- Matriptase, uPA- Urokinase type 
plasminogen activator, uPAR- Urokinase type plasminogen activator receptor, PAI- 
Plasminogen activator inhibitor, TIMP- Tissue inhibitor of metalloproteinases, RECK- 
Reversion-inducing cysteine-rich protein with Kazal motifs . + indicates positive 
correlation, - indicates negative correlation, = indicates no correlation. 
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The studies on the role of proteinases in prostate c ncer have generally investigated the 
effect of proteinase activity on tumourigenesis, tumo r growth, cell motility and 







Tumourigenesis  + Cathepsins 
- Caspases  
Nagler 2004 
Earnshaw 1999, Jiang 2001 
Tumour Growth & 
Proliferation  





Miyamoto 2004  
Fowlkes1994, Manes 1999 
Angelloz-Nicoud 1995 
Lee 1994 
Osman 2006, Horiguchi 2007 
Migration  + Calpains 
+ Thrombin 
Rios-Doria 2003 
Black 2007, Loberg 2007 
Invasion  + MMP-9 




Aalinkeel 2004                                         










Black 1997, Fajardo 1992 








Nemeth 2002                                                    
Romanov 2004 




Table 1.5: Summary some known and putative biological a tivities of proteinases in 
prostate cancer. (+)  indicates a  positive effect, (-) indicates a negative effect. 
  
1.6.1 Tumourigenesis 
The factors that initiate the transformation of normal cells to malignant cells are not 
fully understood. However, the outcome is always an increase in the ratio of cell 
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proliferation relative to cell death. Caspases are members of the cysteine proteinase 
catalytic class. Caspase-induced apoptosis is effect d by a complex cascade, which 
results in the cleavage of cellular and nuclear proteins that are essential for cell survival 
(Earnshaw 1999). Caspase-2, 8, 9 and 10 are initiator c spases, because they cleave the 
precursors of caspase-3, 6 and 7, which are effector caspases. Activation of caspase-3, 
7, 8 and 9 has been shown to effect apoptosis in cells (Wolf 1999), with caspase-9 being 
the initiator caspsase for the intrinsic (mitochondrial) apoptotic pathway and caspase-8 
the initiator for the extrinsic (death receptor) pathway.   Caspase-8 mediated apoptosis 
can be activated by selenium compounds (Jiang 2001). Caspase inhibitors halt the 
cleavage of cellular components (Jiang 2001), thereby restricting the process of 
apoptosis. Apoptosis is the natural process of programmed cell death therefore 
inhibition of the activity of caspase proteinases could be one of the initiating steps in 
tumourigenesis, by allowing uncontrolled cell proliferation and the establishment of 
malignant cell populations.  
 Lysosomal cysteine proteinases, are so called becaus  of the cysteine residue at the 
catalytically active site. This group of proteinases could also be involved in the early 
stages of prostate cancer development. There are high expression levels of cathepsin-X 
in invasive carcinoma of the prostate (Nagler 2004). Differences in protein expression 
were analysed in normal, prostatic intraepithelial neoplasias (PIN) and prostate 
carcinoma tissue. PIN and carcinoma tissue had higher expression of cathepsin–X than 
normal epithelial tissue, suggesting that cathepsin-X may be involved in the early 
change from normal to malignant tissue. These findings are not enough evidence that 
cathepsin-X plays a role in the malignant change of the prostate epithelial cells. 
Functional studies are required to show if indeed, cathepsin-x plays a role in initiating 
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the transformation of the epithelial cells, or the increased expression is a consequence of 
earlier events.   
1.6.2 Tumour Cell Growth & Proliferation 
The transformation of normal prostate epithelial cel s to malignant cells is followed by 
proliferation of the malignant cell population whic may be slow or rapid, depending on 
the phenotype of the cells. Insulin-like Growth Factors (IGFs) are proteins that have 
homology to insulin. Availability and activity of these growth factors and their binding 
proteins, Insulin-like Growth Factor Binding Proteins (IGFBPs), in the prostate are 
under the influence of proteinases.  MMPs are members of the metalloproteinase 
family. MMP-1, 2, 3, 7 and 9, have been shown to cleave IGFBPs in fibroblasts 
(Fowlkes 1994; Miyamoto 2004), thereby releasing the growth factor so it is able to 
bind to its cell surface receptor. MMP-9 has been repo ted to cleave IGFBP-3 in DU-
145 prostate cancer cell lines (Manes 1999). Cleavage of IGFBP-3 caused increased 
activity of IGF-1 and protected against apoptosis (Miyamoto 2004). These findings 
indicate that by cleaving IGFBPs, these MMPs increase the bioavailability of IGF, 
promoting cell growth and proliferation.  
Human Kallikrein-3 (hKLK3, PSA) has also been shown to cleave IGFBP-3 in vitro, 
but serum of men with elevated PSA did not have correspondingly high levels of 
IGFBP-3 fragments (Koistinen 2002). This could be interpreted to mean that even 
though PSA cleaves IGFBP-3 in vitro, serum IGFBP-3 is not cleaved by PSA, perhaps 
as a result of the presence of PSA inhibitors in serum. However, IGFBP-3 in seminal 
plasma is cleaved by PSA (Lee 1994), suggesting that the cleavage of IGFBP-3 by PSA 
is localised to the prostate. Hence proteolytic activity of PSA could also be increasing 
bioavailability of IGFs in the tumour microenvironment and promoting cell 
proliferation.  
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IGFBP-3 is also cleaved by plasmin, a serine proteinase which is itself activated by the 
cleavage of a precursor protein, plasminogen, by the serine proteinase urokinase-type 
plasminogen activator (Lee, M. 2004). The activity of uPA has been shown to increase 
the proliferation rate of PC3 cells in vitro (Angelloz-Nicoud 1995) and the addition of a 
serine proteinase inhibitor, 4-(2-aminoethyl)-benzenesulfonyl fluoride, to the medium 
inhibited the activity of uPA and led to a decrease in cell proliferation. As previously 
mentioned cleavage of IGFBP-3 increases the bioavailability of IGFs and promotes cell 
proliferation. However the use of a broad serine proteinase inhibitor would inhibit other 
serine proteinases meaning that the effects on cell proliferation might not be specifically 
attributed to the activity of uPA. Unlike the proteinases already discussed in this 
section, neprilysin (Neutral Endopeptidase), a cell surface proteinase, is reported to have 
a negative effect on prostate cancer cell proliferation (Osman 2006). Induction of 
neprilysin expression in prostate cancer cells in vivo caused attenuation of tumour 
growth, and over-expression of neprilysin also had the effect of decreasing cell viability 
and proliferation (Horiguchi 2007). The anti-proliferative effect of neprilysin may be as 
a result of the inactivation of fibroblast growth factor-2 (FGF-2) (Horiguchi 2008).  
1.6.3 Tumour Cell Motility, Migration & Invasion 
The invasive potential of tumour cells is determined by their ability to migrate outside 
the confines of the basement membrane and through the surrounding ECM. There is 
also evidence that tumour cells can migrate, albeit ess efficiently, through the ECM in 
the absence of proteinase activity (Wolf 2003). A number of proteinases have been 
found to play a role in the motility and invasive potential of prostate cancer cells. 
Cathepsins B, H, and L are more highly expressed in primary cells cultured from 
cancerous parts of the prostate compared to cells from adjacent non-cancerous tissue 
(Friedrich 1999). Cathepsins B and L have also been reported to be expressed in 
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prostate cancer cell lines (Friedrich 1999; Colella 2002). In the latter study, the cysteine 
proteinase inhibitor, E-64 (trans-epoxysuccinyl-L-leucyl-amido(4-guanido)-butane), 
reduced the invasiveness of PC3 and DU145 cells. However, the inhibitory action of E-
64 is not specific to cathepsins B and L as it inhibits all papain family members. 
Transfection of PC3 cells with a plasmid coding for chicken cystatin, an endogenous 
cysteine proteinase inhibitor, led to decreased invasive potential of the cells (Colella 
2003).  Collectively, these studies suggest that cys eine proteinases play an active role 
in prostate cancer cell invasion. Calpains are cysteine proteinases that have been shown 
to cleave the cytoplasmic domain of E-cadherin (Rios-D ria 2003). E-cadherin is a 
trans-membrane structural protein which mediates lateral intercellular adhesion in 
secretory tissues (Geiger 1992). Calpains are over-exp essed in localised and metastatic 
prostate cancer specimens (Rios-Doria 2003), and prostate cancer specimens have been 
reported to show aberrant or negative staining for E-cadherin (Tomita 2000). Proteolytic 
cleavage of E-cadherin and subsequent loss of latera  c ll-cell adhesion would promote 
cancer cell motility and invasive potential.  
Thrombin is a serine proteinase which is instrumental in blood clotting and is also a 
growth factor, acting through proteinase activation receptors (PARs). Thrombin cleaves 
the N-terminus of PARs, which then act as a tethered ligand and activates the receptor 
(Coughlin 2003). PAR-1, -2 and -4 are over-expressed in malignant prostate cancer 
tissue and high expression of PAR-1 also predicts biochemical recurrence of prostate 
cancer (Black 2007). Activation of PAR-1 and -2 enha ces migration of LNCaP cells 
(Black 2007) and stimulation of PC3 cells with thrombin activated PAR-1 and caused 
cell detachment and increased chemotactic migration (L berg 2007).  These studies 
suggest that activation of PARs by thrombin increases the potential of prostate cancer 
cells to migrate.  
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MMPs are known to degrade ECM components (Lee, M. 2004). The activation of 
MMPs is dependent on cleavage of the propeptide by other MMPs,  cathepsins and 
plasmin (Lee, M. 2004) (Figure 1.10). 
   
   Cathepsin D, 
   Cathepsin G,                             pro-uPA 
   Elastase, or uPA 
       Procathepsin B                  →                 cathepsin B          ↓ 
 
                                      uPA                 proMMP-1,.3,12,13 
 
                            plasminogen      →       plasmin            ↓ 
 
                                          MMP-1,3,12,13 
 
 
    MMP-3 or 2 
 
              ProMMP-9             →            MMP-9 
 
 
                 MMP-14, TIMP-2 
 





Figure 1.10: Activation cascade of some of the proteolytic enzymes involved in tumour 
metastasis. The enzymes in bold type degrade the ECM.
 
This illustrates the point that there is a cascade of events involving a number of 
proteinases and their inhibitors that regulate ECM turnover. In vitro, MMP-9 increases 
the invasive potential of prostate cancer cell lines (Aalinkeel 2004). The more invasive 
PC-3 and DU-145 cell lines have higher expression levels of MMP-9 relative to the less 
invasive LNCaP cells. Over-expression of MMP-9 in LNCaP cells increased their 
invasive potential and knockdown in PC-3 and DU-145 cells reduced their invasive 
potential. In another study, inhibition of MMP-14 (MT-1 MMP) expression also 
decreased the invasive potential of prostate cancer cell lines DU-145, PC-3N and PPC 
(Udayakumar 2003). MMP-9 and 2 are found to localise at the leading edge of tumour 
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tissue (Hamacher 2004). This suggests an active role at the tumour edge. Another study 
showed that there was increased synthesis of collagen in surrounding benign tissue in 
prostate cancer specimens but decreased collagen content within the cancer focus 
(Burns-Cox 2001).  Increasing collagen production may be a host response to counter 
the proteolytic activity of the advancing tumour cells. 
A Disintegrin and Metalloproteinase (ADAM) and A Disintegrin and Metalloproteinase 
with Thrombospondin motifs (ADAMTS) are a relatively newly discovered group of 
metalloproteinases. ADAMs act predominantly as membrane-bound sheddases while 
some ADAMTSs are proteoglycanases. Expression of ADAM-9, -10, -11, -15 and -17 
was detected in prostate cancer lines LNCaP, ALVA-41, DU-145 and PC-3 (McCulloch 
2000). ADAM-15 over-expression has been associated with aggressive prostate cancer 
(Kuefer 2006). ADAMTS expression has also been analysed in prostate cancer cell 
lines. ADAMTS-1 was expressed in PC-3 and LNCaP, ADAMTS-9 was expressed in 
DU-145, and ADAMTS-15 was expressed in all three cell lines (Cross 2005). Unlike 
the more aggressive PC3 and DU145 cell lines, LNCaP cells expressed TIMP-3, the 
main tissue inhibitor of ADAMTSs, which also inhibits ADAM and MMP activity. 
Genome-wide cDNA micro-array analysis of prostate cancer tumours identified 
ADAMTS-1 as one of the genes that are over-expressed in HRPC specimens when 
compared with hormone-sensitive specimens (Tamura 2007). A sub-group of the 
ADAMTSs degrade structural components of the ECM (Jones 2005), which suggests 
that prostate cancer cells expressing these proteinas s could be using them to degrade 
ECM in the TME. Studies into the functional role of the ADAMTS proteinases and their 
major tissue inhibitor, TIMP-3, in the prostate will shed light on their role in prostate 
cancer. 
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 The serine proteinase uPA has been implicated in the invasive potential of prostate 
cancer cells. PC3 cells were compared with PC3CALN, a more aggressive in vivo 
derivative of PC3 cells. PC3CALN cells expressed 3.5 times more uPA than PC3 cells 
and displayed greater invasive potential, and immunohistochemistry of tumour 
xenografts demonstrated localisation of uPA to invasive fronts (Gaylis 1989). 
Supporting these findings, down-regulation of uPA and uPA receptor (uPAR) 
expression decreased the invasive potential of PC3 cells in a Matrigel invasion assay 
(Pulukuri 2005). This probably reflects its role in the activation of plasmin, which can 
then activate MMPs (Figure 1.10), or uPA could be dir ctly acting to facilitate prostate 
cancer cell invasion.  
Prostasin is a serine proteinase that is expressed in normal prostate epithelium as well as 
in the non-invasive LNCaP prostate cancer cell line(Chen 2001). The more invasive 
PC3 and DU145 prostate cancer cell lines do not express prostasin, and over-expression 
of prostasin in PC3 and DU145 cell lines by transfection of prostasin cDNA diminished 
the invasive potential of these cell lines (Chen 2001). This infers that prostasin has a 
negative effect on prostate cancer invasion. The mechanism of this action is not yet 
known. 
PSMA, also known as glutamate carboxypeptidase-2 or folate hydrolase, is a 
transmembrane metallopeptidase. It has been identified as a tumour suppressor in 
prostate cancer. LNCaP, MDA PCa2b and CWR22RV1 prostate cancer cell lines which 
express PSMA were less invasive than PC3 and DU145 cell lines which did not express 
PSMA (Ghosh 2005). Knock-down of PSMA expression in LNCaP cells increased their 
invasive potential, while over-expression of PSMA in PC3 cells decreased their 
invasive potential. This suggests that loss of PSMA expression could be an important 
step in prostate cancer progression, but the mechanism remains unknown. 
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1.6.4 Angiogenesis 
As tumours grow in size, their metabolic demands increase. Blood vessels carry the 
metabolic substrates necessary for tumour growth and remove toxic metabolic end 
products. Theoretically, any factors favouring the growth and proliferation of new 
vessels would favour tumour growth. Studies have implicated some proteinases in either 
stimulating or inhibiting angiogenesis. 
The thrombin receptor, PAR-1, as previously mentioned is over-expressed in advanced 
prostate cancer specimens compared with specimens with localised disease (Kaushal et 
al. 2006). Immunohistochemical staining localised the PAR-1 receptors to endothelial 
cells in vascular networks surrounding prostate cancer cells. Thrombin also increases 
vascular endothelial growth factor (VEGF) secretion, potentiates the action of VEGF in 
inducing endothelial cell proliferation, up regulates expression of VEGF receptors and 
enhances the production of MMP-9 in PC-3 cells (Tsopanoglou 2004). This implies that 
thrombin regulates both ECM breakdown and angiogenesis. A combination of these two 
actions will enhance local tumour growth and survival.  
ADAM-17 has been identified as the main TNF converting enzyme (TACE), which 
sheds membrane-bound TNF into its soluble form (Black 1997). TNF has been 
associated with increased angiogenesis (Fajardo 1992) and so it is possible that TNF 
produced by tumour associated macrophages (TAMs) could, at a certain critical 
concentration, be driving angiogenesis in prostate tumours. ADAMTS-1 (METH-1) and 
ADAMTS-8 (METH-2) inhibit endothelial cell proliferation and VEGF induced 
angiogenesis (Vazquez 1999). The inhibitory effect is due to the binding and 
sequestration of VEGF (Luque 2003). The carboxyl-terminal region of ADAMTS-1 
which consists of thrombospondin-spacer-thrombospondin (T-S-T) repeats has been 
found to be responsible for its antiangiogenic activity (Kuno 2004). ADAMTS-1 also 
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cleaves thrombospondin-1, releasing anti-angiogenic peptides (Lee 2006). Thus 
angiogenesis can be regulated by the activity of these proteinases which are known to be 
expressed in prostate cancer (McCulloch 2000; Cross 2005). 
 Some of the actions of the MMPs lead to a stimulation of angiogenesis, yet others 
inhibit it. For example, breakdown of the ECM releas s ECM-bound growth factors that 
stimulate angiogenesis (Lee, M. 2004). However breakdown of collagen-18 releases 
endostatin, which is angio-inhibitory. Thus a balance is maintained between these 
events, which at different times favours angiogenesis or inhibits it. 
 In addition to its growth inhibitory action, neprilysin inhibits angiogenesis by reducing 
the availability of FGF-2 (Horiguchi 2008). Conditioned medium from DU145 cells that 
were made to over-express neprilysin had decreased concentrations of FGF-2 and 
stimulated less tubule formation by endothelial cells compared to controls. Tumour 
xenografts grown in vivo from neprilysin over-expressing cells were smaller and less 
vascular than controls. This evidence points to an anti-tumour role for neprilysin in 
prostate cancer.   
1.6.5 Establishment of Metastasis 
Relative to other aspects of tumour progression, few studies have been done to 
investigate the action of proteinases in metastatic prostate tumours. Prostate cancer 
metastasises primarily to bone, and bone metastases are a significant cause of mortality 
in patients with prostate cancer. Because clinical ndications for obtaining tissue 
samples from bone metastases in prostate cancer pati nts are rare, there is a paucity of 
metastatic specimens available for study. However, some proteinases have been shown 
to play a role in metastatic sites. 
As well as facilitating tumour cell invasiveness, some MMPs play a role in bone 
metastases in prostate cancer. In an in vivo experiment carried out on nude mice, bone 
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impregnated with PC-3 cells was subcutaneously implanted. MMP inhibition with the 
broad-spectrum MMP inhibitor batimastat administered intraperitoneally reduced 
proliferation of tumour cells, reduced the number of osteoclasts and prevented 
degradation of marrow trabeculae, but had no effect on angiogenesis or apoptosis 
(Nemeth 2002). In the in vitro arm of the study, MMP inhibition with batimastat 
prevented Ca2+ release from bone fragments co-cultured with PC3 cells. The 
concentrations of batimastat used had no toxic effects on the cells. Over-expression of 
the metalloproteinase inhibitors TIMP-1 and TIMP-2 in bone implants led to reduced 
PC3-induced osteoclast recruitment, osteolysis and bone turnover, suggesting that 
metalloproteinase activity is involved in one ECM turnover at sites of bone metastasis 
(Deng 2008). 
 ADAMTS-1 C-terminal fragments inhibit metastatic potential when over-expressed in 
Chinese Hamster Ovary (CHO) tumour cells, TA3 mammary c rcinoma cells and Lewis 
lung carcinoma cells (Kuno 2004; Liu 2006). Over-expression of full length ADAMTS-
1 inhibited metastases in CHO cells (Kuno 2004), but increased metastases formation 
by TA3 mammary carcinoma and Lewis lung carcinoma cells (Liu 2006). The 
ADAMTS-1 gene was one of the genes up-regulated in a genome-wide profiling of 25 
CRPC specimens, 12 of which were from metastatic deposits (8 bone, 3 lymph node 
and 1 liver) (Tamura 2007). It is not known whether ADAMTS-1 up-regulation favours 
metastasis, or is a host response in an attempt to inhibit the metastatic process.  
PSA has been shown to cause preferential adhesion of prostate cancer cells to bone 
marrow endothelium. Down-regulation of  PSA expression in prostate cancer cells by 
siRNA knock-down led to diminished adhesion of the prostate cancer cells to bone 
marrow endothelial cells when co-cultured (Romanov 2004). This may explain the 
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affinity of prostate cancer cells to metastasise to bone, but the mechanism is still not 
fully understood. 
Selective peptide inhibitors of uPA have been reported to inhibit tumour growth and 
metastasis (Lee, M. 2004). Over-expression of plasminogen activator inhibitor-1 (PAI-
1), a natural inhibitor of uPA, caused decreased growth and metastasis of PC3 tumours 
implanted subcutaneously in athymic mice (Soff 1995). Expression of uPA in metastatic 
prostate tumours is reported to be 1.5 times greater relative to prostate primary tumours 
(Kirchheimer 1985), and patients with metastatic prostate cancer have elevated serum 
uPA levels compared with patients with local disease nd healthy controls (Hienert 
1988). These studies implicate uPA in the process of prostate cancer metastasis. 
1.6.6 Clinical Management 
1.6.6.1 Diagnosis and Prognosis  
Serum PSA measurement is already established as a useful test to help in diagnosing 
prostate cancer and monitor disease progression becaus  it is produced almost 
exclusively by prostate epithelial cells. PSA levels can be elevated in other prostatic 
conditions and this has led to the search for a more specific biomarker for prostate 
cancer. Other modalities for diagnostic and prognostic uses of proteinases in cancer are 
being investigated, such as measuring serum levels of uPA and MMPs either alone or in 
conjunction with PSA (Matrisian 2003).  Proteinase-sensitive magnetic resonance 
imaging (MRI) contrast agents have been used in experimental settings to detect 
proteinase expression and activity in vivo (Louie 2006). The para-magnetic ion in the 
contrast agent molecules are bound to and blocked by a substrate that requires cleavage 
by a specific proteinase in order for the contrast agent to become active. This allows 




1.6.6.2 Prevention and Therapy  
Several preventive and therapeutic modalities have be n applied in an attempt to 
modulate the activity of proteinases. Selenium compunds are taken as dietary 
supplements because of their role in activating caspase-induced apoptosis (Jiang 2001). 
A meta-analysis of studies on the relationship betwe n selenium intake and prostate 
cancer concluded that selenium had a protective effect (Etminan 2005). However, more 
recent evidence from the SELECT trial, a randomised double-blind trial of the effect of 
selenium and vitamin E supplementation on prostate, lung and colorectal cancer 
prevention and involving 35,533 men, showed no protective effect with dietary 
selenium supplementation (Lippman 2009). It is not yet clear why the biological activity 
of selenium as a caspace activator did not lead to a decreased incidence of prostate 
cancer. 
Cyclooxygenase-2 (COX-2) is over-expressed in prostate cancer (Madaan 2000). COX 
inhibitors have been shown to reduce MMP production and cell invasiveness in prostate 
cancer cells in vitro (Attiga 2000), and several population-based studies have shown an 
inverse association of non-steroidal anti-inflammatory drug (NSAID) usage with 
prostate cancer (Nelson 2000; Leitzmann 2002; Roberts 2002; Garcia Rodriguez 2004; 
Jacobs 2005; Platz 2005). This suggests that long-term use of NSAIDs may be 
preventing growth and progression of prostate cancer, possibly by the reduction of 
MMP production.  
Epigallocatechin-3-gallate (EGCG), the major polyphenolic constituent of green tea, has 
been shown to inhibit MMP-2 and -9 (Adhami 2003), and ADAMTS-1, -4, and -5 
(Vankemmelbeke 2003). Green tea is reported to havean inhibitory effect on prostate 
cancer growth in vitro and in vivo (Gupta 2001; Adhami 2003). It is not clear whether 
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the inhibitory effect of green tea on prostate cancer growth and progression is a direct 
result of inhibition of these proteinases.  
Inhibitors of MMPs such as batimastat and marimastat have been used in clinical trials 
but were shown to produce un acceptable side effects such as joint and muscle pain 
(Matrisian 2003). Also, results of Phase III clinical trials using marimastat and 
prinomastat in patients with advanced cancers demonstrated no clinical efficacy (Zucker 
2000; Sparano 2004). In another study, batimastat increased metastasis of breast cancer 
cells to the liver in mice (Kruger 2001). A combination of these findings led to the 
discontinuation of clinical trials of these MMP inhbitors.  
Another aspect of therapy under investigation is the use of viral vectors for gene therapy 
in prostate cancer. Theoretical models have been describ d and trials are underway to 
find the most efficient and safe gene delivery system (Foley 2004). Genes for specific 
proteinases or their inhibitors could possibly be targeted to up or down-regulate their 
expression either locally in the prostate, or systemically in cases of widespread 
metastases. Vectors are being designed that have specific affinity for prostate cells, 
hence minimising side-effects (Mabjeesh 2002; Song 2008). 
1.6.7 Summary of Proteinase Activity in Prostate Cancer 
Proteinases play diverse physiological and pathological roles and there is a complex 
array of enzymatic processes and cascades that regulat  the activity of the proteinases, 
with some proteinases playing dual or auto-regulatory roles depending on the 
circumstance. Figure 1.11 shows the prostate and bone environment and biological 
activities regulated by proteinases and inhibitors. The understanding of the function of 
each of the proteinases and how they interact with each other and with other 
components of the cellular environment is essential to determining how they can be 
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exploited as diagnostic, prognostic or therapeutic tools in the management of patients 
with prostate cancer. 
 
Figure 1.11: Schematic diagram of the prostate and bone micro-environment, showing 
the proteinases that are playing a role at the different sites. 
 
1.7 The ADAMTS Proteinases  
1.7.1 Introduction to the ADAMTS Proteinases 
The ADAMTS (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) 
proteolytic enzymes are a group of metalloproteinases belonging to Family M12 in 
proteinase Clan MA on the MEROPS database (www.merops.sanger.ac.uk) (Rawlings 
2008) and are phylogenetically and structurally related to the MMPs and ADAMs 




Figure1.12: Generic domain structure of MMPs, ADAMs and ADAMTSs showing 
similarities between the groups. 
 
There are 19 ADAMTS proteins coded in the human genome and they play diverse 
roles in the tissues in which they are expressed (Jones 2005; Porter 2005). ADAMTS-1 
was the first to be isolated. In 1997, Kuno et al reported the isolation of a 
metalloproteinase with thrombospondin motifs from acachexia inducing 
adenocarcinoma in mice (Kuno 1997). ADAMTS-1 is essential for normal development 
of the urogenital tract in mice (Shindo 2000) and for ovulation (Russell 2003). 
ADAMTS-1 and -8 have anti-angiogenic properties (Vazquez 1999). Anti-angiogenic 
properties have also recently been described for ADAMTS-2 (Dubail 2010). ADAMTS-
1, -4, -5 and –9 have been shown to cleave aggrecan and versican, structural 
components of the ECM (Kuno 2000; Sandy 2001; Russell 2003; Vankemmelbeke 
2003). ADAMTS-5 has been implicated in cartilage brakdown in arthritis (Glasson 


















pro-collagen into the mature form (Colige 2002). Mutations in the ADAMTS2 gene 
leads to development of Ehlers-Danlos syndrome type VII C (Colige 1999; Colige 
2004). ADAMTS-13 has been identified as the von Willebrand factor cleaving 
proteinase, processing the von Willebrand factor precu sor into the active form for 
participation in the blood coagulation cascade (Fujikawa 2001; Soejima 2001; Zheng 
2001). Functions and substrates have not yet been assigned to ADAMTS-6, -7, -10, -12, 
-16, -17, -18 and -19. For this reason, these ADAMTSs are sometimes referred to as 
orphan ADAMTSs. However, ADAMTS-12 has been shown to have proteolytic 
activity (Cal 2001), and ADAMTS-16 mRNA expression is up-regulated in 
osteoarthritic cartilage compared to normal cartilage (Kevorkian 2004).  
ADAMTS proteins can be divided into sub-groups based on evolutionary relationships 
(Nicholson 2005) (Figure 1.13). An important feature to note is that the evolutionary 
sub-grouping closely matches the biological functions f the ADAMTSs. ADAMTS-1, 
-4, -5, -8 and -15 evolved from a common ancestral protein in invertebrates. The Ciona 
intestinalis ADAMTSf gene has been shown to be orthologous with this sub-group of 
ADAMTSs (Huxley-Jones 2007). It appears that the human ADAMTS orthologues 
evolved through a series of gene duplication events, and the differences in protein 
domain structure are likely to be as a result of gains nd losses of introns (Nicholson 
2005). The similarity in structure of the ADAMTS mebers in each sub-group raises 
the possibility of functional redundancy. However this has not been demonstrated 
experimentally. ADAMTS-4 and -5 have been demonstrated to be aggrecanases and 
implicated in cartilage degradation in arthritis but the relative roles of the two enzymes 
in arthritis have not been resolved completely (Verma 2011). Adamts5, but not 
ADAMTS4 or ADAMTS1 knock-out mice were protected from arthritis (Glasson 2004; 
Glasson 2005; Little 2005; Stanton 2005), indicating that ADAMTS-4 and ADAMTS-1 
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do not play redundant roles with ADAMTS-5 in the pathogenesis of arthritis. Temporo-
spatial differences in expression of ADAMTSs (Cal 200 ) also makes it unlikely that 
they play redundant roles in humans, as they are diff rentially expressed in tissues 
during the process of human growth and development.   
 
Figure 1.13: Phylogenetic tree of the ADAMTS proteins. 
 
1.7.2 ADAMTSs in Cancer 
ADAMTSs have been implicated in malignant processes in several organs. Because of 
their multi-domain structure and the potential for pro or anti-tumour activity, the role of 
ADAMTSs in human cancer has attracted interest.   
1.7.2.1 Prostate Cancer 
ADAMTS-1, -9 and -15 mRNA expression has been detect d in prostate cancer cells 
(Cross 2005). In addition to ADAMTS-1, -9 and -15, ADAMTS-4 and -5 mRNA 
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abundantly expressed in the prostate cancer cells. Expression of the ADAMTS inhibitor 
TIMP-3 was comparatively low in the cells with great r metastatic potential. 
ADAMTS-15 was the only one of the ADAMTSs that was expressed in all the prostate 
cancer and stromal cells investigated. Over-expression of ADAMTS-1 has been 
identified in CRPC tissue (Tamura 2007), suggesting a role for ADAMTS-1 progression 
of prostate cancer.  
 
1.7.2.2 Breast Cancer 
Expression of ADAMTSs has been analysed in breast cancer tissue. Comparing mRNA 
expression of ADAMTSs in malignant tissue, adjacent normal tissue and cell lines by 
real-time RT-PCR, ADAMTS-1, -3, -5, -8, -9, -10, and -18 were consistently down-
regulated, while ADAMTS-4, -6, -14, and -20 were up-regulated (Porter 2004). High 
ADAMTS-8 and low ADAMTS-15 expression in malignant breast tumours correlated 
with worse patient prognosis (Porter 2006), suggesting hat ADAMTS-15 may be 
playing a protective role in breast cancer patients. 
 
1.7.2.3 Glioblastoma 
Glioblastoma is a highly invasive form of brain caner. Comparing expression of 
ADAMTSs in malignant and adjacent benign tissue using realtime RT-PCR and 
immunohistochemistry showed that ADAMTS-4 and -5 were over-expressed in tumours 
and ADAMTS-8 was down-regulated (Nakada 2005; Dunn 2006; Held-Feindt 2006). 
Over-expression of ADAMTS-5 in a glioblastoma cell line increased invasive potential. 
The increased invasiveness is thought to be a result of increased cleavage of brevican, a 
major proteoglycan in brain ECM.  
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1.7.2.4 Head and Neck Cancer 
Head and neck squamous cell cancers (HNSCC) affect the oral and pharyngeal 
membranes. Expression profiles of ADAMTS mRNA in localised and metastatic 
HNSCC compared with normal pharyngeal mucosa has reveal d dysregulation of 
ADAMTSs (Demircan 2009). ADAMTS-1, -4, -5, -8, -9 and -15 were down-regulated 
in approximately 50% of primary tumours compared to normal tissue. Comparing 
primary tumours with their corresponding metastatic tumours, ADAMTS-1, -4, -5 and -
15 were up-regulated, ADAMTS-9 was down-regulated. ADAMTS-8 mRNA 
expression was similar between metastatic tumours and their parent tumours. These 
findings suggest that a sub-population of cancer cells with the optimal expression 
profile are able to metastasize, resulting in differences in ADAMTS expression between 
parent and metastatic tumours. An alternative explanation is that the cancer cells are 
able to alter expression profiles of pro and anti-metatastatic proteins at each stage of 
tumour progression. 
 
1.7.2.5 Non-Small Cell Lung Carcinoma 
Non-small cell lung carcinoma (NSCLC) is a variant of lung cancer. Using real-time 
RT-PCR and inmmunohistochemistry, lower expression of ADAMTS-1 and -8 was 
found in NSCLC tissue compared with adjacent normal tissue (Dunn 2004; Rocks 
2006). Abnormal hypermethylation of the ADAMTS8 gene was found in the majority of 
the tumours suggesting epigenetic silencing of ADAMTS8 in NSCLC cells. 
1.7.2.6 Adenocarcinoma of the Colon 
ADAMTS-1 has been detected in cachexia inducing colorectal cancer cells (Kuno 
1997). Subsequent studies have shown that the ADAMTS1 gene is hypermethylated in 
colon cancer cells (Lind, G.E. 2006), and that ADAMTS1 methylation status could be 
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used to differentiate normal colorectal mucosa, benign tumours and malignant tumours 
(Ahlquist 2008).  Mutations and epigenetic silencing of the ADAMTS15 gene have been 
identified in colorectal cancer (Sjoblom 2006; Vilor a 2009). Over-expression of 
ADAMTS-15 in colorectal cancer cells reduces invasie potential (Viloria 2009), 
suggesting an anti-tumour role for ADAMTS-15. 
 
1.7.2.7 Pancreatic Carcinoma 
Pancreatic carcinoma is a tumour with a very poor pr gnosis. ADAMTS-1 mRNA 
expression profiles in malignant pancreatic tissue compared with adjacent normal tissue 
showed that ADAMTS-1 was down-regulated in malignant tissue samples (Masui 
2001). The malignant tumours that had higher expression of ADAMTS-1 also had an 
increased incidence of lymph node metastasis and retroperitoneal invasion. CD34 
staining of the tissue samples did not show any correlation between ADAMTS-1 
expression and microvascular density.  
 
1.7.2.8 Hepatocellolar Carcinoma 
Hepatocellular carcinoma (HCC) is the most common ca cer in the developing world, 
and is associated with Hep-B infection (Michielsen 2005). Expression of ADAMTS-1 
mRNA was compared between malignant and adjacent cirrhotic liver tissue (Masui 
2001). Expression was lower in the malignant tissue samples. Staining for CD34 did not 
show any correlation between ADAMTS-1 expression and microvascular density.  
 
1.7.2.9 Chondrosarcoma 
Chondrosarcoma is a common malignant primary cartilage tumour. Expression of 
ADAMTS-4 and -5 were analysed by immunohistochemistry and staining scores 
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correlated with histological grade (Sugita 2004).  Expression of both ADAMTS-4 and -
5 correlated with histological grade of osteosarcomas, with higher expression levels 
found in grade 2 and 3 tumours compared with grade 1. Expression of the 
metalloproteinase inhibitors TIMP-1, -2 and -3 were also found to correlate with 
histological grades. Put together, this suggests that there is a high rate of ECM turnover 
in the more aggressive tumours. Expression of ADAMTS-9 has also been detected in 
chondrosarcoma cells (Demircan 2005), where expression was up-regulated by TNF 
and IL-1β. 
 
1.7.2.10 Summary of ADAMTS Roles in Cancer 
The expression profiles of ADAMTS proteinases in these various human tumours 
suggests that they may be playing a role in the pathophysiology of these tumours. It 
appears that the expression and role played by individual ADAMTSs varies in different 
tumour sites, as summarised in Table 1.6. The activity of ADAMTSs may be attributed 
to their multi-domain structure and the degree of pr cessing, and the relative abundance 
of the resulting fragments at the tumour sites. Specifically in prostate cancer cells, the 
expression profile of ADAMTS-1 and -15 suggest that t ey may be the most important 
members of this group in prostate cancer biology and may be playing a role in 








Organ Up-Regulated Down-Regulated 
Brain -4, -5 -8 
Lung - -1, -8 
Breast -4, -6, -14, -20 -1, -3, -5, -8, -9,  -10, -18 
Pancreas  - -1 
Liver - -1 
Bone -4, -5 - 
Prostate ? -1, -15 - 
 
Table 1.6: Table summarising the expression of ADAMTS proteins in human cancer 
tissue and cells compared with non-malignant tissue. 
 
1.7.3 Structure of ADAMTS-1 & -15 
The ADAMTS1 gene codes for a 967 aa protein with a relative molecular mass of 
105kDa. The ADAMTS15 gene codes for a similarly sized 950 aa protein with a relative 
molecular mass of 103kDa. ADAMTS-1 and -15 share a similar generic structure with 
other ADAMTS proteins and both belong to the sub-group comprising ADAMTS-1, -4, 
-5, -8 and -15. The ADAMTSs possess a muti-domain structure, with each domain 
potentially conferring different properties to the molecule. Each ADAMTS protein 
consists of a signal peptide and a propeptide domain, a catalytic domain containing a 
zinc-binding motif, a disintegrin-like domain, and thrombospondin motifs separated by 
a cysteine-rich spacer region (Vankemmelbeke MN 2001; Jones 2005; Porter 2005).  
ADAMTS-1 and -15 share similar structure and sequence homology (Cal 2002), with 
the same number and configuration of the thrombospondin motifs (Figure 1.14).  
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Figure 1.14: Generic structure of ADAMTS-1 and -15.  Each ADAMTS protein has a 
central thrombospondin-like domain. The configuration of the rest of the C-terminal 
thrombospondin-like domains differs between the members of the group, but is identical 
for ADAMTS-1 and -15. 
Comparison of the domains of ADAMTS-1 and -15 (Table 1.7) shows the similarity 
between the structure of the two proteins, with potential implications of similar roles for 
the two proteins. 
Domain Domain Position (Amino Acid Length)  
 ADAMTS-1 (967) ADAMTS-15 (950) 
Signal Peptide 1-49 (49) 1-17(17) 
Propeptide 50-252 (203) 18-212 (195) 
Catalytic 253-467 (215) 213-427 (215) 
Disintegrin-like 468-559 (92) 428-515 (88) 
Thrombospondin 1  560-614 (55) 516-571 (56) 
Cysteine-rich 615-724 (110) 572-700 (129) 
Spacer 725-849 (125) 701-838 (138) 
Thrombospondin 2  850-905 (56) 839-895 (57) 
Thrombospondin 3  906-967 (62) 896-950 (55) 
 
Table 1.7: Similarities between the ADAMTS-1 and -15 domain length and 




A recent study reported for the first time the crystal tructure of ADAMTS-1 (Gerhardt 
2007). This has further clarified the domain structure of the ADAMTSs. From the N-
terminal end, the signal peptide consists of a variable length aa sequence which is 
cleaved soon after translation in the endoplasmic reticulum (Porter 2005). The 
propeptide domain may be important for correct protein folding (Cao 2000). Cleavage 
of the propeptide by proprotein convertases like furin in the golgi apparatus is believed 
to be essential for activation of the proteolytic domain (Bergeron 2000; Wang 2004). 
Some recent reports have indicated that the propeptide domain may be retained and 
cleaved extracellularly after secretion (Longpre 2009). Extracellular activation has not 
been reported for ADAMTS-1 or -15. The proteolytic domain contains the catalytic zinc 
pocket which is responsible for the proteolytic properties of the ADAMTSs. MMPs 
have a cysteine residue within the PRCGVPD motif in the propeptide domain 
interacting with the zinc pocket of the proteolytic domain, preventing proteolysis (Van 
Wart 1990). Thus cleavage of the propeptide domain frees the zinc ion to initiate the 
hydrolytic reaction characteristic of metalloproteinases (the cysteine switch). 
ADAMTS-1, and -15 have a similar cysteine-containing motif in the prodomain (Cal 
2002). On the C-terminal end of the proteolytic domain is a disintegrin-like domain.  
The structure of the disintegrin domain of ADAMTS-1 was analysed by Gerhadt et al, 
who concluded that based on the protein fold, the disintegrin domain is actually a 
cysteine-rich domain, which fails to superimpose on the crystal structures of the 
disintegrin domains of ADAM-10, VAP-1 or trimestatin and (Gerhardt 2007), which are 
well characterised disintegrins. It is not yet know if this holds true for the other 
ADAMTSs. The rest of the C-terminal end of ADAMTS-1 and -15 consists of a central 
thrombospondin type-1 motif, a cysteine-rich spacer r gion and two additional 
 72 
thrombospondin motifs. The number and configuration of the thrombospondin motifs 
and spacer regions are different in other members of the group. ADAMTS-1 and -15 do 
not posses PLAC (Protease and Lacunin), CUB (Compleent-Uegf-BMP-1) and mucin 
domains found in some other ADAMTS proteins.  
Unlike the ADAMS, the ADAMTSs do not possess a trans-membrane domain. They are 
therefore secreted from the cell into the ECM where they are sequestered by heparan 
sulphate proteoglygans (Kuno 1998; Gao 2004).  
 
1.7.4 Functions of ADAMTS-1 & -15 
 
ADAMTS-1 has been extensively studied, and its biological functions are better 
understood than ADAMTS-15. Following its discovery as an inflammation-associated 
protein (Kuno 1997), ADAMTS-1 has been shown to be catalytically active and capable 
of cleaving several ECM components (Kuno 1999).  
The mouse Adamts1 gene promoter has been reported to have transcriptor binding sites 
for nuclear factor-1-like factor (NF1-like factor), specificity protein-1/specificity 
protein-3 (Sp-1/Sp-3), CCAAT enhancer binding protein beta (C/EBPβ), and GA 
binding protein (GABP) but no androgen or progesteron  response elements (Doyle 
2004). These transcription factor binding sites were found to be highly conserved 
between the mouse, rat and human orthologues of the ADAMTS1 gene. Selective 
deletion of each of these binding sites reduced ADAMTS-1 transcription, indicating that 
basal transcription of ADAMTS-1 was maintained by a combination of activity from 
each of these binding sites (Doyle 2004). Binding sites have also been reported for 
hypoxia-inducible factor-1 (HIF-1) (Hatipoglu 2009). ADAMTS1 gene transcription is 
up-regulated by progesterone in ovarian granulosa cells via interaction of ligand-
activated progesterone receptor (PR) with Sp1/Sp3 and binding of the PR-Sp1/Sp3 
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complex with the Sp1/Sp3 transcription factor binding sites (Doyle 2004), and by 
hypoxia in endothelial cells via binding of HIF-1 to response elements in the promoter 
by a phosphatidylinositol 3-kinase dependent process (Hatipoglu 2009). IL-1β and TNF 
have also been reported to induce ADAMTS1 transcription by mechanisms that are yet 
to be elucidated (Bevitt 2003; Cross 2006; Ng 2006). 
After co-translational cleavage of the signal peptide, the mature ADAMTS-1 protein is 
sequentially cleaved into two active forms (Rodriguez-Manzaneque 2000). The first 
cleavage is mediated by furin and removes the propetide (Longpre 2004), leaving an 
87kDa form with an activated catalytic site. This 87kDa form is secreted from the cell 
and sequestered in the ECM by binding to heparan sulphate proteoglycans (Kuno 1998). 
The 87kDa form is further processed by autolytic cleavage or by MMP-2, -8, and -15 at 
the spacer region to yield a 65kDa catalytic fragment and a 22kDa C-terminal fragment 
containing the two C-terminal thrombospondin (TSP) motifs (Rodriguez-Manzaneque 
2000).  
The catalytic activity of ADAMTS-1 is evident by the number of substrates that have 
been identified. These include the proteoglycans aggrecan (Kuno 2000; Rodriguez-
Manzaneque 2002; Vankemmelbeke 2003), versican (Sandy 2001; Russell 2003) and 
syndecan (Rodriguez-Manzaneque 2009). ADAMTS-1 has also been shown to cleave 
thrombospondin-1 and -2 (Lee 2006), tissue factor pathway inhibitor-2 (Torres-Collado 
2006) and gelatin (Lind, T. 2006). Type I collagen degradation is enhanced by 
ADAMTS-1 expression (Rehn 2007), but it is not clear whether ADAMTS-1 cleaves 
type-I collagen directly.  
Studies of ADAMTS-1 knock-out mice showed a number of defects including 
malformations of the kidneys, adrenal glands, uterus and ovaries with impaired 
ovulation in females (Shindo 2000; Mittaz 2004). These findings suggest altered ECM 
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turnover. However ADAMTS-1 knock-out mice do not exhibit any changes in cartilage 
turnover, possibly because ADAMTS-1 does not play a major role in the pathogenesis 
of arthritis or due to redundancy of function between the ADAMTS proteoglycanases 
(Little 2005). 
ADAMTS-1 has multiple functions as a result of its multi-domain structure.  
In addition to its proteolytic activity which is mediated by the catalytic domain, the C-
terminal TSP motifs are responsible for anti-angiogenic properties (Iruela-Arispe 2003). 
ADAMTS-1 inhibits bFGF and VEGF induced angiogenesis (Vazquez 1999). VEGF is 
sequestered by binding to the TSP domains of ADAMTS-1 and is thus prevented from 
activating VEGFR2 on endothelial cells (Luque 2003). In addition, cleavage of TSP-1 
by ADAMTS-1 releases anti-angiogenic fragments (Lee 2006). ADAMTS-1 is down-
regulated in proliferating endothelial cells compared to tubular cells (Glienke 2000). 
Two separate studies (Kuno 2004; Liu 2006) have demonstrated that while the full-
length ADAMTS-1 had pro-metastatic activity, the TSP-spacer-TSP segment of the C-
terminal region inhibited angiogenesis and the establi hment of metastases. This shows 
that the degree of processing of ADAMTS-1 determines the predominant effect of 
ADAMTS-1 in the tumour micro-environment (TME). Paradoxically ADAMTS-1 has 
also been shown have pro-angiogenic effects. ADAMTS-1 was up-regulated in 
endothelial cells during angiogenesis and ADAMTS-1 knock-down decreased 
endothelial cell invasion (Su 2008). The up-regulation of ADAMTS-1 was temporal and 
peaked at 4-10 hrs after seeding on a 3D matrix. This possibly indicates that ADAMTS-
1 is required for ECM degradation in the early stages of capillary sprouting. 
The biological functions of ADAMTS-15 have not been reported. By sequence 
homology, ADAMTS-15 is expected to have similar activity to ADAMTS-1 (Cal 2002). 
Low tumour expression is associated with poor prognosis in breast cancer patients 
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(Porter 2006). ADAMTS-15 expression is also reported to have anti-tumour effects in 
colorectal cancer (Viloria 2009). The actual role of ADAMTS-15 is not clear, but the 
multiple domains could be playing different roles, a  is the case with ADAMTS-1, in 
which the proteolytic domain is responsible for ECM-degrading activity, while the C-
terminal domains are responsible for anti-angiogenic activity. The roles played by these 
proteinases in prostate cancer development and progression are yet to be identified. 
Catalytic activity of ADAMTS-1 is inhibited by tissue inhibitor of metalloproteinases 
(Rodriguez-Manzaneque 2002). Tissue inhibitor of metalloproteinases-3 (TIMP-3) is 
the most important tissue inhibitor of the ADAMTSs in tissues, although TIMP-2 has 
less potent inhibitory activity (Hashimoto 2001; Rodriguez-Manzaneque 2002). TIMPs 
are 25-31kDa proteins with a wedge-shaped crystal structure (Fernandez-Catalan 1998). 
They possess an approximately 125a.a. N-terminal domain and a smaller 65 a.a. C-
terminal domain (Williamson 1990).  TIMPs inhibit metalloproteinases by tight binding 
to the catalytic pocket, preventing binding of the substrate to the catalytic site (Brew 
2000). TIMP-3, like ADAMTS-1 is secreted into the ECM where it is sequestered by 
heparan sulphate proteoglycans (Yu 2000). Mutations in TIMP3 gene lead to a 
condition called Sorsby fundus dystrophy characterised by accumulation of ECM 
components in the retina (Weber 1994). Aggrecanase activity of ADAMTS-1 is also 
inhibited by catechin gallate esters, which are constituents of green tea. 
Epigallocatechin gallate and epicatachin gallate sel ctively inhibit aggrecanase activity 
of ADAMTS-1, -4 and -5 (Vankemmelbeke 2003). Oral intake of green tea extract 
inhibited collagen-induced arthritis in mice (Haqqi 1999). The exact mechanism of 




1.8 Inflammation in Prostate Cancer 
1.8.1 Immune Cells and Cytokines 
Immune cells are present in normal prostate epithelial and stromal tissue (McClinton 
1990; Elsasser-Beile 2000; Bostwick 2003). These are mostly T-cells, and are more 
numerous in the stromal component of the gland. The epithelial T-cells are 
predominantly CD8+ cytotoxic cells and the stromal T-cells are predominantly CD4+ 
helper cells (Bostwick 2003). Lymphocytes from prostate cancer tumours have been 
shown to express higher levels of IL-10 and IFN-γ than circulating lymphocytes of the 
same patient (Elsasser-Beile 2000). The pro-inflammtory enzyme, cyclooxygenase-2 
(COX-2), is over-expressed in prostate cancer tissue and correlates with areas 
inflammation and angiogenesis (Wang, W. 2005). Prostate cancer cells secrete a number 
of cytokines into the TME.  TNF, IL-1 and IL-6 are secreted in response to 
inflammation (Wong 2009). IL-6 promotes cell proliferation, and is up-regulated by 
androgen (Okamoto 1997; Lee, S.O. 2003). Constitutive expression of IL-8 by prostate 
cancer cells stimulates cell proliferation (Moore 1999). IL-4 has been shown to activate 
the AR in a ligand-independent manner, and potentiates the growth stimulatory effect of 
DHT (Lee, S.O. 2003; Lee 2008). 
Macrophages, lymphocytes and neutrophils infiltrate tumour sites in response to 
chemokines and cytokines produced by tumour cells (Coussens and Werb 2002; Pollard 
2004), and the hypoxic environment within the tumour (Lewis 2006). TAMs release 
numerous cytokines into the TME as part of the inflammatory reaction to the presence 
of the tumour (Dranoff 2004). TAMs are thought to favour tumour progression as a 
result of the release of pro-tumour and angiogenic cytokines and proteinases including 
TNF and MMPs (Lin and Pollard 2004; Pollard 2004).  Clinical studies have reported 
that patients with advanced prostate cancer have elevat d serum levels of TNF, IL-4, 
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IL-6 and IL-10 (Twillie 1995; Adler 1999; Drachenberg 1999; Wise 2000; Michalaki 
2004). TNF is also over-expressed in prostatic fluid of prostate cancer patients (Fujita 
2008). 
TNF is thought to induce cachexia in cancer patients (Tracey 1992). Prostate cancer 
patients with elevated serum TNF have been shown to have lower haemoglobin and 
serum albumin levels, poorer performance status and poorer prognosis compared to 
patients with low or absent serum TNF (Nakashima 1998). The role of TNF in prostate 
cancer progression therefore can not be ignored. 
1.8.2 TNF Receptor Signalling 
TNF is a multifunctional cytokine that plays a role in systemic inflammatory response, 
apoptosis, angiogenesis, lipid metabolism and insuli  resistance (Beutler 1986; 
Locksley 2001; Balkwill 2006; Bastard 2006). TNF is produced as a 26kDa membrane-
bound protein and is cleaved into a 17kDa soluble form by ADAM-17 (TNF-alpha 
converting enzyme, TACE) (Black 1997). TNF acts viabinding toTNF receptor 1 
(TNFR1) and TNF receptor 2 (TNFR2). TNFR1 is present on cells in most tissue sites, 
while TNFR2 is predominantly expressed in leucocytes. TNF signal transduction is a 
complex process involving many proteins (Camussi 1991; Englaro 1999; Baud 2001; 
He 2002; Kawasaki 2002). Activation of TNFR1 by TNF leads to intracellular 
trimerisation of the receptor and association with TNF receptor-associated death domain 
(TRADD). TRADD activates the fas-associated death domain (FADD), RIP-associated 
ICH-1/CED-3-homologous protein with a death domain (RAIDD), MAPK-activating 
death domain (MADD) and receptor-interacting protein (RIP), leading to activation of 
caspase-8 and the initiation of the apoptosis cascade.   Activation of TNFR2 leads to the 
association of TNF receptor-associated factor 2 (TRAF2) with TRADD, which then 
forms a complex with MADD and RIP. The TRAF2-MADD-RIP complex associates 
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with NFκB-inducing kinase (NIK) and phosphorylates IκK, leading to the translocation 
of NFκB into the nucleus. The TNFR1-TRADD-TRAF2-MADD-RIP complex also 
activates MAPK which in turn activates AP1. The NFκB and AP1 transcription factors 
are responsible for the regulating numerous growth and stress-related genes, including 
proteinases involved in ECM turnover. 
 
1.9 ADAMTS Expression in Inflammatory Disease 
Some cachexia-inducing tumours are known to express high levels of ADAMTS-1 
(Kuno 1997). ADAMTS-1 is highly expressed in inflammed tissue (Kuno 1997). 
ADAMTS-1 and -4 are up-regulated in inflammed atheromatous plaques (Sandy 2001; 
Jonsson-Rylander 2005). ADAMTS-5   aggrecanase activity is essential for disease 
progression in murine models of arthritis (Glasson 2005; Stanton 2005). Regulation of 
ADAMTS-1, -4, -5, -6 and -9 expression by pro-inflammatory cytokines has also been 
reported (Bevitt 2003; Norata 2004; Demircan 2005; Ng 2006). These studies indicate 
that ADAMTSs may be playing an active role at sites of inflammation. Dysregulation of 
proteinases by TNF and other cytokines could alter th  homeostatic balance between 
proteinases and their natural inhibitors in the TME. 
 
1.10 Aims and Hypotheses 
ADAMTS-1, -9 and -15 mRNA expression has been detect d in prostate cancer cells 
(Cross 2005). ADAMTS-1 and -15 were the most abundantly expressed, and 
ADAMTS-15 was the only member of the group that was expressed in all the cancer 
and stromal cells analysed. ADAMTS-1 over-expression has been reported in metastatic 
CRPC tumours compared with primary tumours (Tamura 2007), suggesting a role for 
ADAMTS-1 progression of prostate cancer.   
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The predominant role of ADAMTS-1 in the literature suggests that it plays an active 
role in remodelling of the ECM. Degradation of the ECM could result in the release of 
growth factors sequestered in the ECM, favouring cancer cell proliferation. Break-down 
of the natural tissue barriers constituted by the ECM and basement membranes could 
also allow local spread and metastasis of cancer cells.  There is little information in the 
literature on the function of ADAMTS-15. High tumour expression of ADAMTS-15 in 
breast cancer patients correlates with better prognosis, which suggests that ADAMTS-
15 could have anti-tumour activity. The role of AR signalling in the development and 
progression of prostate cancer has been discussed in Section 1.4.1, and the local and 
systemic inflammatory response in cancer in Section 1.8. 
 
1.10.1 Aims 
The aims of this study were three-fold. Firstly, to determine whether prostate cancer and 
stromal cells were proteolytically active. Secondly, to evaluate the effect of two 
signalling pathways that affect prostate cancer development and progression, androgen 
signalling and inflammation, on the expression of ADAMTS-1, -15 and TIMP-3 in 
prostate cancer cells. Thirdly, to analyse the functio al roles of ADAMTS-1 and -15 in 
prostate cancer cell proliferation, migration and ivasion.  
 
1.10.2 Hypotheses 
The following hypotheses were tested: 
1. Prostate cancer and stromal cells are proteolytica ly active. 
2. The expression of ADAMTS-1, -15 and TIMP-3 is regulated by androgen in 
androgen-sensitive LNCaP cells. 
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3. The expression of ADAMTS-1, -15 and TIMP-3 is regulated by TNF in PC3, LNCaP 
and prostatic stromal cells. 
 
4. Knock-down of ADAMTS-1 expression decreases the proliferation, migration and 
invasive potential of PC3 cells. 
 
5. Knock-down of ADAMTS-15 expression increases the proliferation, migration and 











































CHAPTER 2:  
MATERIALS AND METHODS 
 
2.1 Cell Lines and Culture 
The PC3 and LNCaP cell lines used in this study were obtained from ATCC. PC3 cells 
were originally isolated from bone metastases in a patient with prostate cancer and are 
not androgen responsive due to non-expression of the AR (Kaighn 1979). LNCaP cells 
were originally isolated from lymph node metastases (Horoszewicz 1983). LNCaP cells 
express the AR and are androgen responsive (Horoszewicz 1983). C4-2b4 and PCAF 
(prostate carcinoma associated fibroblasts) cells were a gift from Dr Colby Eaton at the 
University of Sheffield. The C4-2b4 cell line is a derivative of LNCaP cells, obtained 
by repeated passage in castrated male mice (Thalmann 2000), and PCAF cells were 
isolated from peri-tumoural prostatic stroma (Olumi 1999). BPH45 cells are prostate 
fibroblasts that were generated in our laboratory by Dr. Colby Eaton (Klingler 1999). 
The breast cancer cell line MDA-G8, is a derivative of the MDA MB-436 breast cancer 
cell line (Cailleau 1978; Ottewell 2008) and was a gift from Dr. Ingunn Holen. The 
U373 astrocytoma cell line (Ponten 1968) was a gift from Prof. Nicola Woodroofe. The 
PNT1 and PNT2 non-tumourigenic prostatic epithelial cell lines (Berthon 1995) were 
not used in this study. They were immortalised using the Simian Virus-40 (SV40) viral 
vector which up-regulates ADAMTS-1 expression (Freimann 2005). As a result of this, 
the PNT1 and PNT2 cell lines were not considered to be true ‘normal’ prostatic 
epithelial cell lines for the purpose of this study. Prostatic stromal cells (BPH45), 
prostate carcinoma associated fibroblasts (PCAF), the prostate carcinoma cell lines 
(PC3, LNCaP, and C4-2b4), astrocytoma cell line (U373) and the breast carcinoma cell 
line (MDA-G8) were routinely cultured in  DMEM (Gibco, Invitrogen) supplemented 
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with 10% (v/v) FCS (Invitrogen), 100units/ml penicillin (Invitrogen), 100µg/ml 
streptomycin (Invitrogen) and 0.25µg/ml amphotericin B (Invitrogen), unless otherwise 
stated. FCS is added to cell culture medium as a supplement to serve as a source of 
protein, growth factors, hormones, lipids and minerals (Freshney 2005). The cells were 
grown in a humidified incubator at 37°C in a 5% CO2 atmosphere unless stated 
otherwise. Plated cells were detached when required by aspirating and discarding spent 
medium, gently washing twice with PBS and adding 1 X trypsin-EDTA solution (0.25% 
(w/v) trypsin, 0.1% EDTA, pH 7.2-8.0) (Sigma). Enough trypsin-EDTA was added to 
completely cover the cell layer (2ml for a T75 tissue culture flask) for 5 minutes at 
ambient temperature. After cell detachment, an equivalent amount of complete medium 
was added to inactivate the trypsin and the cells were used as required.   
  
2.2 RNA Extraction 
For RNA extraction, cells were lysed with Tri Reagent (Sigma), based on the method 
described by Chomczynski (Chomczynski 1987). The cell lysates were stored at -80°C 
until ready for RNA extraction. The protocol provided by Sigma with the Tri Reagent 
was used for RNA extraction. Ninety-nine percent Chloroform (Sigma) was added to 
the cell lysate at 0.2mls/ml Tri reagent used. The mixture was agitated in a tube by hand 
and then left to stand at ambient temperature for 3 minutes. The tubes were centrifuged 
at 12,000 x g for 15 minutes at 4°C. The aqueous phase at the top was carefully 
removed with a pipette and placed in a fresh tube. Ninety-nine Isopropanol (Sigma) was 
added at a volume of 0.5ml/ml Tri reagent used at the s art and the tubes were incubated 
at ambient temperature for 10 minutes. The tubes were c ntrifuged at 12,000 x g for 10 
minutes at 4°C. The supernatant was removed with a pipette, leaving the RNA pellet at 
the bottom of the tube. The RNA pellet in the tube was washed by adding 75% (v/v) 
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Ethanol (Sigma) at a volume of 1ml/ml of Tri reagent used at the start. The tube was 
vortexed and centrifuged at 7,500 x g for 5 minutes at 4°C. The ethanol wash solution 
was removed with a pipette leaving the RNA pellet at the bottom of the tube. The RNA 
pellet was air-dried and then re-dissolved in 10-20 µl of Diethyl pryrocarbonate (DEPC) 
(Ambion, Applied Biosystems) treated water. The RNA solution was stored at -80°C 
until ready for cDNA synthesis. RNA purity was determined using the A260/A280 ratio, 
with an acceptable ratio being > 1.8 (Glasel 1995). 
 
2.3 cDNA Synthesis 
cDNA was synthesised from previously extracted RNA using Superscript II –Reverse 
Transcriptase (Invitrogen) according to the supplier’s protocol. Twenty microlitres 
reactions were set up in 200µl thin-walled PCR tubes. Each reaction tube contained 4µl 
of 5x 1st strand buffer (250mM Tris-HCl, 375mM KCl, 15mM MgCl2, pH 8.3), 2µl of 
0.1M dithiothreital (DTT) solution, 0.5µl of 10mM deoxyribonucleotide triphosphate 
(dNTP) (Bioline), 0.5µl of 50µM Random Hexamers (Invitrogen) and 0.5µl (20 units) 
of RNase Inhibitor (Invitrogen), 10.5µl of DEPC-treat d water, 1µl (200 units) of 
reverse transcriptase and 1µl of the RNA extract. Negative controls contained all the 
reaction components except reverse transcriptase. Reactions were run on a Gene Amp 
PCR System 9700 (Applied Biosystems). The thermal cyc er was set at 25°C for 2 
minutes, 42°C for 50 minutes, 70°C for 15 minutes and then cooled to 4°C. cDNA was 
stored at -20°C until ready for use in real-time RT-PCR reactions.  
 
2.4 Real-time RT-PCR 
Relative quantification of gene expression was undertak n by realtime RT-PCR 
according to the principles and protocol described in the Applied Biosystems User 
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Bulletin #2: ABIPrism 770 Sequence Detection System, 2001. Real-time RT-PCR was 
run in 10µl reactions in duplicate using 384-well plates on the ABI Prism 7900HT 
sequence detector using SDS 2.1 software (Applied Biosystems). For reactions using 
SYBR-Green, each well contained 5µl of SYBR-Green master mix (Applied 
Biosystems) 1µl each of forward and reverse primers (Table 2.1) 1µl of DEPC-treated 
water and 2µl of cDNA to be analysed. For reactions using Taqman assays, 5µl of 
Taqman master mix (Applied Biosystems) 0.5µl of Taqm n gene expression assay 
(Table 2.2), 2.5µl of DEPC-treated water and 2µl of cDNA for analysis. Sequence 
detection was either with SYBR-Green or Taqman prime -probes with a FAM reporter 
and a non-fluorescent quencher. The thermal cycle was 95°C for 5 minutes, then 40 
cycles of 95°C for 15s and 60°C for 1 minute. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) or RNA polymerase II (RNAP) was used as the endogenous 
control to normalise between samples (Janssens 2004; Radonic 2004). Relative 
expression levels were determined using the 2-∆∆CT method (Livak 2001), where ∆∆CT 
=  


































R 1034 AAGCATGGTTTCCACATAGCG 
 
90 b.p. 
























F 7 GCTCCTCCTGTTCGACAGTCA GAPDH/ 
 





Table 2.1: Gene, primer and amplicon data for primer products supplied by Applied 












Hs00199608_m1 1151 FAM Non-Fluorescent 68 b.p. 
ADAMTS-15/ 
NM_139055 
Hs00373520_m1 1512 FAM Non-Fluorescent 60 b.p. 
ADAMTS-20/ 
NM_175851 
Hs00228033_m1 2712 FAM Non-Fluorescent 107 b.p. 
TIMP-3/ 
NM_000362 
Hs00165949_m1 1280 FAM Non-Fluorescent 59 b.p. 
PSA/ 
NM_001030047 
Hs00426859_g1 170 FAM Non-Fluorescent 153 b.p. 
GAPDH/ 
NM_002046 
Hs99999905_m1 71 FAM Non-Fluorescent 122 b.p. 
RNAP II/ 
NM_000937.3 
Hs00172187_m1 481 FAM Non-Fluorescent 61 b.p. 
 
Table 2.2: Gene, assay, probe, reporter and amplicon data for Taqman primer products 






2.5 Protein Extraction from Cultured Cells 
2.5.1 Extraction using Mammalian Cell Lysis Kit (RIPA Buffer) 
The reagents in the Mammalian cell lysis kit (Sigma) re similar to the 
radioimmunoprecipitation assay (RIPA) buffer (Escribano 1987). Reagents in the kit 
were stored at -20°C and brought to 4°C prior to use. To make up 1ml of lysis buffer 
200µl each of 5x Tris-EDTA buffer, 5x NaCl, 5x SDS, 5x Deoxycholic acid and 5x 
Igepal CA-630 (Nonyl phenoxylpolyethoxylethanol) were mixed with 10µl proteinase 
inhibitor cocktail containing 4-(2-aminoethy)benzenesulfonyl fluoride (AEBSF), 
pepstatin A, bestatin, leupeptin, aprotinin, and trans-epoxysuccinyl-L-leucyl-amido(4-
guanido)-butane (E-64). Cell lysis was performed according to the supplier’s protocol. 
Medium was removed from the cells to be lysed the cells were gently washed with PBS. 
The lysis buffer was applied to the cells (1ml/106 cells) and placed on a rotating 
platform in a cold room at 4°C for 1 hour. A cell scraper was used to detach any cells 
still attached. The cell lysate was triturated with a 1ml pipette to aid cell membrane 
disruption. The lysate was centrifuged at 12,000 x g for 10 minutes at 4°C. The 
supernatant was removed with a pipette and saved while the pellet containing cell debris 
was discarded. The protein solution was stored at -40°C until ready for protein 
quantification. 
2.5.2 Extraction using Triton X-100 
The non-ionic detergent, Triton X-100 (Sigma), (Le Maire 1983) was diluted to 0.1% 
(v/v) in TBS and stored at 4°C. Prior to use, 10µl of proteinase inhibitor cocktail 
described above was added per 1ml of 0.1% (v/v) Triton. Cell lysis was carried out as 




2.6 Protein Quantification 
Protein quantification for the cell lysate solutions was done using the Bicinchonic acid 
(BCA) method (Smith 1985) with the Micro BCA assay kit (Pierce, Perbio). The 
protocol provided with the product was followed. Dilutions of bovine serum albumin 
(BSA) of known concentrations were used as standards. The micro-plate procedure was 
used. 150µl of standard and unknown samples were pipetted into a 96-well polystyrene 
plate in duplicate. BCA working reagent was prepared by mixing reagents MA, MB and 
MC in a ratio of 25:24:1 ie 25 parts MA + 24 parts MB + 1 part MC. 150µl of working 
reagent was added to each standard and unknown sample. The samples were incubated 
at 37°C for 1 hour and then absorbance was read at 562 nm on a Spectramax M5e plate 
reader (Molecular Devices) running on Softmax Pro version 5.2 software (Molecular 
Devices). A standard curve was generated and the concentration of the unknown 
samples was plotted from the curve. 
 
2.7 Immunoprecipitation using Protein A-Agarose  
Immunoprecipitation using protein A entails incubating a solution containing a protein 
of interest with an antibody raised against the protein of interest and precipitating with 
agarose beads covalently linked to protein A. Protein A binds strongly to rabbit 
immunoglobulin G (Lubahn) antibodies (Langone 1982; Lindmark 1983). Centrifuging 
separates the beads which have been bound to the protein of interest via the antibody 
(Figure 2.1). The protein of interest can then be rel ased by heat, which denatures the 
proteins and reverses the non-covalent protein-antibody interactions, but not the 
agarose-protein A covalent bond. The protocol for immunoprecipitation was obtained 
from the Technical Appendix Section of the Sigma 2007 Antibody Catalogue. Protein 
A-agarose beads (Sigma) were rehydrated for 1 hour fr m the lyophilised form with 
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distilled water. Two millilitres of the rehydrated beads were washed five times in 50ml 
of TBS then re-suspended in 4ml of TBS to give a 50% (v/v) slurry. The slurry was 
stored at 4°C. Anti-ADAMTS-15 antibody (Abcam ab28516, See Section 2.10.2) of 
known concentration was added to the specified amount f cell lysate or medium and 
incubated for 1 hour at 4°C on a rotating platform to provide gentle mixing. Thirty 
microlitres of the 50% (v/v) bead slurry was added to the tube and incubated for another 
hour. Immunoprecipitated complexes were collected by centrifuging at 3000 x g for 2 
minutes at 4°C. The supernatant was discarded and the pellet was washed by re-
suspending in ice-cold TBS and centrifuging at 3,000 x g for 2 minutes at 4°C. The 
wash was repeated three times. After the last wash,  syringe with a 26-polystyrene 
needle was used to completely remove all the wash solution. Thirty microlitres of 
Laemmli sample buffer (Section 2.9.3) was added to the beads and the samples heated 
to 95°C. After heating, the samples were centrifuged at 12,000 x g for 30 seconds at 
ambient temperature. The supernatant was used for SDS polyacrylamide gel 
electrophoresis (SDS-PAGE).   
 
Figure 2.1:  Performing immunoprecipitation using protein A-agarose beads. Protein A 
is covalently bonded to the agarose beads, and protein A has a strong affinity for rabbit 
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IgG. After incubation, the protein of interest is bound to the agarose beads via the 
protein A/antibody complex, while other proteins remain in solution. Centrifuging the 
mixture will result in the protein of interest being pulled down. The protein is released 
from the complex by heating. 
 
2.8 Precipitation using Heparin-Agarose 
Heparin-agarose beads are agarose beads with heparin molecules covalently bonded. 
Proteins with binding affinity for heparin can be sparated from a milieu of proteins by 
incubating with heparin-agarose beads or by running the protein solution through a 
heparin-agarose column (Sanz 1993; Ticha 1994; Kraus 2001; Manaskova 2002). 
ADAMTSs are known to bind to heparan sulphate in the ECM (Kuno 1998; Gao 2004). 
Heparin-agarose beads (Sigma) were used to pull out ADAMTS-1 and -15 from cell 
lysates. The protocol for heparin-agarose precipitat on was obtained from the Technical 
Appendix Section of the Sigma 2007 Antibody Catalogue for immunoprecipitation with 
a few modifications. Heparin-agarose beads (Sigma) were supplied in a suspension of 
0.5M sodium chloride (NaCl) containing 0.02% thimerosal as a preservative. Two 
millilitres of beads were washed five times in 50ml of TBS then re-suspended in 4ml of 
TBS to give a 50% (v/v) bead slurry. The slurry was stored at 4°C.  30µl of the 50% 
(v/v) bead slurry was added to either the cell lysate (containing both the cellular and 
ECM components), or 3-day conditioned medium and incubated for 1 hour at 4°C on 
rotating platform to provide gentle mixing. Heparin-agarose beads with bound protein 
were collected by centrifuging at 3000 x g for 2 minutes at 4°C. The supernatant was 
discarded and the pellet was washed by re-suspending in ce-cold TBS and centrifuging 
at 3,000 x g for 2 minutes at 4°C. The wash was repeated three tim s. After the last 
wash, a syringe with a 26-guage needle was used to completely remove all the wash 
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solution. Thirty microlitres of Laemmli sample buffer was added to the beads and the 
samples were heated to 95°C. After heating, the samples were centrifuged at 12,000 x g 
for 30s at ambient temperature. The supernatant was used for SDS polyacrylamide gel 
electrophoresis (SDS-PAGE).  
  
 
Figure 2.2: Performing precipitation using heparin-agarose beads. Heparin is 
covalently bound to the agarose beads. Proteins with affinity for heparin will bind to the 
agarose beads via heparin during incubation, while non heparin-binding proteins 
remain in solution. After incubation, the heparin-bound proteins are pulled down with 
the heparin-agarose beads by centrifugation. The prci itated proteins are released 
from the beads by heating. 
 
2.9 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins according to their molecular weight (Raymond 1959; Chrambach 
1971). The steps were as follows 
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2.9.1 Resolving Gel Preparation 
SDS-PAGE was undertaken using 10% (v/v) polyacrylamide gels. To make the 
resolving gels, 2.5mls of 40% (w/v) acrylamide (Bio-Rad), 2.5mls of resolving gel 
buffer (1.5M Tris HCl, pH 8.8) (Bio-Rad), 4.83mls of distilled water, 0.1mls of 10% 
(w/v) SDS (Bio-Rad), 0.05mls of 10% (w/v) ammonium persulphate (APS) (Bio-Rad), 
and 6µl of tetramethylethylenediamine (TEMED) (Bio-Rad) were mixed in a 50ml tube. 
The mixture was quickly loaded into a glass spacer ssembly (Bio-Rad). This volume of 
resolving gel mix was enough to make two gels. Five hundred microlitres of 99.9% 
butan-2-ol (Sigma) was gently added into the glass spacer above the mixture to flatten 
the meniscus and prevent oxygen from the air from inhibiting the free radical-mediated 
polymerisation reaction. The mixture was left to polymerise at ambient temperature. 
When the resolving gels were polymerised, the glass spacer assembly was tilted 
sideways to pour out the butan-2-ol. The meniscus wa ashed twice with distilled 
water and carefully blotted dry with filter paper. 
2.9.2 Stacking Gel Preparation 
To make the stacking gel, 0.36mls of 40% (w/v) acrylamide, 1.2mls of stacking gel 
buffer (0.5M Tris HCl, pH 6.8) (Bio-Rad), 3.14mls of distilled water, 48µ of 10% (w/v) 
SDS, 0.048mls of 10% (w/v) APS and 0.0048mls of TEMED were mixed in a 15ml 
tube. The mixture was quickly loaded into the glass spacer assembly above the solid 
resolving gel. This volume of stacking gel mix was enough to make two gels. A ten-
well gel comb was inserted into the stacking gel mix in the glass plate assembly and 
then the gel was left to polymerise. 
2.9.3 Sample Preparation 
Protein concentration in the samples was determined as described in Section 2.6. 
Optimal loading volume for the wells in the stacking gel was 10-15µl. Therefore, after 
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the desired protein quantity to be loaded was decided, protein samples were diluted in 
1% (v/v) SDS to make up a volume of 10µl if necessary. Sample preparation was done 
according to the method described by Laemmli (Laemmli 1970) with minor 
modifications. Five microlitres of sample buffer (0.125M tris base, 10% (w/v) SDS, 
20% (v/v) glycerol, 0.01% (w/v) bromophenol blue, 2.5% (w/v) dithiothrietol) was 
added to the sample if reducing conditions were requi d. If non-reducing conditions 
were required, sample buffer without the reducing agent, dithiothreitol (DTT) (Cleland 
1964) was used. The samples were heated at 95°C for 5 minutes in 500µl tubes. A hole 
was made at the top of each tube with a needle to prevent pressure build-up within the 
tube. If the sample volume was more than 20µl, the cap of the tube was left open to 
allow evaporation down to the required volume. After h ating, the samples were cooled 
to ambient temperature.  
2.9.4 Electrophoresis 
The glass spacer plate was assembled into a tank (Bio-Rad). Fifty microlitres of 
electrophoresis buffer (25mM Tris base, 0.192M glycine, 0.1% (w/v) SDS, pH 8.3) was 
used to test for any leakage from the inner chamber. The inner chamber was then filled 
with electrophoresis buffer. The comb was carefully removed and protein samples were 
loaded into the wells of the stacking gel using a long-tipped sample loading pipette tip 
(Alpha Laboratories) in the desired lane order. All-Blue or Dual-Colour protein standard 
ladders (Bio-Rad) were loaded in one of the wells to make it possible to estimate protein 
size from the bands produced from electrophoresis. The outer chamber was half-filled 
with electrophoresis buffer; the tank was covered an then connected to a Bio-Rad 
Power-Pac 300 current source. Electrophoresis was done at 200V until the bromophenol 
blue reached the bottom of the gel. Overheating of the gel was prevented by placing the 
electrophoresis tank on ice.  
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2.10 Western-Blotting 
Western blotting was undertaken as described by Towbin et al (Towbin 1979) with 
minor modifications. The aim of the western blot technique is to transfer proteins that 
were separated on the electrophoresis gel onto a solid membrane in order to allow 
immuno-probing. 
2.10.1 Protein Transfer 
After electrophoresis was completed, a blotting sandwich was assembled in a blotting 
cassette. Polyvinylidene difluoride (PVDF) membrane (Immobilon, Millipore) was 
soaked in methanol for 5 minutes and then in transfer buffer (60mM tris base, 40mM 
CAPS, 15% (v/v) methanol, pH 11).  Scourer pads, cellulose blotting paper (Sigma) and 
the gel were also soaked in transfer buffer for 10 minutes. The blotting sandwich was 
assembled in the cassette, clear side down in the following order: scourer pad, cellulose 
blotting paper (Sigma), PVDF membrane, gel, blotting paper, and scourer pad. The 
cassettes were placed in a vertical tank with the clear side facing the anode. The tank 
was filled with ice-cold sample buffer and the tank was placed on ice. The proteins were 
transferred from the gel to the PVDF membrane by electro-blotting at a constant current 
of 400mA for 30 minutes (Matsudaira 1987). 
2.10.2 Immuno-probing 
After electro-blot transfer of the proteins to the PVDF membrane, the membrane was 
blocked for 1 hour in blocking buffer (1% (w/v) casein, 0.05% (v/v) Tween-20, 20mM 
Tris, 0.5M NaCl, pH 7.4) (Bio-Rad). Primary immuno-detection of ADAMTS-1 was 
done with either rabbit polyclonal C-terminal antibody (Abcam, ab39194) or mouse 
monoclonal proteolytic domain antibody (R&D Systems, MAB2197). Dilutions used 
were 1:1000 (1µg/ml) for the polyclonal antibody, or 1:500 (1µg/ml) for the 
monoclonal antibody. Recombinant human ADAMTS-1 (R&D Systems, 2197-AD) was 
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used as a positive control for the MAB2197 antibody in western blot experiments. This 
recombinant protein consisted of amino acids Arg258 – Phe849 which contains the 
proteolytic and disintegrin domains, the first thrombospondin motif, the cyteine-rich 
domain and spacer region, with a predicted mass of 66kDa on western blotting.  
Primary immunodetection of ADAMTS-15 was done with either rabbit polyclonal 
cysteine-rich domain antibody (Abcam, ab28516) or rabbit polyclonal propeptide 
antibody (Abcam, ab45047). The antibodies were used in a dilution of 1:1000 (1µg/ml) 
and 1:5,000 (200ng/ml) respectively according to the supplier’s recommendation for 
western blotting. The cysteine-rich ADAMTS-15 antibody was raised against a peptide 
sequence 'HSTNRLTLAVAW', corresponding to His592 – Trp603 in the cysteine-rich 
domain. This peptide was custom-synthesised (Bachem), with an approximate mass of 
1.3kDa. The peptide was used in a 1000-molar excess to pre-adsorb the antibody as a 
negative control. The pre-adsorption protocol was obtained from the Millipore 
Technical Library (www.millipore.com/userguides/tech1/mcproto016). The peptide was 
supplied in powder form and was dissolved to a stock concentration of 769nM in 
blocking buffer. The ab28516 antibody was supplied in a concentration of 1mg/ml 
(6.67nM), and was diluted 1:1000 in blocking buffer as recommended by the supplier’s 
protocol for western blotting, giving a final working molar concentration of 6.67pM. 
Antibody-peptide solutions were mixed and incubated for 1 hour at 37ºC before use in 
primary incubation of membranes. GAPDH was detected with a rabbit polyclonal anti-
GAPDH antibody (Abcam ab9485) in a dilution of 1:1000 (1µg/ml).  
Secondary immuno-detection was done with swine anti-r bbit horseradish peroxidise 
(HRP) conjugated antibody (P0399) (Dako) for the rabbit primary antibodies, or goat 
anti-mouse HRP-conjugated antibody (P0447) (Dako) for the mouse primary antibodies 
in a dilution of 1:3000 (113ng/ml). The stock antibodies were diluted in blocking buffer. 
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The PVDF membrane was incubated in the primary antibody solution for 12 hours at 
4°C. After primary incubation, the membrane was washed three times for 5 minutes 
each in wash buffer (0.05% (v/v) Tween-20 in TBS) and incubated in secondary 
antibody for 1 hour at ambient temperature. 
 
2.11 Horseradish Peroxidase (HRP) Detection 
The PVDF membranes were washed three times for 5 minutes each in wash buffer after 
the secondary antibody incubation to remove unbound secondary antibody. HRP 
detection was done with ECL Plus western blotting detection kit (Amersham, GE 
Healthcare). The chemilumminescent substrate, Lumigen PS-3 Acridan is cleaved by 
horseradish peroxidise and acridinium esters react with peroxide in the reagent to emit 
light as a by-product, which can be detected on x-ray film.  Detection solutions A 
(containing ECL Plus substrate solution with Tris buffer) and B (containing stock 
acridan solution in dioxane and ethanol) were mixed in a ratio of 40:1. Excess wash 
buffer was drained off the membrane and the membrane was placed protein-side-up on 
a flat surface. The protein side of the membrane was covered with detection solution 
and left to incubate for 5 minutes. Excess detection s lution was drained off. The 
membrane was covered in plastic film and placed in an x-ray cassette. Hyperfilm ECL 
(Amersham, GE Healthcare) x-ray film was exposed on the membranes in the cassette 
and developed using developer and fixer solutions (AGFA). 
 
2.12 PVDF Membrane Stripping 
When re-probing of PVDF membranes was required, the membranes were stripped to 
remove bound primary and secondary antibodies from the membrane. This was done by 
incubating the PVDF membranes in TBST brought to pH 2.0 by titrating with HCl. The 
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membranes to be stripped were incubated for 6 hours at 4°C with agitation. After 
incubation, the membrane was washed three times with washing buffer to remove the 
acidic solution. In order to ensure that the primary ntibody from the previous 
experiment had been completely removed, the membranes were then probed with 
secondary antibody and HRP detection was done as describ d above.  
 
2.13 Densitometry 
Bands detected on x-ray films from western blotting experiments were semi-
quantitatively analysed by densitometry when required using a GS 710 Calibrated 
Imaging Densitometer (Bio-Rad) running on Quantity One version 4.5.1 software (Bio-
Rad).  A boundary was drawn around each band for analysis. The adjusted area and 
density (volume) of the band from each treatment sample was compared with the band 
from the control sample, measured as ODmm2, and was defined by the software as the 
sum of the intensities of the pixels (in OD) within a volume boundary multiplied by the 
area of a single pixel (in mm2) minus the background volume. 
 
2.14 Fluorescence Immunocytochemistry 
Fluorescence immunocytochemisty was undertaken following the protocol in the 
Abcam Online Technical Manual (www.abcam.com/technial). Fifty thousand cells 
were plated in each chamber of 4-chamber cell culture chamber slides (BD 
Biosciences). Cells were left to incubate for 48 hours. The medium was washed off with 
TBS and the cells were fixed and permeabilised by adding 200µl of ice-cold acetone 
(Sigma) to the cells in each chamber for 10 minutes at -20°C. The cells were then 
washed three times with TBS and incubated with 1% (w/v) bovine serum albumin 
(BSA) for 1 hour to block non-specific antibody bind g, followed by three washes in 
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TBS for 5 minutes each. The rabbit polyclonal ADAMTS-15 propeptide antibody 
(Abcam, ab45047) was diluted 1:1,000 (1µg/ml) in 1%(w/v) BSA and 500 µl was 
added to each chamber. The cells were incubated for 12 hours at 4°C with gentle 
agitation. The antibody solution was decanted and the cells were washed three times in 
TBS for 5 minutes each. Secondary antibody incubation was done using Alexa Fluor 
594 fluorescent tagged goat anti-rabbit IgG antibody (Molecular Probes, Invitrogen). 
According to the product information sheet, the Alexa Fluor 594 fluorescent dye has an 
excitation maximum of approximately 590nm (orange) and a fluorescence emission 
maximum of approximately 617nm (red). The Alexa Flour 594-tagged secondary 
antibody was supplied at a concentration of 2mg/ml and diluted 1:1000 in 1% (w/v) 
BSA. The cell monolayer was incubated in antibody solution for 1 hour at ambient 
temperature in the dark. The antibody was decanted and the cells were washed in TBS 3 
times in the dark for 5 minutes each. The nuclei of the cells were counter-stained with 
1µg/ml DAPI (4’, 6-diamidino-2-phenylindole) (Sigma) in TBS. DAPI binds to groves 
that lie between the DNA strands in the DNA double-helix (Kapuscinski 1995). DAPI 
has an excitation maximum of approximately 358nm (ultraviolet) and a fluorescence 
emission maximum of 461nm (blue) when bound to double-stranded DNA (Manzini 
1983; Kapuscinski 1995), making it possible to identify cell nuclei. The chambers were 
separated from the slides using the instrument provided by the manufacturer. A drop of 
mounting fluid was used to cover the cells and a glass cover slip placed on top. Images 





2.15 Regulation of ADAMTS and TIMP-3 mRNA Expression by DHT in LNCaP 
Cells 
The androgen-sensitive LNCaP prostate cancer cell lin  was used to test the effects of 
DHT on ADAMTS expression. LNCaP cells were plated into 24-well culture plates at a 
density of 1 x 104 cells/well for RNA extraction, and in 6-well culture plates at 5 x 104 
for protein extraction. Cells were grown for 48 hours in DMEM supplemented with 
10% FCS, 100units/ml penicillin, 100µg/ml streptomycin and 0.25µg/ml amphotericin 
B, at 37°C in a humidified atmosphere of 5% CO2. Medium was changed to serum-free 
DCCM (Biological Industries), supplemented with 2mM L-glutamine, and the cells 
were allowed to acclimatise to the new medium for 48 hours. This change of medium 
was done 48 hours before DHT treatments to minimise the effects of a change of 
medium on the experimental outcome. The medium was then removed and cells were 
treated in fresh DCCM medium for 24 hours with DHT (Sigma), or with flutamide 
(Sigma), a non-steroidal AR antagonist (Peets 1974).  The treatment doses used were 
0.1, 1.0 and 10nM DHT, 1µM flutamide, or 10nM DHT + 1µM flutamide. DHT and 
flutamide were dissolved in 0.1% ethanol. The control arm was treated with 0.001% 
ethanol, as this was the final concentration of ethanol in the treatment arms. For mRNA 
expression analyses, medium was removed after 24 hours and Tri Reagent (Sigma) was 
applied to the wells to lyse the cells. The resulting cell lysate was stored at -80°C 
awaiting RNA extraction. RNA was extracted and cDNA synthesized as previously 
described in Sections 2.2 and 2.3. For protein expression analyses, cells were treated 
with DHT and flutamide for 72 hours in 6-well cell culture plates after which medium 
was removed and the cells gently washed with phosphate buffered saline (PBS). 0.01% 
(v/v) Triton X-100 in Tris-buffered saline (TBS) was mixed at 4oC in a volume ratio of 
100:1 with Proteinase Inhibitor Cocktail (Sigma) as described in Section 2.5.2. Two 
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hundred microlitres of the mixture was applied to each well for 1 hour at 4oC to lyse the 
cells. The lysate was centrifuged at 12,000 x g for 10 minutes at 4oC. The supernatant 
was removed and saved while the pellet containing cell debris was discarded. The 
supernatant was stored at -40oC awaiting protein quantification and western blotting.  
 
2.16 Identification of Putative AREs 
The genomic sequences for ADAMTS1, ADAMTS15, TIMP3, hKLK3 (Human 
Kallikriein 3, PSA) and FOLH1 (Folate Hydrolase 1, PSMA) were obtained from the 
Ensembl genome database, Release 49 (www.ensembl.org) (Birney 2004). The 5’ 
flanking sequence containing the gene regulatory region, the transcription start point 
(TSP) and the gene sequence with intron and exon inf rmation were identified. Using 
an in silico approach with the online nuclear receptor binding site search tool 
NUBIScan version 2.0 (www.nubiscan.unibas.ch) (Podvinec 2002), a matrix was 
created consisting of the following nine ARE half-site  AGAACA, TGTACC, 
TGTACA, TGTTCT, GGTACA, AGTGCT, TGGTCA, AGTTCT and AGTACG. Each 
half site has previously been shown to be a functioal AR binding site (Monge 2006) 
(Table 2.3). 
 
Description ARE Sequence Specificity for 
Androgen Receptor  
ARE Consensus 5’-GGTACAgggTGTTCT-3’ Specific 
PSA ARE I 5’-AGAACAgcaAGTGCT-3’ Specific 
Slp HRE 5’-TGGTCAgccAGTTCT-3’ Specific 
C3 (1) ARE 5’-AGTACGtgaTGTTCT-3 Non-specific 
GRE Consensus  5’-TGTACAggaTGTTCT-3’ Non-specific 
NR3C Consensus ARE 5’-AGAACAnnnTGTACC-3’ Non-specific 
 
Table 2.3: Six HREs that have been experimentally verified and shown to be functional 
AR binding sites). The 6 bp half-sites from these HRE sequences (bold italics) were used 
to generate the matrix used for the in silico searches. 
 101 
 
A search strategy was designed to perform a search fo  putative AREs composed of 
direct repeats (DRs), inverted repeats (Patel), and everted repeats (ERs) of these half-
sites interposed by a non-specific 3 bp sequence, forming a complete 15 bp ARE. A 
threshold score of 0.8 was set to minimize false-positive predictions. This threshold 
setting ensured that only putative AREs with quality corresponding to 80-100% 
similarity with the half-sites in the matrix were dtected. The frequency and position of 
response elements identified in the ADAMTS1 and ADAMTS15 promoters and gene 
sequences which met the search criteria were recordd. For comparison, the promoter 
region and sequence of the KLK3 and FOLH1 genes were also analyzed using the 
same strategy. hKLK3 gene expression is known to be up-regulated by androgen, and 
the promoter region contains the functional ARE (AGAACAgcaAGTGCT) at -170 bp 
from the TSP (Riegman 1991). The expression of the FOLH1 gene is down-regulated 
by androgen (Israeli 1994). 
 
2.17 Regulation of ADAMTS-1, -15 and TIMP-3 mRNA Expression by TNF in 
PC3, LNCaP and Prostate Stromal Cells  
PC3, LNCaP and BPH45 cells were plated in 12-well plates at a density of  
5 x 104 cells/well for PC3 and LNCaP, and 1 x 105 cells/well for the stromal cells. Cells 
were grown to 60% confluence. Medium was changed as above. Cells were treated for 
24 hours with TNF (Biosource) at concentrations of 10pg/ml (0.571pM), 100pg/ml 
(5.71pM) or 10ng/ml (571pM). TNF was dissolved in 0.1% (w/v) bovine serum 
albumin (BSA) in phosphate buffered saline (PBS). The control arm was treated with 
0.0001% (w/v) BSA, as this was the final concentration of BSA in the treatment arms. 
After 24hour of treatment, medium was removed and Tri Reagent (Sigma) was applied 
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to the wells as described in Section 2.2. The resulting cell lysate was stored at -80°C 
awaiting RNA extraction. RNA was extracted and cDNA synthesized as previously 
described (Section 2.3). 
 
2.18 Transfection Protocols 
Silencing of gene expression by RNA interference is widely used in the study of gene 
function and several methods for delivery of siRNA have been described (Sandy 2005). 
Electroporation, calcium phosphate and lipid-based m thods were used in this study.   
2.18.1 Electroporation 
Electroporation was done using the Nucleofector II (Amaxa, Lonza) and electroporation 
Kit-V for PC3 cells and Kit-R for LNCaP cells. Cells to be electroporated were 
trypsinised as described in Section 2.1. Five millilitres of complete medium was used to 
inactivate the trypsin and the cells were counted using an Improved Neubauer 
haemocytometer (Hawksley). 1 x 106 PC3 cells or 2 x 106 LNCaP cells were placed in 
1.5ml tubes corresponding to the number of transfections to be done. The cells were 
centrifuged at 800 x g for 1 minute and the supernatant removed. The cells were re-
suspended in nucleofector solution for 5 minutes. 0.5 – 5µg of DNA or 0.5 – 3µg of 
siRNA was added to each tube and mixed with the cell suspension. The contents of each 
tube were transferred into separate Amaxa cuvettes, avoiding creation of bubbles while 
pipetting. Cuvettes were placed in the nucleofector machine and electroporated using 
program T-13 for PC3 cells and program T-09 for LNCaP cells. The cells were quickly 
transferred into 6-well plates containing complete m dium with no antibiotics, pre-
warmed to 37°C. The plastic pipettes provided in the kit were used for transferring the 
cells in order to minimise damage to the cells. Thecells were subsequently incubated in 
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a humidified incubator at 37°C in a 5% CO2 atmosphere. Knock-down of target siRNA 
was analysed by real-time RT-PCR at specified time points after transfection. 
2.18.2 Calcium Phosphate 
Calcium phosphate transfection was done using a Profecti n kit (Promega) by the 
reverse transfection method described in Ambion TechNotes 11(6) 2004. Cells were 
trypsinised (Section 2.1). Five millilitres of complete medium was added to inactivate 
the trypsin. The cells were centrifuged 800 x g for 1 minute and the trypsin-containing 
supernatant was removed. The cells were re-suspended i  complete medium without 
antibiotics and counted using an Improved Neubauer haemocytometer (Hawksley). 
Wells of a 96-well polystyrene plate were used to prepare the reagents and siRNA for 
the transfections. For each transfection, 0.4µg of siRNA was added to 1.2µl of 2M 
calcium chloride (CaCl2) in 10µl of nuclease free water. Ten microlitres of 2x 4(-2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffered saline (HBS) 
containing 50mM HEPES (pH 7.1), 280mM NaCl, and 1.5mM Na2HPO4 was pipetted 
into a separate well. The siRNA-CaCl2 mix was added drop-wise into the HBS and the 
mixture was incubated at ambient temperature for 30 minutes. A 48-well plate was 
prepared for the final transfection by adding 80µl of complete medium with no 
antibiotics to each well to be used. The siRNA-CaCl2-HBS mix was added to the 
medium in the respective wells. Thirty thousand cells were added to each of the wells 
containing the siRNA mix and the final volume of each well was made up to 200µl with 
complete medium containing no antibiotics. The cells were left in the transfection 
reagent for 16 hours during which time they attached to the bottom of the plate. 
Medium containing the transfection reagents was removed and replaced with fresh 
complete medium containing no antibiotics.  Knock-down of target siRNA was 
analysed by real-time RT-PCR at specified time points after transfection. 
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2.18.3 Lipid-based Methods 
2.18.3.1 Metafectene Pro 
Metafectene Pro transfection was done by the revers transfection method described in 
Ambion TechNotes 11(6) 2004. Cells were trypsinised (Section 2.1) and 5ml of 
complete medium was added to the tube to inactivate the trypsin. The cells were 
centrifuged briefly and the trypsin-containing medium was removed. The cells were re-
suspended in complete medium without antibiotics and counted using an Improved 
Neubauer haemocytometer (Hawksley). Wells of a 96-well polystyrene plate were used 
to prepare the reagents and siRNA for the transfections. In one well, 0.5µg of siRNA 
was added to 50µl of serum-free medium and in a seprate well, 3µl of Metafectene Pro 
(Biontex) was added to 50µl of serum-free medium. The contents of the first well were 
added to the second and the siRNA mix was incubated t ambient temperature for 20 
minutes. The mix was then placed into the wells of a 48-well plate which was to be used 
for transfection. Thirty thousand cells were added to each of the wells containing the 
siRNA mix and final volume of each well was made up to 200µl with complete medium 
containing no antibiotics. Knock-down of target siRNA was analysed by real-time RT-
PCR at specified time points after transfection. 
2.18.3.2 Dharmafect 2 
Transfection with Dharmafect 2 was also done by the reverse transfection method as 
described in Ambion TechNotes 11(6) 2004. Cells were trypsinised (Section 2.1) and 
5ml of complete medium was added to the tube to inactiv te the trypsin. The cells were 
centrifuged briefly and the trypsin-containing medium was removed. The cells were re-
suspended in complete medium without antibiotics and counted using an Improved 
Neubauer haemocytometer (Hawksley). Wells of a 96-well polystyrene plate were used 
to prepare the reagents and siRNA for the transfections. In one well, 2.5µg of siRNA 
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was added to 10µl of serum-free medium and in a seprate well, 0.4µl of Dharmafect 2 
(Dharmacon, Thermo Fisher) was added to 19.6µl of serum-free medium. The contents 
of the first well were added to the second and the siRNA mix was incubated at ambient 
temperature for 20 minutes. The mix was then placed into the wells of a 48-well plate 
which was to be used for transfection. Thirty thousand cells were added to each of the 
wells containing the siRNA mix and final volume of each well was made up to 200µl 
with complete medium containing no antibiotics. Knock-down of target siRNA was 
analysed by real-time RT-PCR at specified time points after transfection. 
 
2.19 Transient Knock-down of ADAMTS-1 and -15 
Transient transfection was undertaken using siGENOME SMARTpool siRNA 
synthesized commercially by Dharmacon. Each SMARTpool siRNA vial contained a 
pool of four different siRNA sequences directed against the gene of interest. The 
sequences are listed in Table 2.4. GAPDH was knocked down to serve as a positive 
control, and a non-targeting siRNA sequence (NTC) bearing no identity to any sequence 
in the human genome was transfected into cells in a separate set of wells as a negative 
control. The sequences of the positive and negative control were proprietary. GAPDH 
and NTC experiments were carried out using siControl GAPD (Cat# D-001140-01-05) 
and siControl Non-Targeting siRNA (Cat# D-001206-13) respectively. To monitor 
transfection efficiency, separate cells were transfected with siGLO Red (Cat# D-
001630-02-05). Cells were transfected using either electroporation with the 
Nucleofector II kit (Amaxa, Lonza), calcium phosphate with the Profection kit 
(Promega), Metafectene Pro (Biontex) or Dhamafect 2 (Dhamacon), as described in 
































Sense GCGCGGACCUGGAACAUUAUU D-005766-01 
Antisense 5’-UAAUGUUCCAGGUCCGCGCUU 
Sense CUGCGACGCUGCUUCUAUUUU D-005766-03 
Antisense 5’-AAUAGAAGCAGCGUCGCAGUU 










Table 2.4: Sequence data for siGENOME SMARTpool siRNA from Dharmacon showing 
the sequence ID and the nucleotide sequence for each of the siRNA duplexes. For each 
gene, four siRNA duplexes were pooled together and supplied in one vial. 
 
2.20 Stable Knock-down of ADAMTS-1 
Two shRNA sequences against ADAMTS-1 mRNA were designed using a web design 
tool on the Ambion website (www.ambion.com), and synthesised by Ambion. They 
were designated ATS1a and ATS1b (Figure 2.3). The oligonucleotides were annealed 
and inserted into the p-Silencer CMV vector (Invitrogen) using the manufacturer’s 
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protocol. TOP-10 competent E.coli (Promega) were transformed with the vector and 
incubated in LB broth (Invitrogen) at 37°C for 24hours. Plasmid DNA from the E.coli 
was then extracted with Maxipreps (Qiagen) using the supplier’s protocol. PC3 cells 
were transfected using either electroporation with the Nucleofector II kit (Amaxa, 
Lonza) or calcium phosphate with the Profection kit (Promega) as described in Sections 
2.18.1 and 2.18.2 respectively (Figure 2.4). Successfully transfected cells were selected 
by growing in complete medium containing 12.5µg/ml puromycin (Invitrogen) for 
ATS1a or complete medium containing 500µg/ml geneticin (neomycin) (Invitrogen) for 

























Figure 2.3: shRNA sequences designed for ATS1a and ATS1b showing expected hairpin 
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Figure 2.4: Schematic represesntation of transient and stable knock-down of ADAMTS-
1 and ADAMTS -15. 
 
2.21 Proteolysis Assays 
Methods to image proteolytic activity were adapted from Sameni et al (Sameni 2003). 
To create multicellular spheroids, PC3 or stromal cells were grown until confluent then 
trypsinised. The trypsinised cells were gently transferred using a pipette into a 100mm 
dish that had its base coated with 1% (w/v) agar. Clumps of cells formed spheroids in 
24-48 hours. Quenched fluorescent gelatin, (DQ-Gelatin) (Molecular Probes, 
Invitrogen) was added to ECM Gel (Sigma) at 4°C in a concentration of 25-40µg/ml. 
ECM Gel is a solubilised extract from the Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma which is rich in ECM proteins including laminin, collagen IV, heparan 
sulphate proteoglycans, enactin and nidogen (Kleinman 1982). DQ-Gelatin consists of 
molecules of a fluorescent probe and a quencher bound to gelatin. As the gelatin 























visualised (Jones, L.J. 1997) (Figure 2.5). Gelatin is a partially denatured form of 
collagen, and gelotinolytic activity has been used a measure of proteolytic activity 










Figure 2.5: Cleavage of quenched fluorescent gelatin by proteolysis. Gelatin molecules 
in DQ-Gelatin are conjugated to a fluorophore and a fluorescence quencher. 
Proteolytic cleavage of the gelatin molecule separates the fluorophore from the 
quencher and fluorescence is emitted. 
Spheroids or cells were left to sediment by gravity in a 1.5ml tube, and then pipetted 
from the bottom of the tube using a Pasteur pipette. ECM gel is in a liquid state between 
0-8°C and solidifies at temperatures above 8°C. They w re suspended in ECM Gel mix 
at 4°C and plated onto sterile glass cover slips in 6-well plates. The ECM Gel was left 
for 10-15 minutes in a tissue culture hood to solidify. Five millilitres of complete or 
serum-free medium was added to each well. Plates were incubated and photographs 
were taken at various time points up to 7 days. 
 
2.22 Chemotaxis Assay 
Chemotaxis assays were perfomed using modified Boyden chambers (Boyden 1962; 
Albini and Benelli 2007). Two hundred thousand PC3 cells were placed in the upper 
chamber in 200µl of serum-free medium and 500µl of the chemo-attractant to be tested 












DMEM as follows. Serum-free DMEM, DMEM with 10% (v/v) FCS added (complete 
medium), or stromal cell-conditioned complete medium conditioned for different 
durations. The conditioning was done using confluent BPH45 cells in T75 tissue culture 
flasks. Ten millilitres of complete medium was adde and left to condition for 24 hours, 
48 hours, 72 hours or 7 days. The medium was then removed and centrifuged at 5,000 x 
g for 10 minutes to remove cells or debris. The supernatant was placed in a fresh tube 
and stored at -40°C until ready for use. Chemotaxis ssays were perfomed by incubating 
the cells at 37°C for 12 hours in the upper compartment of the Boyden chambers with 
no Matrigel coating on the filters (Figure 2.6). After incubation, the filters were stained 
with 4% (w/v) crystal violet in ethanol for 1 hour and then counted. The non-migrating 
cells were first wiped off the top of the filter mebrane using moistened cotton buds. 
The filters were stained for 1 hour and then washed g ntly with tap water. Four high 
power fields (hpf) were counted at magnification of x 20 and the mean was calculated. 
 
Figure 2.6: Modified Boyden chamber used for chemotaxis assays.  PC3 cells were 
plated in the upper compartment and the test chemo-attractant medium in the lower 
compartment. There was no Matrigel coating on the filt rs. Number of cells migrating 












filter with pores 














2.23 Proliferation Assays 
2.23.1 Haemocytometer Cell Counts 
Proliferating cells were counted directly using an Improved Neubauer haemocytometer 
(Hawksley) to produce a growth curve (Jones, H.E. 1997; Wiepz 2006). Fifty thousand 
cells/well were placed in 12-well plates in quadruplicate in serum-free medium. At 24, 
48, and 60 hours, cells were detached using trypsin-EDTA (Section 2.1), res-suspended 
in serum-free medium and counted. After each count, the cells were re-plated and 
incubated until the next time point. 
2.23.2 MTT Assay 
Cell proliferation was analysed using the In vitro Toxicology Assay Kit (Sigma), which 
is based on the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) 
reaction. The assay was done according to the protocol provided by the supplier. 
Mitochondrial dehydrogenases of viable cells cleave th  tetrazolium ring of MTT 
forming formazan crystals which change the colour of the solution from yellow to 
purple (Vistica 1991). The intensity of the purple colour is directly proportional to the 
number of viable cells. Fifty thousand cells were plated in 12-well plates in triplicate. 
For each experiment, 4 sets of cells were plated, 1 set to be counted on day 0, day 1, day 
2 and day 5 of the experiment. The MTT vial provided in the kit was reconstituted with 
3mls of DMEM without phenol red. At the designated time point, the cells were 
removed from the incubator and 100µl of the MTT soluti n was added to 900µl of 
DMEM without phenol red in each well. The cells were returned to the incubator for 2 
hours. After the 2 hours incubation, the cells were removed from the incubator and 
100µl MTT solubilisation solution was added to each well with gentle trituration to 
dissolve the purple formazan crystals.  200µl of formazan solution from each well was 
transferred into separate wells of a 96-well plate and absorbance was measured using a 
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Spectramax M5e plate reader (Molecular Devices) running on Softmax Pro version 5.2 
software (Molecular Devices). Background absorbance of the plate was measured at 
690nm and subtracted from the absorbance of the formazan solution measured at 
570nm.  
 
2.24 Migration Assays 
For the purpose of this thesis, migration refers to the movement of living cells in contact 
with a biologic or synthetic scaffold, from one position to another, with no physical 
barrier between the two positions. Migration assays were perfomed either with the 
Boyden chamber or with the scratch assay. 
2.24.1 Migration using the Scratch Assay 
The scratch assay (O'Toole 1997; Cao 2006; Liang 2007) was used with some 
modifications. Matrigel (BD Biosciences), similar to ECM gel (Sigma), is a solubilised 
extract from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma containing laminin, 
collagen IV, heparan sulphate proteoglycans, enacti and nidogen (Kleinman 1982). 
Matrigel was diluted in ice-cold serum-free medium to a concentration of 60µg/ml. 
Twelve-well plates were coated with 500µl of the Matrigel solution and allowed to dry 
overnight in a tissue culture hood. The excess Matrigel was gently washed off using 
PBS. One hundred thousand cells were plated in each well to be used and left for 24 – 
48 hours to attach. A 200µl plastic pipette tip was used to scratch the bottom of the 
plate, creating a gap in the cell monolayer. The medium was removed and disrupted 
cells were gently washed off with PBS. One millilitre of fresh serum-free medium was 
added to each well. Cytosine arabinoside (Ara-C) (Sigma) was added at a concentration 
of 500ng/ml to inhibit a cell proliferation during the migration process (Dawson 1986). 
The plate was placed for 24 hours in a humidified time-lapse microscopy chamber at 
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37°C in 5% CO2 for image capture. Images were captured with a Leica DMI 6000B 
time-lapse microscope running on LAS AF software version 1.7.0 (Leica 
Microsystems). Distance migrated was calculated by subtracting the width of the start 
gap from the width of the end gap (Figure 2.7). 
 
Figure 2.7: Cell migration using the scratch assay. PC3 cells were allowed to grow to 
confluence and then a scratch created using a sterile plastic 200µl pipette tip. Cytosine 
arabinoside was added to inhibit cell proliferation during the assay. The width of the 
gap at the end of the assay was subtracted from the width at the start (W1 – W2) to give 
distance migrated. 
 
2.24.2 Migration using the Boyden Chamber Assay 
The modified Boyden chamber was adapted for use in migration assays (Boyden 1962; 
Albini 1987; Taniguchi 1989; Szpaderska 2001; Albini 2007).  Transwell permeable 
polycarbonate 13mm filter wells with 8µm pore size (Corning, Fisher Scientific) were 
used with no Matrigel coating applied to the filters. Two hundred thousand cells were 





hour conditioned medium from prostatic stromal cells was placed in the lower chamber 
as a chemo-attractant (Figure 2.6). Previous experiments had confirmed the chemotactic 
effect of prostatic stromal cell-conditioned medium on PC3 cells (Section 3.5). The 
chambers were placed in a humidified incubator at 37°C in 5% CO2 for 6 hours. This 
duration was determined to be the optimal time for counting migrating PC3 cells using 
this method in preliminary experiments. The number of cells migrating to the lower 
surface of the filter was counted by staining the filt rs with either haematoxylin and 
eosin (H&E), or with 4% (w/v) crystal violet in 95% ethanol (Sigma).  For H&E or 
crystal violet staining, the non-migrating cells were first wiped off the top of the filter 
membrane using moistened cotton buds. The filters were stained for 1 hour and then 
washed gently with tap water. Four high power fields (hpf) were counted at 
magnification of x 20 and the mean was calculated. 
 
2.25 Invasion Assays 
For the purpose of this thesis, invasion refers to the movement of living cells in contact 
with a biological or synthetic scaffold, from one point to another, with a biological 
barrier separating the two points. Thus, the cells must penetrate the intervening 
biological barrier to get from one point to the other. Invasion assays were adapted for 
modified Boyden chambers (Boyden 1962; Albini 1987; Taniguchi 1989; Szpaderska 
2001; Albini 2007). Matrigel (BD Biosciences) supplied at a concentration of 6.5mg/ml 
was diluted with chilled serum-free medium. The medium had to be chilled as Matrigel 
solidifies at temperatures above 8°C. Transwell permeable polycarbonate 13mm filter 
wells with 8µm pore size (Corning, Fisher Scientific) were coated with 5µg or 20µg or 
no Matrigel. Some filters were also coated on the under-surface with Matrigel 
containing 50µg/ml of DQ-Gelatin. This is method was developed to enable detection of 
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invading cells in real-time and was used to determine the optimal time to terminate the 
assay. Filters were left to dehydrate by air drying i  a tissue culture hood overnight. 
They were then rehydrated in serum-free medium for 1 hour prior to experiments. Two 
hundred thousand cells were plated in the upper chamber of the transwell inserts in 
serum-free medium. Forty-eight hour conditioned medium from prostatic stromal cells 
was placed in the lower chamber as a chemo-attractant (Figure 2.8). Previous 
experiments had confirmed the chemotactic effect of pr static stromal cell-conditioned 
medium on PC3 cells (Section 3.5). The number of invading cells was counted either by 
staining the filters with either haematoxylin and eosin (H&E), or with 4% (w/v) crystal 
violet in 95% ethanol. In the wells with the under-coating of DQ-Gelatin in Matrigel, 
invading cells were detected by counting fluorescent spots as the invading cells 
proteolytically cleaved the DQ-Gelatin on the under-su face of the filter (Figure 2.8). 
For H&E or crystal violet staining, the non-invading cells were first wiped off the top of 
the filter membrane using moistened cotton buds. The filters were stained for 1 hour and 
then washed gently with tap water. Four high power fi lds (hpf) were counted at 





Figure 2.8: Modified Boyden chamber used for invasion assays. Some filters were 
coated on the under-surface with Matrigel containing DQ-Gelatin. This enabled 
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counting of invading cells by the fluorescence emitted as they made contact with the 




2.26 Statistical Analysis 
Data from preliminary ADAMTS mRNA expression studies using realtime RT-PCR 
had shown wide variations in expression levels. The D’Agostino-Pearson test for 
normality did not support a Gaussian distribution of the data. Therefore for mRNA 
expression experiments, non-parametric statistical tests were used. The Kruskall-Wallis 
test was used to test for statistically significant differences between the medians of each 
treatment group. Differences in expression levels were tested for significance with the 
Dunn’s multiple comparison test, which analyzes differences in rank sum between each 
treatment group and control. The Grubb’s test was used to identify and remove outlying 
samples where appropriate.  
Data from chemotaxis, proliferation, migration and i vasion assays appeared to be 
normally distributed. The D’Agostino-Pearson test for normality supported a Gaussian 
distribution of the data and therefore parametric statistical tests were used. For the 
chemotaxis assays, analysis of variance (ANOVA) and Dunnett’s post test was used to 
determine if there was variance between the means of the test chemo-attractant groups 
and if the means differed significantly from the contr l mean. For the proliferation, 
migration and invasion experiments, the unpaired t-test was used to analyse for 
statistically significant differences between the control and knock-down cell groups. All 
statistical tests were performed on Graphpad Prism 5.0 (GraphPad Software Inc). 







































































































ECM degradation and remodelling is a hallmark of cancer progression (Rowe 2009). 
The exact mechanisms of ECM invasion and metastasis are not fully elucidated but 
ECM proteolysis has been demonstrated around invadig cancer cells (Wolf 2009). 
Stromal cells are reported to be active participants i  ECM proteolysis and degradation 
(Sameni 2003; Sloane 2005; Sloane 2006; Sameni 2009). Gelatinolysis has been used to 
evaluate proteolytic activity (Fields 1990; Wilson 1993; Ratnikov 2000; Frederiks 
2004). ADAMTS-1 is reported to have gelatinolytic ativity (Lind, T. 2006), but 
gelatinolytic activity of ADAMTS-15 has not been determined. The purpose of the 
experiments described in this chapter was to investigate the gelatinolytic activity of 
prostate cancer and stromal cells in a 3D culture model. Gelatinolytic activity of the 
cells would suggest proteolytic ECM degradation by extracellular proteinases possibly 
including ADAMTS-1.  
 
3.2 Gelatinolytic Activity of Multicellular Tumour Spheroids 
Multicellular tumour spheroids were made from PC3 cells (Figure 3.1), LNCaP cells 
(Figure 3.2) and BPH45 prostate stromal cells (Figure 3.3) and grown in 3D culture in 
ECM gel containing DQ-Gelatin as described in Section 2.21. Images were captured 
under a fluorescence microscope at 12, 24, 48 and 60 hours after culture. There was no 
fluorescence visible at the 12 and 24 hour time points (Figures not shown). 
Fluorescence became visible after 48 hours in culture and increased in intensity up to 
the 60 hour time point with no appreciable increase in intensity after 60 hours. The 
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tumour sphroids produced cellular projections indicating that the cells were invading the 
ECM gel (Figures 3.1 and 3.3). The LNCaP spheroids di  not produce any cellular 
projections at the 60 hour time point, suggesting that LNCaP cells were slower than 
PC3 and BPH45 cells to invade the ECM gel. Fluorescence appeared to be most intense 
over the body of the tumour spheroids, while there was comparatively less intense 
fluorescence around the invading cells (Figures 3.1B and 3.3B). Fluorescence from 
BPH45 tumour spheroids was brighter than fluorescence from the PC3 spheroids 
(Compare Figure 3.1B with Figure 3.3B).  Representative images from three separate 
experiments were shown. 
 
 
Figure 3.1: PC3 multicellular tumour spheroid grown i  3D culture in ECM gel 
containing 25mg/ml DQ-Gelatin. Images were captured under a fluorescence 
microscope after 60 hours in culture. A, in white+blue light and B blue light only. 
Green fluorescence indicated areas of gelatinolytic activity (black arrows). Cellular 
projections were seen as the cells in the tumour spheroid began to invade the ECM gel 









Figure 3.2: LNCaP multicellular tumour spheroid grown in 3D culture in ECM gel 
containing 25mg/ml DQ-Gelatin. Images were captured under a fluorescence 
microscope after 60 hours in culture. A, in white+blue light and B, blue light only. 
Green fluorescence indicated areas of gelatinolytic activity (black arrows). No cellular 
projections were seen at this time point suggesting that LNCaP tumour spheroids are 
slower at invading the ECM gel than PC3 tumour spheroids (Figure 3.1). 
 
 
Figure 3.3: BPH45 (stromal cell) multicellular tumour spheroid grown in 3D culture in 
ECM gel containing 25mg/ml DQ-Gelatin. Images were captured under a fluorescence 
microscope after 60 hours in culture. A, in white light and B, blue light. Green 
fluorescence indicated areas of gelatinolytic activity (black arrow). Cellular projections 
were seen as the cells in the tumour spheroid began to i vade the ECM gel (white 






projections, but there was intense fluorescence over the body of the tumour spheroid, 
which was brighter than fluorescence seen around the PC3 and LNCaP spheroids 
(Figures 3.1 and 3.2). 
 
 
3.3 Gelatinolytic Activity of PC3 Cells in Monolayer Culture 
PC3 cells were suspended in ECM gel containing DQ-Gelatin and grown in monolayer 
3D culture in a tissue culture dish (Section 2.21). The cells settled to the bottom of the 
dish before the ECM gel was fully set. The cells were observed for fluorescence at 24 
hour intervals after culture. Fluorescence became visible after 7 days in culture, in 
contrast with the multicellular tumour spheroids which were fluorescent after 2 days. 
Fluorescence was greater around elongated cells compared to rounded cells (Figures 3.4 
and 3.5), suggesting that migrating cells in monolayer culture are more proteolytically 





Figure 3.4: PC3 cells in monolayer 3D culture in ECM gel containing 25mg/ml DQ-
Gelatin. Images were captured under a fluorescence mi roscope after 7 days of culture. 
A, in white+blue light and B, blue light. Green fluorescence indicated areas where 
gelatinolytic activity was present. The boxed area is showed under higher magnification 






Figure 3.5: PC3 cells in Figure 3.4 (inset boxes) at higher magnification. A, in 
white+blue light and B, blue light only. Green fluorescence indicated areas of 
gelatinolytic activity. Elongated cells (black arrows) emitted more fluorescence than 
round cells (white arrows). 
 
 
3.4 Co-Culture of PC3 Cells and Prostate Stromal Cells  
To determine whether interaction between prostate cncer and stromal cells would 
affect the pattern of gelatinolytic activity, PC3 multicellular tumour spheroids were co-
cultured with BPH45 prostate stromal cells in ECM gel containing DQ-Gelatin. At 7 
days, the PC3 tumour spheroids and the stromal cells w re well established. The stromal 
cells were distinguished by their large, elongated shape and characteristic bright-green 
fluorescence (Figures 3.3, 3.6B and 3.7). PC3 cells migrated out from the PC3 
spheroids and formed aggregates around the stromal cells (Figures 3.6 and 3.7).  










Figure 3.6: PC3 and BPH45 stromal cell co-culture in ECM gel containing 25mg/ml 
DQ-Gelatin after culture for 7 days. A, in white light and B, in blue light. Areas of 
green fluorescence indicated proteolytic activity. PC3 cells formed aggregates around 




Figure 3.7: PC3 and BPH45 stromal cell co-culture fom Figure 3.6 (inset boxes) A, in 
white+blue light and B, in blue light. PC3 cells (round shaped cells) formed aggregates 
around the stromal cells (SC). The stromal cells were identifiable by their elongated 
shape and the characteristic bright green fluorescence (see Figure 3.3A and B). 
 
 
3.5 Chemotactic effect of Conditioned Medium from Stromal Cells on PC3 Cells 
Co-culture of PC3 and stromal cells (Section 3.4) suggested that PC3 cells were 
attracted to or divided preferentially near to the surrounding stromal cells. To determine 
whether prostatic stromal cells released factors that produced a chemo-attractive or 















in the upper compartment of a modified Boyden chamber with conditioned medium 
from stromal cells in the lower compartment (Section 2.22). DMEM with 10% (v/v) 
FCS was used as the control chemo-attractant in separate wells. One-way ANOVA was 
used to test for variance in the means of the groups, and the Bonferroni multiple 
comparison test was used to compare DMEM + 10% (v/v) FCS with each of the other 
chemo-attractant media. Similar results were obtained in two separate experiments. 
There was a significant variance between the means (p<0.001). The chemo-attraction of 
PC3 cells increased with the duration of conditioning of DMEM in stromal cell culture, 
with p<0.001 after 48 hours of conditioning (Figure 3.8). The decrease in chemo-
attraction between 48 hour and 72 hour conditioning was not statistically significant. 
Conditioning was extended to 7 days. There was a further increase in the chemo-
attractive gradient at 7 days (p<0.001). However at 7 days, there was detachment of 
cells from the culture flask and the phenol red indicator in the culture medium changed 





Figure 3.8: Chemotaxis assay showing the chemo-attractive force on PC3 cells by 
DMEM conditioned with BPH45 stromal cells. PC3 cells were seeded in the upper 
compartment in serum-free DMEM. DMEM with 10% (v/v) FCS was conditioned for 
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the specified durations and used in the lower compartment of a modified Boyden 
chamber (Figure 2.7). Serum-free DMEM was also used as one of the test chemo-
attractants. DMEM + 10% FCS was designated as the control group. Each experiment 
was done with 4 replicates. Mean (±) SEM is shown.  SCCM= stromal cell conditioned 
medium; * = p<0.05, **=p<0.01, ***=p<0.001. 
 
3.6 Discussion 
This chapter describes demonstrated the proteolytic activity of prostate cancer and 
stromal cells in 3-D culture and the chemotactic effect of prostatic stromal cells on 
cancer cells.Prostate cancer and stromal cells  proteolytically degraded components of 
the surrounding ECM, visualised by cleavage of DQ-Gelatin which was added to the 
ECM gel in which the cells were cultured. Gelatinolysis could be due to the activity of a 
number of proteinases including MMP-2 (gelatinase A) and MMP-9 (gelatinase B). 
ADAMTS-1 has also been shown to have gelatinolytic activity (Lind, T. 2006). 
Proteinase-specific inhibitors were not used, so it is not possible to identify specifically 
which proteinases were responsible for the gelatinase activity. 
In the proteolysis experiments, the stromal tumour spheroids and stromal cells emitted 
brighter fluorescence than the PC3 and LNCaP cancer spheroids and cells, suggesting 
that the stromal cells were more proteolytically active. Some reports have suggested that 
cross-talk between cancer and stromal cells results in tromal cells executing pro-
tumour activity, including excessive proteolysis and ECM degradation (Sameni 2003; 
Sloane 2005; Sloane 2006; Sameni 2009). Experiments in this chapter also imaged the 
early invasion of the ECM by tumour cells as they migrated out of the multicellular 
spheroids (Figures 3.1 and 3.3). The invading cellular projections did not emit obvious 
fluorescence compared to the body of the tumour spheroids. This could be because 
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invading cells are able to switch between proteolysis dependent and independent states 
as they migrate (Sahai 2003; Wolf 2003), suggesting that some stages of ECM invasion 
by cancer cells may not be entirely proteolysis dependent. The multicellular tumour 
spheroid model could be further developed to give further insights into the interactions 
between invading tumour cells and the TME during invasion. Imaging of PC3 cells in 
monolayer 3D culture suggested that elongated cellswere more proteolytically active 
than round cells (Figure 3.5). The experiments were not designed to study cell 
migration, so it is not possible to conclude that te elongated cells were in the process of 
migrating, but this may be the case. The images of the proteolysis experiments generally 
showed limited pericellular detail, which should be taken into account when making 
inferences on the observations from these experiments. 
Co-culture of PC3 and prostatic stromal cells result d in PC3 cells aggregating around 
the stromal cells. This could either be due to PC3 cells migrating towards the stromal 
cells in response to a chemotactic gradient, or the PC3 cells around the stromal cells 
proliferating at a higher rate than those more distant o the stromal cells. To investigate 
this phenomenon, chemotaxis assays were perfomed with PC3 cells using stromal cell-
conditioned medium. There was strong evidence of chemo-attraction of PC3 cells by 
stromal cell-conditioned medium, and the chemo-attrac ive effect increased with longer 
duration of conditioning. This infers that there ar soluble factors released by prostatic 
stromal cells that influence the behaviour of cancer cells. Growth factors produced by 
stromal cells, for example fibroblast growth factor (FGF) (Byrne 1996; Culig 1996) 
could be responsible for the chemotactic effect. Conditioning up to seven days appeared 
to have depleted the nutrients in the medium. The increased chemo-attraction seen at the 
7-day time point may be due to cell lysis and release of soluble cytoplasmic molecules 
into the culture medium,   It is known that tumour-stromal interaction has an important 
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influence on tumour progression (Chung 2005; Thalmann 2010), but no experiments in 
this study were performed to further characterise these interactions.  
In conclusion, imaging of proteolytic activity by prostate cancer and stromal cells 
showed evidence of ECM proteolysis and has demonstrated that prostatic stromal cells 
play a contributory role in ECM remodelling. There is interaction between cancer and 
stromal cells via the release of soluble factors into the ECM and also possibly via direct 





















































EXPRESSION OF ADAMTS-1, -15 &  























CHAPTER 4:  
 
EXPRESSION OF ADAMTS-1, -15 & TIMP-3 IN PROSTATE CELLS 
 
4.1 Introduction 
Work by Cross et al analysed the relative expression of ADAMTS-1, -15 and TIMP-3 in 
PC3, LNCaP and DU145 prostate cancer cell lines and BPH45 prostate stromal cells 
(Cross 2005). ADAMTS-1 and -15 were the most abundantly expressed. TIMP-3 
expression was relatively higher in BPH45 and LNCaP cells.  To confirm these findings 
and to perform further expression analyses, ADAMTS-1, -15 and TIMP-3 mRNA 
relative expression was determined by realtime RT-PCR in PC3, LNCaP and C4-2b4 
prostate cancer cell lines, and PCAF prostatic fibroblasts ( Section 2.1). Expression in 
U373 astrocytoma and MDA-G8 breast cancer cell lines was also analysed as positive 
controls. The U373 cell line has been reported to express ADAMTS-1 (Dr Martin Reid, 
pers commun), and the MDA-G8 cell line has been report d to express ADAMTS-15 
(Dr Julia Woodward, pers commun). SDS-PAGE and western blotting were undertaken 
as described in Sections 2.5 to 2.11 to investigate ADAMTS-1 and -15 protein 
expression in prostate cancer and stromal cells. 
 
4.2 ADAMTS-1, -15 and TIMP-3 mRNA Expression 
The PC3 cell line was arbitrarily chosen as the calibr tor sample for mRNA relative 
expression analyses. ADAMTS-1 expression was detected in all the cell lines (Figure 
4.1). Expression was highest in C4-2b4 and PCAF cells and lowest in the U373 and 




Figure 4.1: ADAMTS-1 mRNA expression levels in LNCaP, C4-2b4, PCAF, U373 and 
MDA-G8 cell lines relative to PC3 plotted on a log scale. U373 and MDA-G8 are 
astrocytoma and breast carcinoma cell lines respectiv ly and were used as positive 
controls. Each data point represents an individual s mple of cDNA (n=4). The 
horizontal bars indicate the value of the median expr ssion level for each cell line.  
 
ADAMTS-15 mRNA expression was also detected in all the cell lines used (Figure 4.2). 
Expression was highest in the U373 cell line, and lowest in the C4-2b4 cell line. The 
relative expression levels between the prostate cell lin s was in keeping with findings of 
Cross et al (Cross 2005), who detected highest expression of ADAMTS-15 mRNA in 





Figure 4.2: ADAMTS-15 mRNA expression levels in LNCaP, C4-2b4, PCAF, U373 and 
MDA-G8 cell lines relative to PC3 plotted on a log scale. Each data point represents an 
individual sample of cDNA (n=4). The horizontal bars indicate the value of the median 
expression level for each cell line. 
 
TIMP-3 is the main inhibitor of the ADAMTS proteinases in tissue (Hashimoto 2001; 
Rodriguez-Manzaneque 2002). Expression levels of TIMP-3 were also analysed (Figure 
4.3) to enable comparisons between proteinase and inhibitor expression levels. TIMP-3 
expression levels were highest in the PCAF and U373 cell lines, and lowest in the C4-
2b4 and MDA-G8 cell lines. The PC3, LNCaP and C4-2b prostate cancer cell lines all 
expressed low levels of TIMP-3 mRNA compared to PCAF cells. This is in keeping 
with previous reports (Cross 2005) in which prostate stromal cells had higher 




Figure 4.3: TIMP-3 mRNA expression levels in LNCaP, C4-2b4, PCAF, U373 and 
MDA-G8 cell lines relative to the PC3 cell line plotted on a log scale. Each data point 
represents an individual sample of cDNA (n=4). The horizontal bars indicate the value 
of the median expression level for each cell line. 
 
In summary, the results show that relative to PC3 cells. The LNCaP cell line expressed 
moderate levels of ADAMTS-1, low levels of ADAMTS-15 and high levels of TIMP-3. 
The C4-2b4 cell line expressed high levels of ADAMTS-1, low levels of ADAMTS-15, 
and moderate levels of TIMP-3. The PCAF cell line expr ssed high levels of 
ADAMTS-1, low levels of ADAMTS-15 and high levels of TIMP-3. This summary is 
based on an arbitrary definition of low expression being ≤ 0.3-fold, moderate expression 





4.3 ADAMTS-1 and -15 Protein Expression 
At the time of this study, no commercially available antibodies against ADAMTS-1 and 
-15 had been validated in the published literature. Of the antibodies that were 
commercially available, two antibodies each were usd to probe for ADAMTS-1 and -
15. The anti-ADAMTS-1 rabbit polyclonal antibody was directed against the C-
terminus while the mouse monoclonal antibody was directed against the proteolytic 
domain. For ADAMTS-15, one antibody was directed against a peptide sequence 
'HSTNRLTLAVAW' located in the cysteine rich region. The other antibody was 
directed against the pro-peptide domain. Cell lysate solutions and conditioned culture 
medium were prepared from the cell lines (Section 2.5, .7 and 2.8) and used for 
western blot experiments.  
4.3.1 Probing for ADAMTS-1 in Cell Lysate Preparations 
Probing for ADAMTS-1 with the C-terminal antibody detected multiple bands ranging 
from 15-150kDa in size (Figure 4.4). The greatest number of bands was detected in the 
C4-2b4 cell line which also had relatively high mRNA expression levels. There was a 
single dark band of approximately 23kDa detected in the U373 lane. MDA-G8, PC3 and 
LNCaP cell lines had bands ranging from 15kDa to 75kDa. C4-2b4 and PCAF lysates 
had bands ranging from 15kDa to 150kDa, but the bands were faint in the lane loaded 
with PCAF. Dilution of the antibody solution to 1:10, 1:100 and 1:1000 caused the 
intensity of all the bands to be attenuated uniformly and did not identify any bands with 




Figure 4.4: Western blotting of cell lysates using a rabbit polyclonal antibody (Abcam, 
ab39194) raised against the C-terminus of ADAMTS-1. 100µg of cell lysate protein was 
loaded in each lane. Multiple bands were detected ranging in size from 15kDa to 
100kDa. The greatest number of bands was detected in the C4-2b4 cell line. The image 
is representative of two experiments with similar results. 
 
Probing with the catalytic domain antibody detected bands in PC3, LNCaP and C4-2b4 
cell lines ranging from 30-100kDa in size (Figure 4.5). The band with the highest 
intensity was detected in the C4-2b4 cell line at a size of approximately 70kDa, and 
fainter bands at 100kDa and 50kDa. The PC3 cell lysate had bands of 100kDa, 70kDa 
and 50kDa, and the LNCaP cell lysate had bands at 70kDa and 50kDa. The U373 and 
MDA-G8 samples had faint bands at 50kDa and 30kDa. Ten nanograms of human 
recombinant ADAMTS-1 proteolytic domain (Section 2.10.2) was also loaded and a 
band of 50kDa was detected, with a fainter band of size 75kDa (Figure 4.5). The 
product literature for the recombinant ADAMTS-1 protein had predicted a size of 
66kDa on western blot. 
105kDa→ 





Figure 4.5: Western blotting of cell lysates using a mouse monoclonal antibody (R&D 
Systems, MAB2197) raised against the catalytic domain of ADAMTS-1. 100µg of cell 
lysate protein was loaded in each lane.  Bands were d t cted ranging from 30kDa to 
100kDa in the PC3, LNCaP and C4-2b4 cell lines, with the most intense band in the 
C4-2b4 cell line. 10ng human recombinant ADAMTS-1 (RhADAMTS-1) was loaded as 
a positive control. Bands of size 50kDa and 75kDa approximately were detected with 
higher intensity in the 50kDa band. The image is representative of two experiments with 
similar results. 
 
Cleavage of full-length ADAMTS-1 yields products of ranging in size from 22kDa to 
87kDa (Rodriguez-Manzaneque 2000). The first cleavage removes the propeptide 
leaving an 87kDa form with an activated catalytic site. The 87kDa form is further 
cleaved at the spacer region to yield a 65kDa catalytic fragment and a 22kDa C-terminal 
fragment containing the two C-terminal thrombospondin motifs (Rodriguez-
Manzaneque 2000). This did not fully explain the number of bands detected using the 
105kDa→ 
Predicted size for 
Full-length ADAMTS-1 
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ADAMTS-1 C-terminal antibody (Figure 4.4). The bands detected using the ADAMTS-
1 catalytic domain antibody (Figure 4.5) were more in keeping with the sizes of 
expected ADAMTS-1 cleavage fragments. This suggested that the catalytic domain 
antibody was the more reliable of the two antibodies and was therefore selected for 
further experiments.  
4.3.2 Test of Validity of the Anti-ADAMTS-1 Antibody Raised Against the Catalytic 
Domain 
Western blotting experiments using the mouse monoclal anti-ADAMTS-1 catalytic 
domain antibody (R&D Systems, MAB2197) detected bands i  PC3, LNCaP and C4-
2b4 cell lysates (Figure 4.5). The bands were of expected sizes for ADAMTS-1 
fragments. The intensity of the bands was also greate  than those detected with the 
rabbit polyclonal anti-ADAMTS-1 antibody raised against the C-terminus (Abcam, 
ab39194). Western blotting experiments were perfomed to validate the specificity of the 
catalytic domain antibody. ADAMTS-1 expression in PC3 cells was transiently 
knocked down by electroporation (Section 2.18.1) using iRNA specific for ADAMTS-
1 (Section 2.19). At 48 hours post-transfection, ADAMTS-1 mRNA expression in PC3 
prostate cancer cells, analysed by real-time RT-PCR (Sections 2.2, 2.3 and 2.4), was 
inhibited by 80% (+/- 10%, n=2).  
  NTCKd ATS1Kd GAPKd 
Experimant 
1 




1 0.1 0.99 
Experiment 
1 




1 0.85 0.1 
 
Table 4.1: Relative expression of ADAMTS-1 and GAPDH in PC3 cells determined by 
realtime RT-PCR following knock-down of ADAMTS-1 and GAPDH. 
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At day 5 post-transfection, cells were lysed and protein samples were prepared as 
previously described (Section 2.5.2). Protein expression was analyzed by western 
blotting (Sections 2.9 and 2.10). Fifty kDa bands were detected in all the lanes. Bands 
from the cells treated with ADAMTS-1 siRNA (Lane 4)was not attenuated (Figure 
4.6). To control for errors in sample loading, the m mbrane was stripped and then re-
probed with anti-GAPDH antibody. Thirty-four kDa bands were detected with equal 
intensity in the NTCKd and ADAMTS-1 knock-down lanes, indicating equal sample 
loading in these two lanes. The band was attenuated with GAPDH knock-down (Figure 
4.6, Lane 6). Similar results were obtained when the experiment was repeated using 
LNCaP and C4-2b4 cells. ADAMTS-1 knock-down did not lead to attenuation in the 
intensity of the band in the ATS1Kd lane compared to the NKCKd lane as would be 
expected, therefore the mouse monoclonal anti-ADAMTS-1 catalytic domain antibody 
(R&D Systems, MAB2197) could not be reliably used to analyse ADAMTS-1 protein 




Figure 4.6: Test of specificity of the mouse monoclonal anti-ADAMTS-1 catalytic 
domain antibody (R&D Systems, MAB2197). ADAMTS-1 expression in PC3 prostate 
cancer cells was transiently knocked down and western blotting was performed with the 
cell lysates. 100µg protein was loaded per lane, except Lane 2 which was loaded 
with1ng recombinant human ADAMTS-1 (RhATS1). Lane 3 was loaded with cell lysate 
from non-targeting knock-down cells (NTCKd), Lane 4 was loaded with cell lysate from 
ADAMTS-1 knock-down cells, Lane 5 with WT PC3 cell lysates and Lane 6 was loaded 
with cell lysate from GAPDH knock-down cells. The upper panel is an image of the blot 
after probing with the ADAMTS-1 antibody. A 50kDa band was detected in each lane 
(white inset box). The band in Lane 4 (ADAMTS-1 knoc -down) was not attenuated 
compared with Lane 3 (control).  The lower panel is an image of the same membrane 
after it had been stripped and re-probed with anti-GAPDH antibody. 34kDa bands were 
detected in Lanes 3 and 4 of equal intensity, showing that sample loading was equal in 
105kDa→ 
Predicted size for 
Full-length ADAMTS-1 
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the two lanes. GAPDH knockdown led to attenuation of the band in Lane 6 on the lower 
panel. These results are representative of two experiments. 
 
 
4.3.3 Probing for ADAMTS-15 in Cell lysate and Culture Medium 
Cell lysate preparations were probed for ADAMTS-15 using an antibody raised against 
the cysteine rich domain of ADAMTS-15. This was done by western blotting 
experiments using cell lysates, and by using samples prepared from 
immunoprecipitation and heparin-agarose precipitation of cell lysates and culture 
medium.   
4.3.3.1 Probing for ADAMTS-15 in Cell lysates using the ab28516 Antibody 
Cell lysate preparations were probed for ADAMTS-15 as described (Section 2.9 and 
2.10). An antibody (ab28516) raised against the cysteine rich domain of ADAMTS-15 
(amino acids Ser572-Val700) was used. The peptide sequence, ‘HSTNRLTLAVAW’, 
used as the immunogen was custom-synthesized by Bachem. This peptide was used to 
pre-adsorb the antibody as described (Section 2.10.2) for use as a negative control in 
western blot experiments. For all experiments using this antibody, corresponding 
membranes were probed with non pre-adsorbed antibody s lution and with pre-
adsorbed antibody solution. Western blotting using this antibody produced very low 
intensity bands from PC3 and LNCaP cell lysates (Lanes 4 and 5) of approximately 
25kDa size (Figure 4.7A). This raised the possibility that ADAMTS-15 was being 
expressed in very low concentrations in our cell lines. Mature ADAMTS-15 is 
approximately 100kDa (Cal 2002), and cleavage products of 25kDa have not been 





Figure 4.7: Detection of ADAMTS-15 using the rabbit polyclonal cysteine-rich domain 
antibody (Abcam, ab28516). A, using the non pre-adsorbed antibody, and B, using the 
pre-adsorbed antibody for primary immuno-probing. 100µg protein each from U373, 
MDA-G8, PC3, LNCaP, C4-2b4 and PCAF cell lysate were loaded on respective lanes. 




Predicted size for 
Full-length ADAMTS-15 
103kDa→ 
Predicted size for 
Full-length ADAMTS-15 
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at approximately 25kDa (white inset box). The images are representative of two 
separate experiments.  
 
4.3.3.2 Immunoprecipitation and Probing for ADAMTS-15 in Cell Lysates and Culture 
Medium using the ab28516 Antibody 
Low intensity bands were detected using the ADAMTS-15 cysteine-rich domain 
antibody (Section 4.3.3). This possibly could have been as a result of ADAMTS-15 
being present in relatively small concentrations in the lysates being used for the 
western-blotting experiments. To increase the detection of ADAMTS-15, 
immunoprecipitation of ADAMTS-15 was done as described in Section 2.7.  
Performing western blotting with immunoprecipitate samples, it is expected that bands 
at 25kDa and 50kDa will be detected, corresponding to the immunoglobulin light and 
heavy chains respectively. ADAMTS-15 has a predicte relative mass of 100kDa (Cal 
2002). The antibody was raised against a 12 aa sequence in the cysteine-rich domain of 
ADAMTS-15. 
Samples obtained by immunoprecipitation were used for western blotting experiments. 
One nanogram of anti-ADAMTS-15 antibody was added to 1ml of 1mg/ml of cell 
lysate protein and immunoprecipitation was undertakn as described in Section 2.7. 
Intense staining was detected ranging in size from 17kDa to 60kDa in all the lanes. The 
same appearance was seen on the membrane probed with the pre-adsorbed antibody, 
which served as a negative control (Figure 4.8). Similar pattern and intensity of staining 
was observed reducing the x-ray film exposure time from ten to two seconds.  
 143 
 
Figure 4.8: Immunoprecipitation and western blotting for ADAMTS-15.  
Immunoprecipitation was done on 1ml of 1mg/ml cell lysate protein solutions 
containing both the cellular and ECM components and 10ml of 3-day conditioned 
medium from PC3 and LNCaP cells. 1ng of antibody and 30µl protein A-agarose bead 
slurry was used for immunoprecipitation. Multiple hig -intensity bands of size 20kD-
50kDa were detected in all the lanes. 
 
This result was unexpected. The fact that bands were d tected on the negative control 
meant that there was a source of error in the method, or the specificity of the antibody. 
To find out the source of the error, several control experiments were required. 
The protein A beads were washed five times in TBS, 1ml beads in 50mls TBS for each 
wash. This was done to remove any residual unbound protein A from the beads. 
Western blot experiments were repeated with modificat ons introduced in a logical 




Firstly, a western blot was done with two membranes (Figure 4.9). The lysates used 
were identical. Membrane 1 was probed with the anti-ADAMTS-15 antibody as the 
primary antibody, and the HRP-labelled anti-rabbit an ibody as the secondary antibody. 
Membrane 2 was incubated with TBST primarily, and then secondary incubation with 
the same HRP-labelled anti-rabbit antibody. The intnse bands seen in Figure 4.8 were 
seen again on both membranes, indicating that the detection did not require the presence 
of the anti-ADAMTS-15 (primary) antibody and the secondary antibody was binding 
directly to proteins of size 15-50kDa that were present in relatively large amounts in the 
samples (Figure 4.9).  
 
Figure 4.9:  PVDF membranes were probed with either anti-ADAMTS-15 primary and 
HRP-labelled secondary antibodies (Membrane 1), or TBST as primary and HRP-
labelled secondary antibody (Membrane 2). The same pattern of multiple bands was 
seen as in Figure 4.8. The presence of the bands on Membrane 2, which had only TBST 
for the primary incubation indicated that the HRP-labelled secondary antibody was 
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binding directly to the proteins in the PVDF membrane and did not require the 
presence of the primary antibody. 
 
The membranes were stripped as described (Section 2.12) and HRP detection done after 
incubating for 6 hours in TBST. No bands were detect d (Figure not shown), indicating 
that the detection reagents were not contaminated, an  the bands were as a result of 
detection of a protein present in the loaded samples, possibly the antibody used for 
immunoprecipitation, or protein A from the beads. The secondary antibody was a swine 
anti-rabbit IgG antibody, which would have an affinity to bind to protein A. 
To determine whether the antibody used for immunopreci itation was the source of the 
bands detected in Figure 4.9, serially diluted anti-ADAMTS-15 antibody (1ng, 100pg, 
10pg and 1pg) was loaded and used for western blotting. The resulting PVDF 
membrane was incubated in HRP-labelled anti-rabbit secondary antibody for 1 hour and 
HRP detection performed. There were no bands detected (Figure not shown), indicating 
that the immunoprecipitation antibody was not respon ible for the intense bands 
detected on Figures 4.8 and 4.9. 
To determine whether the intense bands were coming from the immunoprecipitation 
beads, a western blot experiment was set up with separate samples as follows; Laemmli 
sample buffer with 2ng anti-ADAMTS-15 antibody, Laemmli sample buffer with 
protein A-agarose beads, Laemmli sample buffer withprotein A-agarose beads that had 
been incubated with PC3 cell lysate without any immunoprecipitation antibody, and 
lastly,Laemmli sample buffer after with protein A-agarose beads that had been 
incubated with PC3 cell lysate and 1ng of anti-ADAMTS-15 antibody. Each of the 
samples was heated as described in Section 2.9.3. The samples were loaded and 
electrophoresis and western blotting performed as previously described (Section 2.9 and 
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2.10). A duplicate set of samples was used for the negative control (pre-adsorbed 
antibody). Multiple bands were again seen on both membranes (Figure 4.10, non-pre-
adsorbed and pre-adsorbed). The most intense band in each lane was approximately 
50kDa. All the lanes with samples that had been in co tact with the protein A-agarose 
beads had the bands, including the sample that had sample buffer heated with beads that 
had not been in contact with cell lysate or antibody (Figure 4.10 Lane 3 on both blot 
images). The lanes with 2ng antibody had no bands detected (Figure 4.10, Lane 2 on 
both blot images). This experiment confirmed that te protein A-agarose beads were the 
source of the multiple bands seen in the immunopreci itation western blotting 
experiments. For this reason, plans further western blotting experiments using protein A 
immunoprecipitation were abandoned. 
 
Figure 4.10: Western blot to determine the source of bands detected on lysates after 
immunoprecipitation. Bands were detected on the negative control membrane (probed 
103kDa→ 
Predicted size  
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with pre-adsorbed antibody) on the right as well as the membrane on the left which was 
probed with antibody which was not pre-adsorbed. 2ng of ADAMTS-15 antibody was 
loaded in Lane 2, which was not detected. All the lanes loaded with lysates that had 
been in contact with the protein A-agarose beads had multiple bands detected, 
including Lane 3, which was loaded with Leammli sample buffer which contained 
protein A  beads but contained no lysate protein. 
 
4.3.3.3 Heparin-agarose Precipitation and Probing for ADAMTS-15 in Cell lysates and 
Culture Medium using the ab28516 Antibody 
ADAMTS-1, -4, -5 and -9 are known to bind heparan sulphate in the ECM (Kuno 1998; 
Somerville 2003; Gao 2004; Zeng 2006). Heparan sulphate and heparin are negatively 
charged polysaccharides composed of α1-4 linked repeating disaccharide units 
containing a uronic acid and an amino sugar that may be repeated to form a structure of 
varying lengths (Powell 2004). Heparan sulphate is present on cell surfaces and in the 
ECM where it is covalently bound to several core proteins to form heparan sulphate 
proteoglycans (Bernfield 1999).  
Cell lysates containing the cellular and ECM components from PC3, LNCaP, C4-2b4 
prostate cancer cell lines and PCAF stromal cells were incubated with heparin-agarose 
beads to concentrate ADAMTS-15 from the lysate solutions for detection by western 
blotting. One millilitre of 2mg/ml lysate solution was incubated with 30µl of 50% (v/v) 
heparin-agarose bead slurry as described in Section 2.8.  The anti-ADAMTS-15 
antibody raised against the cysteine-rich domain was used for primary incubation. 
Western blotting experiments did not detect any bands i  the samples prepared from the 
cell lysates from PC3, LNCaP, C4-2b4 and PCAF cells (Figure not shown). 
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Medium from PC3 and LNCaP cells was also incubated with heparin-agarose beads to 
determine whether ADAMTS-15 protein was released into the medium and could be 
precipitated and detected by western blotting. Ten millilitres of 3-day conditioned 
medium from confluent PC3 and LNCaP cells was used for incubation with heparin-
agarose beads as described in Section 2.8. No bands were detected in any of the lanes. 
4.3.3.4 Probing for ADAMTS-15 in Cell lysates using the ab45047 Antibody 
Western blotting experiments were performed on celllysate samples as previously 
described in Sections 2.9, 2.10 and 2.11. Protein qua tification was done using the BCA 
method as described in Section 2.6. Probing with the anti-ADAMTS-15 antibody 
(ab45047), raised against the propeptide domain of ADAMTS-15, bands of 50kDa were 
detected in the lanes with MDA-G8, PC3, LNCaP and C4-2b4 cell lysate (Figure 4.11). 
The 50kDa band was most intense in the lane loaded with C4-2b4 lysate. Lanes with 
U373 and PCAF cell lysates produced no bands. 
 
Figure 4.11: Western blotting for ADAMTS-15 protein expression using a rabbit 
polyclonal propeptide domain antibody (Abcam ab45047). 100µg of cell lysate protein 
103kDa→ 
Predicted size for 
Full-length ADAMTS-15 
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was loaded in each lane.  50kDa bands were detected in the MDA-G8, PC3, LNCaP 
and C4-2b4 cell lines, with the most intense band arising from the lane with the C4-2b4 
lysate. 
 
4.3.5 Validation of the Anti-ADAMTS-15 Antibody Raised Against the Propeptide 
Domain 
Western blotting experiments using the rabbit polycl nal propeptide domain antibody 
(Abcam ab45047) detected a 50kDa band in MDA-G8, PC3, LNCaP and C4-2b4 cell 
lysate (Figure 4.11). To validate the specificity of this antibody to ADAMTS-15, 
expression of ADAMTS-15 in C4-2b4 cells was transietly knocked down by 
transfecting the cells with siRNA specific for ADAMTS-15 (Section 2.19) using 
Dharmafect 2 transfection reagent (Section 2.18.3.2). At 48 hours post-transfection, 
ADAMTS-15 mRNA expression in C4-2b4 prostate cancer cells, analysed by real-time 
RT-PCR (Sections 2.2, 2.3 and 2.4), was inhibited by 80% (+/- 10%, n=3). At day 5 
post-transfection, cells were lysed and protein samples were prepared as previously 
described (Section 2.5.2). Protein expression was an lyzed by western blotting (Section 
2.9 and 2.10). Fifty kDa bands were detected in all the lanes but the band was attenuated 
in the cells treated with ADAMTS-15 siRNA (Figure 4.12). Densitometric analysis of 
the 50kDa band showed that its expression was knocked down by over 80%. To control 
for errors in sample loading, the membrane was stripped and then re-probed with anti-
GAPDH antibody. Thirty-four kDa bands were detected with equal intensity in the non-
targeting knock-down control (NTCkd) and ADAMTS-15 knock-down (ATS15kd) 
lanes (Figure 4.12), indicating equal sample loading in these two lanes. The band was 
absent in the GAPDH knock-down (GAPkd) lane. The detection of down-regulated 
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expression of the 50kDa band by the antibody in the cells treated with siRNA to the 
ADAMTS15 gene verified the specificity of the ab45047 antibody. 
 
Figure 4.12: Validation of the specificity of the rabbit polyclonal anti-ADAMTS-15 
antibody (Abcam ab45047). ADAMTS-15 expression in C4-2b4 prostate cancer cells 
was transiently knocked down. Western blotting was performed with the cell lysates. 
100µg protein was loaded per lane. Lane 1 had the lysate from wild-type C4-2b4 cells 
(Gerhardt), Lane 2 had the lysate from non-targeting k ock-down cells (NTCkd), Lane 
3 was from ADAMTS-15 knock-down cells (ATS15kd) and L e 4 from GAPDH knock-
down cells (GAPkd). The upper panel is an image of the blot after probing with the anti-
ADAMTS-15 antibody. A 50kDa band was detected in each l ne. The band in Lane 3 
was attenuated compared with Lane 2, in keeping with ADAMTS-15 knock-down in 
Lane 3. The lower panel is an image of the same membrane after it had been stripped 
and re-probed with anti-GAPDH antibody. Lane 4 is attenuated. Bands in Lanes 2 and 
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3 are of similar intensity, signifying equal sample loading. These results are 
representative of two experiments. 
 
4.3.6 Heparin-agarose Precipitation and Probing for ADAMTS-15 in Cell lysates and 
Culture Medium using the ab45047 Antibody 
Western blotting experiments using samples prepared from heparin-agarose experiments 
in Section 4.3.3.3 did not detect any bands when th PVDF membrane was probed with 
the ab28516 antibody. The ab45047 antibody detected ban s when used to probe for 
ADAMTS-15 in cell lysates, and these bands were shown to be attenuated when 
ADAMTS-15 was knocked down (Section 4.3.5), thereby validating the specificity of 
the ab45047. To determine whether ADAMTS-15 could be detected following heparin-
agarose precipitation, the experiment in Section 4.3.3.3 was repeated using the ab45047 
antibody for immunodetection. Cell lysates containing the cellular and ECM 
components from PC3, LNCaP, C4-2b4 prostate cancer cell lines and PCAF stromal 
cells were incubated with heparin-agarose beads to concentrate ADAMTS-15 from the 
lysate solutions for detection by western blotting. One millilitre of 2mg/ml lysate 
solution was incubated with 30µl of 50% (v/v) heparin-agarose bead slurry as described 
in Section 2.8. Western blotting experiments did not detect any bands in the samples 
prepared from the cell lysates from PC3, LNCaP, C4-2b  and PCAF cells (Figure not 
shown) 
 
4.4 Fluorescence Immunocytochemistry for Detection of ADAMTS-15 Expression 
in PC3 Prostate Cancer Cells 
ADAMTS-15 expression was transiently knocked down in PC3 cells by electroporation 
(Section 2.18.1) using siRNA specific for ADAMTS-15 (Section 2.19). At 48 hours 
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post-transfection, ADAMTS-15 mRNA expression, analysed by real-time RT-PCR 
(Sections 2.2, 2.3 and 2.4), was inhibited by 90% (+/- 10%, n=3). At day 5 post-
transfection, fluorescence immunocytochemistry was used to detect ADAMTS-15 
expression in PC3 cells as described in Section 2.14. The rabbit polyclonal anti-
ADAMTS-15 antibody (Abcam ab45047) was used as the primary antibody. This 
antibody was raised against the propeptide domain of ADAMTS-15. Secondary 
antibody incubation was done using Alexa Fluor 594 goat anti-rabbit fluorescent tagged 
antibody, which has a fluorescence emission maximum of 617nm (red). GAPDH 
expression was also knocked down in a separate set of PC3 cells and fluorescence 
immunocytochemistry done using the same protocol. The nuclei of the cells were 
counter-stained with DAPI (4’, 6-diamidino-2-phenyli dole). DAPI has a fluorescence 
emission maximum of 461nm (blue) when bound to double-stranded DNA (Manzini 
1983; Kapuscinski 1995). Fluorescence was compared between ADAMTS knock-down 
cells and non-targeting knock-down controls. Images w re acquired with a Leica DMI 
4000B microscope using LAS AF version 1.6.3 software.  
ADAMTS-15 expression was detected in the non-targetin  knock-down (NTCkd) cells 
(Figure 4.13) but not in the ADAMTS-15 knock-down (ATS15kd) cells (Figure 4.14). 
As expected the nuclei emitted blue fluorescence duto the DAPI stain. The red 
fluorescence signal detected was very weak, and without staining of the cell 
membranes, detailed localisation of ADAMTS-15 was not possible. However,  
the areas of red fluorescence relative to the position of the nuclei suggests the staining 






Figure 4.13: Fluorescence immunocytochemistry for detection of ADAMTS-15 
expression. Non-targeting knock-down PC3 cells were cultured in monolayer in 
chamber slides. At day 5 post-transfection, fluorescence immunocytochemistry was 
undertaken. Rabbit anti-ADAMTS-15 antibody (Abcam ab45047) raised against the 
propeptide domain was the primary antibody. Secondary antibody incubation was 
performed using Alexa Fluor 594-tagged goat anti-rabbit  antibody, which emits red 
fluorescence. The nuclei of the cells were counter-stained with DAPI. Weak red 






fluorescence signal (B). The composite image (C) suggested that the red signal was in 
the cytoplasm (white arrows). 
 
Figure 4.14: Fluorescence immunocytochemistry probing for ADAMTS-15 in ADAMTS-
15 knock-down cells. ADAMTS-15 mRNA expression was knocked down by 90% in PC3 
cells using siRNA. The cells were cultured in monolayer in chamber slides. At day 5 
post-transfection, fluorescence immunocytochemistry was performed using the same 
methodology as for Figure 4.13. No fluorescence signal was detected in (A). The nuclei 






bottom left of each image denotes 100µm. The red dot appearing in image A and also in 
C (red arrows) is an artefact, as it did not change position when the field of view was 
changed. 
 
Immunodetection of GAPDH showed that there was red fluorescence emitted by the 
non-targeting knock-down (NTCkd) cells (Figure 4.15) but no red fluorescence emitted 
by the GAPDH knock-down (GAPkd) cells (Figure 4.16). DAPI staining emitted blue 
fluorescence from the nuclei. The red fluorescence signal was weak, but the staining 





Figure 4.15: Fluorescence immunocytochemistry for detection of GAPDH expression. 
Non-targeting knock-down PC3 cells were cultured in monolayer in chamber slides. At 
day 5 post-transfection, fluorescence immunocytochemistry was performed using the 
same methodology as for Figure 4.13, except rabbit anti-GAPDH antibody (Abcam 
ab9485) was used for primary immunodetection. Weak r d fluorescence signal was 
detected (A). The nuclei emitted a blue fluorescence signal (B). The composite image 







appearing in image A and also in C (green arrows) was an artefact, as it did not change 
position when the field of view was changed. 
 
 
Figure 4.16: Fluorescence immunocytochemistry probing for GAPDH in GAPDH 
knock-down cells. GAPDH mRNA expression was knocked down by 99% in PC3 cells 
using siRNA. The cells were cultured in monolayer in chamber slides. At day 5 post-
transfection, fluorescence immunocytochemistry was performed using the same 






was used for primary immunodetection. No fluorescence signal was detected in (A). The 
nuclei emitted a blue fluorescence signal (B). The composite image is shown in (C). 
 
4.5 Discussion 
This chapter reports the results of experiments analysi g the expression of ADAMTS-1 
and -15 in prostate cancer and stromal cells using real-time RT-PCR, western blotting 
and fluorescence immunocytochemistry. 
Real-time RT-PCR was used to analyse ADAMTS-1 and -15 expression at 
transcriptional level in PC3, LNCaP, C4-2b4 and PCAF cells (Section 4.2). Expression 
levels of TIMP-3, the main inhibitor of the metallopr teinases, was also analysed. For 
comparison, expression in U373 (astrocytoma) and MDA-G8 (breast cancer) cells were 
analysed because these cells have been reported to xpress ADAMTS-1 (Dr Martin 
Reid, pers commun) and ADAMTS-15 (Dr Julia Woodward, pers commun) 
respectively. The relative expression method was used, with PC3 cells acting as the 
calibrator sample in each experiment, ie expression levels were calculated relative to 
expression in PC3 cells.  
The mRNA expression analyses showed variability of expression in some cell lines 
between experiments, for example ADAMTS-1 expression in LNCaP cells (Figure 4.1) 
and TIMP-3 expression in C4-2b4 cells (Figure 4.3). Variability in ADAMTS and 
TIMP gene expression in cell lines between experiments has been previously reported 
(Giricz 2010; Stokes 2010), with variability of up to 1000-fold. This could partly be 
explained by the existence of sub-clones within cell line populations. PC3 and LNCaP 
cell lines are reported to have sub-clones (Festuccia 2000; Wan 2003). This is also 
supported by findings in this study (Section 6.2.2) which showed that sub-clones of the 
PC3 cell line had varied expression of ADAMTS-1. This limitation has to be taken into 
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account when interpreting mRNA expression data from cell lines especially with low 
experiment numbers. 
The results show that in relative terms, the LNCaP cell line expressed moderate levels 
of ADAMTS-1, low levels of ADAMTS-15 and high levels of TIMP-3. The C4-2b4 
cell line expressed high levels of ADAMTS-1, low levels of ADAMTS-15, and 
moderate levels of TIMP-3. The PCAF cell line expressed high levels of ADAMTS-1, 
low levels of ADAMTS-15 and high levels of TIMP-3. This is based on an arbitrary 
definition of low expression being ≤ 0.3 fold, moderate expression being 0.4-2.9 fold 
and high expression being ≥3 fold relative to expression in PC3 cells.  
The data showed that there were high expression levels of TIMP-3 in the LNCaP and 
PCAF cells, indicating that TIMP-3 activity may be attenuating the action of 
metalloproteinases in these cells. The high expression levels of TIMP-3 in PCAF cells 
also suggests that stromal cells adjacent to cancer cells may be modulating the activity 
of cancer cells by secreting a proteinase inhibitor into the TME. Several reports have 
reported that interactions between cancer and stromal cells can alter tumour 
characteristics (Chung 2005; Thalmann 2010).   
It would have been ideal to analyse expression using normal epithelial prostate cells as 
the calibrator samples but at the time of these experiment, no normal epithelial cells 
were available in our laboratory. The PNT1 and PNT2 non-tumourigenic prostatic 
epithelial cell lines were immortalised using the SV40 transfection vector (Berthon 
1995), which is reported to up-regulate ADAMTS-1 expression in human transformed 
ovarian granulosa cells compared with non-transformed granulosa cells (Freimann 
2005). As a result of this, the PNT1 and PNT2 cell lines were not considered to be true 
‘normal’ prostatic epithelial cell lines for the pur ose of this study.   
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The mRNA expression data confirmed that ADAMTS-1, -5 and TIMP-3 were 
expressed in prostate cancer and stromal cell as was previously reported by Cross et al 
(Cross 2005), with similar expression patterns. Relative expression levels of ADAMTS-
1 and -15 in PC3, LNCaP and PCAF stromal cells show a similar pattern with the work 
of Cross et al. However, Cross et al found undetectable levels of TIMP-3 in PC3, 
whereas data from my experiments showed that TIMP-3 expression was detected and 
was approximately 3-fold higher in LNCaP cells compared to PC3 cells. The Ct values 
(the cycle number during the PCR reaction at which fluorescence level generated by the 
amplification of the gene of interest exceeds the background fluorescence) for TIMP-3 
in PC3 cells usually ranged from 32-35, compared with 16-18 for GAPDH. This 
indicates very low transcript levels of TIMP-3.   Expression of TIMP-3 in BPH stromal 
cells reported by Cross et al was approximately 100 fold relative to LNCaP cells. In my 
experiments, TIMP-3 expression was also 100 fold in PCAF stromal cells relative to 
LNCaP. The data are not directly comparable because of the fact that transcript levels 
have been analysed using the relative expression method, but the pattern of mRNA 
expression is similar for the two studies. 
Semi-quantitative analysis of ADAMTS-1 and -15 by western blotting was challenging 
for a number of reasons. The main reason was that a the time of these experiments, 
there were no commercially available antibodies against ADAMTS-1 and -15 that had 
been validated in published reports (to my knowledge). Antibodies are useful tools for 
laboratory research, but the lack of specificity of c mmercially available antibodies 
continues to be a source of concern (Bordeaux 2010). The utility of two anti-ADAMTS-
1 and two anti-ADAMTS-15 antibodies were evaluated. 
The first anti-ADAMTS-1 antibody (Abcam, ab39194) was raised against the C-
terminal domains of ADAMTS-1. The product literature did not indicate specifically the 
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size or sequence of the antigen used for antibody synthesis. The western blot 
experiments which were perfomed using this antibody detected multiple bands of 
varying sizes (Figure 4.4). This image was difficult to evaluate. It is possible that the 
antibody was reacting non-specifically to other proteins in the lysate. However it is 
known that fragments of 87kDa, 65kDa and 22kDa are sequentially cleaved from full 
length ADAMTS-1 (Rodriguez-Manzaneque 2000), and it is possible that the multiple 
bands detected were C-terminal fragments of varying le ths. Alternatively, the cells 
could have been producing splice-variants of ADAMTS-1, although this has not been 
reported previously. Because of the multiplicity of bands detected, it would have been 
difficult to assess the effect of ADAMTS-1 knock down in subsequent experiments 
using this antibody.  The second anti-ADAMTS-1 antibody (R&D Systems, MAB2197) 
used was raised against the catalytic domain (amino acids Arg258 – Phe849). This 
antibody detected bands of size 75kDa-100kDa (Figure 4.5). This variation in size could 
be as a result of splice variants of ADAMTS-1 or post-translational processing 
(Rodriguez-Manzaneque 2000) as mentioned earlier. Validation of this antibody using 
ADAMTS-1 knock-down cells showed that mRNA knock-down did not attenuate the 
intensity of the bands on western-blots (Figure 4.6). Importantly, the bands detected in 
Figure 4.6 were of 50kDa size. No bands of 75kDa or 100 kDa were detected in the 
lanes with PC3 cell lysate blots but were present in the lane with recombinant human 
ADAMTS-1. Again, this could be as a result of post translational processing of full-
length ADAMTS-1 from 105kDa to smaller fragments of 50kDa, but could also be due 
to non-specific antibody binding to another protein of 50kDa. 
Western blotting for detection of ADAMTS-15 was done with two antibodies. The first 
antibody (Abcam, ab28516) was raised against a peptide sequence 
'HSTNRLTLAVAW', corresponding to His592 – Trp603 in the cysteine-rich domain. This 
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antibody detected faint bands of 25kDa in PC3 and LNCaP cells (Figure 4.7). 
Immunoprecipitation was used in an attempt to increase the concentration of ADAMTS-
15 protein in the samples. This created a problem bcause multiple high intensity bands 
were detected of size ranging from 15kDa to 50kDa (Figure 4.8). A number of control 
experiments were perfomed to detect the source of the bands. The results showed that 
the protein A-agarose beads were the source of the prot in being detected. Protein A has 
a mass of   40-60kDa and binds strongly to IgG (Lindmark 1983). The unknown protein 
was binding directly with the HRP-labelled IgG secondary antibody (Figure 4.9, 
Membrane 2). Immunoprecipitation had to be abandone because the dark bands were 
attributed to release of protein A from the agarose beads into solution, which was 
contaminating the immunoprecipitation samples. This s ould not have occurred, as the 
product information sheet stated that the protein A was covalently bound to the agarose 
via covalent bonds. However, this process must have be n incomplete, with non-
specifically adsorbed protein A being released in the detergent-containing buffers used 
for this experiment 
Heparin-agarose precipitation was also undertaken in another attempt to concentrate 
ADAMTS-15 and enable detection with the ab28516 antibody. Immobilised heparin has 
been used to separate heparin-binding proteins froms lution (Manaskova 2002) and 
ADAMTS-1, -4, -5 and -9 are known to bind heparin and heparan sulphate (Kuno 1998; 
Somerville 2003; Gao 2004; Zeng 2006). In the western blot experiments using heparin-
agarose precipitation to prepare the samples, no distinct bands were detected. This could 
possibly be because other heparin-binding proteins were more abundant in the cell 
lysates and had higher binding affinity to heparin than ADAMTS-15. For example β-
microseminoprotein and spermadhesins have been reported t  have the greatest affinity 
for heparin of the heparin-binding proteins in prostate tissue (Manaskova 2002). 
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Alternatively, ADAMTS-15 may have been undetected bcause the ab28516 antibody 
was not binding to ADAMTS-15 with high enough affinity. No control experiments 
were perfomed to identify the reason for the absence of bands, and the use of this 
antibody was discontinued in further experiments. 
The second anti-ADAMTS-15 antibody used (ab45047) was raised against the 
propeptide domain of ADAMTS-15. This antibody detected 50kDa bands on western 
blots (Figure 4.11). ADAMTS-15 knock-down using siRNA led to attenuation of the 
intensity of the 50kDa band (Figure 4.12), indicating that this antibody was specifically 
binging to ADAMTS-15. The full length ADAMTS-15 (including the signal peptide) is 
predicted to be a 103kDa protein (Cal 2002). The propeptide domain, Gly18 – Arg212 is 
approximately 21kDa. A 50kDa band suggests that ADAMTS-15 was processed post-
translationally, with cleavage yielding a 50kDa propeptide-containing fragment. 
Alternatively, the cells in the experiments were expr ssing a 50kDa splice variant of 
ADAMTS-15. Another possibility is that the 21kDa pro eptide could have been 
dimerised or glycosylated, with a resulting mass of 50kDa. Splice variants and 
dimerisation of ADAMTS-15 have not been described previously, but the ADAMTS-15 
propeptide has a potential glycosylation site at N141 (N-A-S).  
With the validation of the ab45047 antibody, heparin-agarose precipitation was repeated 
and western blotting performed using this antibody. No bands were detected. This 
suggests that if ADAMTS-15, like some of the other ADAMTSs, is a heparin-binding 
protein, there were other proteins in the cell lysate  that had stronger binding affinity for 
heparin than ADAMTS-15. Another possibility is that the C-terminal heparin-binding 
domains have been cleaved off and were precipitated by the heparin-agarose beads but 
not detected by the propeptide domain antibody, which would be in keeping with 
reports showing that ADAMTSs bind to heparan sulphate nd heparin via the TSP 
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domains at the C-terminal (Kuno 1998; Somerville 2003; Gao 2004; Zeng 2006). 
TIMP-3 protein expression was not analysed in this study. Validation of commercially 
available TIMP-3 antibodies was the subject of a doctorate study by another member of 
this research group, Miss Olajumoke Adeniji. Her effort was therefore not duplicated. 
The ab45047 antibody was used in fluorescence immunocytochemistry to probe 
expression of ADAMTS-15 in ADAMTS-15 knock-down and non-targeting knock-
down control cells. ADAMTS-15 expression was detected in the non-targeting knock-
down cells but not the ADAMTS-15 knock-down cells (Figures 4.13 and 4.14). This 
provided further evidence of the validity of the ab45047 antibody. 
In conclusion, this chapter describes experimental steps taken to validate antibodies for 
use in expression studies of ADAMTS-1 and -15. Neither of the two anti-ADAMTS-1 
antibodies was found to be reliable in analysis of ADAMTS-1 expression, one of the 
anti-ADAMTS-15 antibodies was validated and this antibody was used in further 
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CHAPTER 5:  
 
REGULATION OF ADAMTS-1 AND -15 mRNA EXPRESSION IN P ROSTATE 
CELLS BY DHT AND TNF 
 
5.1 Introduction 
Prostate epithelial cells depend on androgens for pr liferation and differential gene 
expression (Sandberg 1980). Growth and proliferation is mediated by growth factors 
which are secreted in response to androgen stimulation (Steiner 1993; Hellawell 2002). 
Testosterone from the circulation is converted in the prostate by 5-α reductase to DHT, 
the androgen which is most active in prostate tissue (Steers 2001; Zhu 2003). ADT in 
the form of surgical or medical castration is used in the management of locally 
advanced, metastatic, or relapsing disease. Androgen deprivation leads to reduction in 
the size of local tumours, and the size and number of metastatic deposits, as well as 
changes in gene expression (Huggins 1942; Nishi 1996). ADT reduces serum androgen 
concentration from about 2nM to undetectable levels (de Jong 1991; Anderson 2008), 
which has an adverse effect on castration-sensitive prostate cancer cell survival.  
ADAMTS-1 mRNA has been shown to be up-regulated by DHT in endometrial stromal 
cells after 24 hour treatments (Wen 2006). In vitro, LNCaP cell proliferation is 
maximally stimulated by DHT at concentrations between 1 and 10nM (Horoszewicz 
1983; Lin 1998; Sherwood 1998; Zhu 2003). The dissociation constant of the androgen 
receptor with DHT in prostate is 0.34nM at 0°C and pH7.5, and by extrapolation 
approximately 0.15nM at 37°C (Wilson 1976). 
LNCaP cells were treated with DHT to analyse the eff ct of DHT on ADAMTS-1 and -
15 expression as described in Section 2.15. To cover the range between castrate levels 
and maximal DHT stimulation, treatment doses of 0.1, 1 0 and 10nM DHT were used 
and compared with the control cells which had no DHT. Flutamide is a non-steroidal 
anti-androgen (Peets 1974). The inhibitory constant of flutamide is approximately 
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175nM at 4°C and pH7.5 (Kemppainen 1999). Prostate c ncer cells have been reported 
to carry mutations of the AR, which are thought to facilitate the progression to 
metastasis and castration resistance (Taplin 1995). Non-steroidal anti-androgens have 
been shown to paradoxically have agonistic activity in LNCaP cells and derivative cell 
lines as a result of AR mutations (Veldscholte 1990; Culig 1999).  To determine the 
effect of an excess of flutamide, LNCaP cells were also treated with 1µM flutamide, or 
10nM DHT + 1µM flutamide. PSA expression was used as a positive control. 
Patients with advanced prostate cancer are reported to have elevated serum levels of 
TNF (Michalaki 2004). As macrophages infiltrate the tumour site, they release 
cytokines locally as part of the inflammatory reaction to the presence of the tumour 
(Coussens 2002). This could explain the elevated levels of TNF and IL-6 in patients 
with advanced prostate cancer (Michalaki 2004). In that study, serum TNF and IL-6 
levels were as high as 6.3 and 9.3 pg/ml respectively in patients with metastatic disease, 
compared with TNF and IL-6 serum levels of 1.1 and 1.3 pg/ml respectively in patients 
with localised disease. TNF concentrations may be much higher locally at the tumour 
site. In patients with rheumatoid arthritis (RA), TNF levels are approximately five times 
higher in synovial fluid than in serum (Steiner 1999). TNF levels in synovial fluid, the 
local site of inflammation in RA range from 39 – 382pg/ml (Lettesjo 1998; Steiner 
1999). ADAMTS-1, -4, -5, -6 and -9 are reported to be regulated by pro-inflammatory 
cytokines (Bevitt 2003; Demircan 2005; Ng 2006). TNF induces cancer cachexia 
(Tracey 1992), an activity that is mediated by TNF receptor type I (TNFR1) activation 
(Llovera 1998). ADAMTS-1 is highly expressed in some cachexia-inducing tumours 
(Kuno 1997). TNF and other cytokines could have an effect on prostate cancer 
progression by modulating the expression of ECM proteinases, and altering the 
homeostatic balance between proteinases and their natural inhibitors. 
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To cover the range of TNF concentrations detected in serum and tissue in physiological 
and pathological states, PC3, LNCaP and BPH45 prostatic stromal cells were treated 
with TNF at concentrations of 10pg/ml (0.571pM), 100pg/ml (5.71pM), 10ng/ml 
(571pM) or control (solvent only) as described in Section 2.17. The dissociation 
constant of TNF with TNFR1 and TNFR2 is 19pM and 420pM respectively at 37° and 
pH7.5 (Grell 1998). 
 
5.2 Regulation of PSA, ADAMTS-1, ADAMTS-15 and TIMP-3 mRNA expression 
by DHT and Flutamide 
The effect of DHT and flutamide on PSA, ADAMTS-1 and -15 mRNA expression was 
analysed. Changes in expression of the metalloproteinas  inhibitor, TIMP-3, was also 
analysed. 
5.2.1 Regulation of PSA Expression by DHT 
PSA mRNA expression in LNCaP cells was up regulated when the cells were treated 
with increasing concentrations of DHT (Figure 5.1), with median up-regulation of  1.5, 
6.9 and 16-fold when treated with 0.1, 1.0 and 10nM DHT respectively. There was 
significant variance in the medians using the Kruskall-Wallis test (p = 0.0076).  Using  
Dunn’s multiple comparison test, there was a significant difference in PSA mRNA 
expression between control and 10nM DHT treatment (p<0.01), but not DHT 0.1nM or 
DHT 1nM treatment (p>0.05). Flutamide 1µM treatment did not regulate PSA 
expression compared with control (p>0.05), which suggests that flutamide did not have 
AR agonist activity at 1µM. Comparing DHT 10nM treatment and DHT 10nM + 
Flutamide 1µM treatment showed no significant difference (p>0.05), indicating that 
Flutamide did not inhibit the effect of DHT 10nM (Figure 5.1). 
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Figure 5.1: Relative expression of PSA mRNA in LNCaP cells treated with DHT and the 
non-steroidal androgen antagonist flutamide. Cells were treated for 24 hours with the 
specified doses of DHT or flutamide, lysed and cDNA was synthesized for analysis by 
real-time RT-PCR. Each data point represents an indiv dual sample of cDNA. The 
horizontal bars denote the median expression level for each treatment group. 
Expression levels in treated cells shown as fold changes relative to controls. Results 
were collated from 4 separate experiments (n=4) showing the expression level of PSA 
mRNA in the treated cells relative to expression in untreated cells (control).The 
Kruskall-Wallis test for variance of the medians and Dunn’s multi-comparison test was 
used to analyse for differences between the groups. Asterisks at the top denote treatment 
groups in which difference in expression levels relative to control were statistically 





5.2.2 Regulation of ADAMTS-1 mRNA Expression by DHT 
DHT treatment did not significantly regulate expression of ADAMTS-1 mRNA at any 
of the concentrations used (Figure 5.2). The Kruskall-W llis test demonstrated that the 
medians had no significant variance (p = 0.2172). Dunn’s multiple comparison test was 
used to analyze differences in rank sum between each treatment group and control. 
ADAMTS-1 mRNA expression was not significantly regulated with any of the 
treatments used.  
 
 
Figure 5.2: Expression of ADAMTS-1 mRNA in LNCaP cells treated with DHT and the 
non-steroidal androgen antagonist flutamide. Experim ntal conditions were the same as 
described in Figure 5.1. Results were collated from 15 separate experiments (n=15) 
showing the expression level of ADAMTS-1 mRNA in the treated cells relative to 
expression in untreated cells (control). The Kruskall-Wallis test for variance of the 
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medians and Dunn’s multi-comparison test were used to analyse for differences in 
expression between the groups. 
 
5.2.3 Regulation of ADAMTS-15 mRNA and Protein Expression by DHT 
DHT treatment down-regulated the expression of ADAMTS-15 mRNA by 40% and by 
70% with treatments of 0.1nM and 1nM DHT respectively (Figure 5.3). The Kruskall-
Wallis test demonstrated that the medians had a significantly different variance (p = 
0.0022). Dunn’s multiple comparison test was used to analyze differences in rank sum 
between each treatment group and control. ADAMTS-15 mRNA expression was 
significantly down-regulated with treatments of 0.1nM DHT (p<0.05), 1nM DHT (p 
<0.001), 1µM flutamide (p<0.01) and 10nM DHT with 1µM flutamide (p<0.05). 
Comparing the 10nM DHT treatment group with the 10nM DHT plus 1µM flutamide 
treatment group showed no significant difference in ADAMTS-15 expression. Grubb’s 
test was applied to the 10nM DHT treatment group to identify and remove an outlying 
sample, after which the difference in the median ADAMTS-15 mRNA expression 
between control and the 10nM DHT group was significant (p<0.05).  
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Figure 5.3: Expression of ADAMTS-15 mRNA in LNCaP cells treated with DHT and 
the non-steroidal androgen antagonist flutamide. Experimental conditions were the 
same as described in Figure 5.1. Results collated from 11 separate experiments (n=11) 
showing the expression level of ADAMTS-15 mRNA in the treated cells relative to 
expression in untreated cells (control). The Kruskall-Wallis test for variance of the 
medians and Dunn’s multi-comparison test were used to analyse for differences 
between the groups.  Asterisks were used to denote treatment groups in which difference 




To analyze the effect of DHT stimulation on ADAMTS-15 protein expression, LNCaP 
cells were treated with DHT with and without flutamide for 72 hours as described in 
Section 2.15. Western blotting was done using the ab45047 anti-ADAMTS-15 antibody 
which was validated previously (Section 4.3.5).  50kDa bands were detected in all the 
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lanes (Figure 5.4). To determine if there were differences in intensity of the bands, they 
were analyzed by densitometry as described previously (Section 2.13). In keeping with 
the mRNA data, ADAMTS-15 protein was down-regulated by DHT. Densitometric 
analysis showed that down-regulation by DHT was in a dose-dependent manner (Table 
5.1). This effect was not inhibited by flutamide. In fact, as had been observed at the 




Figure 5.4:  Expression of ADAMTS-15 protein in LNCaP cells treated with DHT. 
Western blotting was used to detect ADAMTS-15 expression in LNCaP cells treated for 
72hours with control, 0.1nM DHT, 1nM DHT, 10nM DHT, 1µM flutamide and 10nM 
DHT plus flutamide.  Cellular protein and surroundig ECM were solubilised with 
Triton X-100 and protein was quantified with the MicroBCA assay. 100µg of protein 
was loaded in each lane. Bands of 50kDa were detected (Upper Panel). The PVDF 
membrane was stripped and re-probed with anti-GAPDH antibody (Lower Panel) as a 





Table 5.1: Densitometric analysis of 50kDa bands detect d on western blots. The bands 
detected in each lane were analysed by densitometry for differences in intensity. The 
adjusted volume of the bands were quantified and compared with control. Results from 
two separate experiments are shown, the western blot for one of which is shown in 
Figure 5.4. 
 
5.2.4 Regulation of TIMP-3 mRNA Expression by DHT 
There was a dose dependent down-regulation of TIMP-3 mRNA expression by DHT 
which was not reversed with flutamide (Figure 5.5). The Kruskall-Wallis test 
demonstrated that the medians had a significantly different variance (p<0.0001). Dunn’s 
multiple comparison test was used to analyze differences in rank sum between each 
treatment group and control. Median expression of TIMP-3 was down-regulated by 
50% with treatment of 1nM DHT (p<0.05), 60% with treatment of 10nM DHT 
(p<0.001), 60% with treatment of 1µM flutamide (p<0.01) and 80% with treatment of 
10nM DHT plus 1µM flutamide (p<0.001). Flutamide did not inhibit the effect of DHT. 
Comparing the 10nM DHT treatment group with the 10nM DHT plus 1µM flutamide 
treatment group showed no significant difference in TIMP-3 expression. Flutamide 
again had a similar effect as DHT by down-regulating TIMP-3 expression.  
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Figure 5.5: Expression of TIMP-3 mRNA in LNCaP cells treated with DHT and the 
non-steroidal androgen antagonist flutamide. Experim ntal conditions were the same as 
described in Figure 5.1. Results were collated from 12 separate experiments (n=12). 
The Kruskall-Wallis test for variance of the medians and Dunn’s multi-comparison test 
were used to analyse for differences between the groups. Asterisks were used  to denote 
treatment groups in which difference in expression levels relative to control were  
statistically significant (p<0.05 *, p<0.01 **, p<0. 01***). 
 
5.3 Putative AREs in the ADAMTS1 and ADAMTS15 Genes 
AREs are 15-base pair (bp) DNA sequences comprising two six-bp half sites separated 
by a three-bp spacer. The sequence 5’-GGA/TACAnnnTGTTCT-3’ has been described 
as the consensus ARE (Roche 1992), but there is considerable variation in the sequence 
and configuration of AREs located in association with androgen responsive genes 
(Monge 2006).  
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Expression of ADAMTS-15 was down-regulated by DHT (Section 5.2.3), but the 
ADAMTS15 gene has not been previously described as an androgen- e ulated gene. The 
ADAMTS1 and ADAMTS15 gene promoters and gene sequences were screened to 
identify putative AREs using the online nuclear receptor binding site search tool, 
NUBIScan as described in Section 2.16.  
One ARE was identified in the ADAMTS15 promoter and 12 AREs in the gene 
sequence. ADAMTS-1 mRNA expression was not regulated by DHT in previous 
experiments (Section 5.2.2). The ADAMTS1 gene had no putative AREs in the promoter 
region and only two in the gene sequence. Tables 5.2 and 5.3 give the position, 
orientation, sequence and score for the putative AREs identified.  
Schematic representations of the ADAMTS1 and ADAMTS15 genes in Figure 5.6 and 





Orientation ARE Sequence Score 
Promoter - - - - 
4933(-) DR GGTGCTacaTGTGCT 0.82 Sequence 
7676(+) DR TGGTCAtcaTGTTCT 0.81 
 
Table 5.2:  Positions, orientation, sequence and similarity score of the AREs detected in 
the ADAMTS1 Gene. For the repeat orientation, DR  denotes direct repeat.  
 
 
Figure 5.6:   Putative AREs identified in the ADAMTS1 gene. The transcription start 
point (TSP) denotes the end of the promoter and the start of the gene sequence. 2 AREs 
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was identified in the gene sequence. The positions (bp) of the AREs relative to the TSP 





Orientation ARE Sequence Score 
Promoter -2319(+) ER GGAACAtaaGGTGCG 0.81 
DR AGCACCccgAGTACT 0.81 
ER AGCACCccgAGTACT 0.88 
914(+) 
914(+) 
914(+) IR AGCACCccgAGTACT 0.81 
928(-) DR AGTACTcggGGTGCT 0.88 
2357(+) ER GGCACAgctAGTCCC 0.81 
6884(-) DR AGTGCTctgAGTGCA 0.87 
6893(-) DR AGTGCCgagAGTGCT 0.84 
7038(+) IR TGTGCTgccTGGACT 0.86 
12880(-) DR TGTCCCcacAGTGCC 0.81 
16123(+) DR TGAACCgttAGTTCA 0.82 
16123(-) ER TGAACCgttAGTTCA 0.89 
19163(+) IR AGCACTctcTGAACT 0.81 
19177(-) DR AGTTCAgagAGTGCT 0.90 
Sequence 
24790(+) IR AGTGCAactTGCACC 0.84 
 
Table 5.3: Positions, orientation, sequence and similarity score of the AREs detected in 
the ADAMTS15 Gene. For the orientation, DR, ER, and IR enote direct repeat, everted 
repeat and inverted repeat respectively. 
 
Figure 5.7:   Putative AREs identified in the ADAMTS15 gene. The transcription start 
point (TSP) denotes the end of the promoter and the start of the gene sequence. 1 ARE 
was identified in the promoter and 12 in the gene sequence. The positions (bp) of the 
AREs relative to the TSP are indicated; (+) and (-) denote sense and antisense strands 
respectively.  
 
The same search was performed on the TIMP3 gene, which was also down-regulated by 
DHT (Section 5.2.4), and for comparison, the hKLK3 gene, which is up-regulated by 
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androgen (Riegman 1991), and the FOLH1 gene, which is down-regulated by androgen 
(Israeli 1994). The results are shown in Table 5.4.One of the AREs detected in the 
hKLK3 promoter region is known to be a functional PSA ARE sequence 
AGAACAgcaAGTGCT (Riegman 1991). The hKLK3 promoter had approximately 
double the ARE to base pair ratio compared to the ADAMTS15 and FOLH1 promoters, 
and 1.5 times that of the TIMP3 promoter. The hKLK3 gene sequence had 
approximately 1.5 times the ratio found in the ADAMTS15, TIMP3 and FOLH1 gene 
sequences and approximately 3 times the ratio in the ADAMTS1 gene sequence. 
























1,786 2,576 1,942 2,434 2,618 
AREs 0 1 1 2 1 Promoter 
AREs per 
base pair 




9,121 24,848 62,829 5,850 62,033 
AREs 2 12 31 4 25 Sequence  
AREs per 
base pair 
0.00022 0.00048 0.00049 0.00068 0.0004 
 
Table 5.4:  Summary of the ARE data for ADAMTS1, ADAMTS15, TIMP3, hKLK3 and 
FOLH1 genes.  
 
5.4 Regulation of ADAMTS-1 ADAMTS-15 and TIMP-3 mRNA Expression by 
TNF in PC3, LNCaP and Stromal Cells 
Prostate cancer and stromal cells were treated with TNF to determine the effect on 
ADAMTS-1, -15, and TIMP-3 mRNA expression. 
 
5.4.1 Regulation of ADAMTS-1 Expression by TNF 
ADAMTS-1 expression was not regulated by TNF in PC3, LNCaP and BPH45 cells at 
treatment doses of 10pg/ml, 100pg/ml or 10ng/ml (Figure 5.8). The Kruskall-Wallis test 
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showed that there was no significant variance betwen the medians of experiments with 








Figure 5.8: Expression of ADAMTS-1 mRNA in A) PC3, B) LNCaP and C) BPH45 cells 
treated with TNF. Cells were treated for 24 hours with the specified doses of TNF, lysed 
and cDNA was synthesized for analysis by real-time RT-PCR. Results were collated 
from 6 separate experiments (n=6) in A and B, and 4 separate experiments (n=4) in C. 
Each data point represents an individual sample of cDNA. The horizontal bars denote 
the median expression level for each treatment group. The expression levels of 
ADAMTS-1 mRNA in treated cells are shown as fold changes relative to controls. The 
Kruskall-Wallis test for variance of the medians and Dunn’s multi-comparison test were 
used to analyse for differences between the groups. Asterisks were used  to denote 
treatment groups in which difference in expression levels relative to control were  
statistically significant (p<0.05 *, p<0.01 **, p<0. 01***).  
 
5.4.2 Regulation of ADAMTS-15 mRNA Expression by TNF 
ADAMTS-15 expression was regulated by TNF in LNCaP and BPH45 cells but not in 
PC3 cells (Figure 5.9). The Kruskall-Wallis test showed no significant variance between 
C 
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the medians of experiments with PC3 cells (p=0.0806) and LNCaP cells (p=0.1070), but 
a significant variance in BPH45 cells (p=0.0043). Dunn’s post test showed that there 
was significant down-regulation of ADAMTS-15 in LNCaP cells at a treatment dose of 








Figure 5.9: Expression of ADAMTS-15 mRNA in A) PC3, B) LNCaP and C) BPH45 
cells treated with TNF. Cells were treated for 24 hours with the specified doses of TNF, 
lysed and cDNA was synthesized for analysis by real-time RT-PC. Results were collated 
from 6 separate experiments (n=6) in A and B, and 4 separate experiments (n=4) in C. 
Each data point represents an individual sample of cDNA. The horizontal bars denote 
the median expression level for each treatment group. The expression levels of 
ADAMTS-15 mRNA in treated cells are shown as fold changes relative to controls. The 
Kruskall-Wallis test for variance of the medians and Dunn’s multi-comparison test were 
used to analyse for differences between the groups. Asterisks were used  to denote 
treatment groups in which difference in expression levels relative to control were  
statistically significant (p<0.05 *). 
 
5.4.3 Regulation of TIMP-3 mRNA Expression by TNF 
As with ADAMTS-15, TIMP-3 expression was down-regulated by TNF in BPH45 cells 
but not in PC3 and LNCaP cells (Figure 5.10). The Kruskall-Wallis test showed no 
C 
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significant variance between the medians of experiments with PC3 cells (p=0.0882) and 
LNCaP cells (p=0.4387), but a significant variance in BPH45 cells (p=0.0101). Dunn’s 
post test showed that there was significant down-regulation of TIMP-3 in BPH45 cells 








Figure 5.10: Expression of TIMP-3 mRNA in A) PC3, B) LNCaP and C) BPH45 cells 
treated with TNF. Cells were treated for 24 hours with the specified doses of TNF, lysed 
and cDNA was synthesized for analysis by real-time RT-PCR. Results were collated 
from 4 separate experiments (n=4). Each data point represents an individual sample of 
cDNA. The horizontal bars denote the median expression level for each treatment 
group. The expression levels of TIMP-3 mRNA in treated cells are shown as fold 
changes relative to controls. The Kruskall-Wallis te t for variance of the medians and 
Dunn’s multi-comparison test were used to analyse for differences between the groups. 
Asterisks were used  to denote treatment groups in wh ch difference in expression levels 
relative to control were  statistically significant (p<0.05 *, p<0.01 **). 
 
5.5 Discussion 
In this chapter, the effects of DHT and TNF on exprssion of ADAMTS-1, -15 and 





 ADAMTS-1 ADAMTS-15  TIMP-3 
DHT LNCaP ↔ ↓ ↓ 
PC3 ↔ ↔ ↔ 
LNCaP ↔ ↓ ↔ TNF  
BPH45 ↔ ↓ ↓ 
 
Table 5.6: Summary of effect of DHT and TNF treatment on expression of ADAMTS-1, 
ADAMTS-15 and TIMP-3. Androgen-sensitive LNCaP cells were treated with DHT. 
PC3, LNCaP and BPH45 cells were treated with TNF. ↔ = Not regulated, ↓ = Down-
regulated. 
 
LNCaP androgen-sensitive cells were treated with DHT. DHT up-regulated PSA 
mRNA expression. DHT down-regulated the expression of ADAMTS-15 but had no 
effect on ADAMTS-1 expression. TIMP-3, an inhibitor f the ADAMTSs and other 
metalloproteinases, was also down-regulated by DHT. The non-steroidal AR inhibitor, 
flutamide did not inhibit the effect of DHT, but rather, had a similar effect of down-
regulating ADAMTS-15 (Figure 5.3) and TIMP-3 (Figure 5.5). The mRNA expression 
data for PSA, ADAMTS-1, -15 and TIMP-3 showed variability in mRNA expression in 
response to DHT treatment between treatments (Figures 5.1, 5.2, 5.3, & 5.5). Previous 
reports have shown a similar degree of variability in ADAMTS and TIMP mRNA 
expression in cell lines between experiments, resulting in a wide range of expression 
levels (Giricz 2010; Stokes 2010). LNCaP cells in culture are an aggregate of several 
sub-populations of cells (Wan 2003), and different sub-clones of LNCaP cells show 
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varying response to androgen treatment (Iguchi 2007). Iguchi et al stimulated two 
different populations of LNCaP cells and found that one had a greater response to 
androgen in terms of proliferation and PSA expression. One or more of these factors 
could explain the wide range of expression levels. In keeping with its role as an 
androgen antagonist, flutamide has been shown to inhibit up-regulation of ADAMTS-1 
by 100nM DHT in endometrial stromal cells at a concentration of 100nM (Wen 2006), 
and androgen receptor activation by 10pM DHT in PNTIA prostate epithelial cells at 
10nM concentration (Avances 2001). Previous studies have reported that mutations in 
the ARs of prostate cancer cells could lead to aberr nt activation by non-steroidal AR 
antagonists. LNCaP cells are known to have such a mutation in the LBD of the AR 
(Veldscholte 1992). This could account for the similar effect of DHT and flutamide on 
the LNCaP cells used in this study. 
Androgen-regulated gene expression is mediated via the ction of nuclear receptors. The 
activated AR binds to AREs in promoter regions of androgen regulated genes, where 
transcription factors are recruited by the receptor-ligand complex (Heinlein 2002). 
Transcription factors could either be co-activators r co-repressors. Recruitment of co-
activators by the receptor will lead to increased transcription of mRNA, while 
recruitment of co-repressors leads to decreased transcription (Heinlein 2002). Further 
experiments wre not performed to determine the mechanism of down-regulation of 
ADAMTS-15 by DHT. An in silico screen of the ADAMTS1 and ADAMTS15 genes for 
putative AREs found one ARE in the promoter region of ADAMTS15 but none in the 
promoter region of ADAMTS1. Some AR co-repressors for example the transcription 
factor ERG, have been reported to effect down-regulation of androgen-regulated genes 
by forming complexes with ligand-activated AR and sub equent binding to AREs on 
androgen-repressed genes (Chng 2012). It is also posible that the down-regulation of 
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ADAMTS-15 by DHT is an indirect effect, and is mediated by interaction of other 
androgen regulated proteins with the transcription mechanism of ADAMTS15 gene. 
Inhibition of protein synthesis by cyclohexamide attenuated AR mediated gene down-
regulation (Prescott 2007), suggesting that AR actsvia intermediary proteins to effect 
gene repression. 
The search strategy used a matrix comprising nine ARE half-sites derived from six 
AREs that are known to functionally bind to AR. The search strategy identified putative 
AREs that had two half-sites (each with at least 80% similarity to any of the nine known 
half-sites) separated by a non-specific 3bp sequence. This strategy would therefore not 
detect putative non-canonical AREs with more or less than 15bp or putative 6bp ARE 
half-sites.  In vitro studies have shown specific binding of AR to non-canonical AREs 
(Zhou 1997) and 6bp half-sites (Massie 2007), but functional binding and gene 
transcription has not been demonstrated. An analysis of the sequences of genomic AR 
binding sites showed that 27% were of the canonical sequence (Massie 2007). In a 
subsequent study by the same investigators, imposing a requirement of AR and RNA 
polymerase II co-binding found that 54% of indentified sites were of the canonical 
format (Massie 2011). This indicates that binding to 6bp ARE half-sites does not 
necessarily lead to recruitment of the key components of the trancsription mechanism. 
Seventy percent of the 6bp half-sites identified were located in close proxity to ETS 
transcription factor binding sites, and direct interaction between AR and ETS family 
transcription factors was required for binding at the 6bp half-sites (Massie 2007).  
Several putative AREs were also found down-stream of the TSP of the ADAMTS15 
gene. This raises the possibility that one or more of these AREs could be acting as an 
enhancer. Unlike gene promoters, gene enhancers can be located many thousand bp 
upstream or downstream of the TSP (Kleinjan 2005). The hKLK3 gene has such an 
 188 
enhancer containing an ARE which is located 4,200 bp upstream of the TSP (Cleutjens 
1997), and several studies have found that proportiona ely more AREs were located in 
the gene sequence than in the promoter region of androgen-regulated genes (Horie-
Inoue 2004), which is in keeping with the findings in this study.  
The significance of the ARE to base-pair ratio with respect to androgen up- or down-
regulation is not known. Analysis of the gene sequences showed that the hKLK3 
promoter region had twice the density of putative AREs as the FOLH1 and ADAMTS15 
promoters (Table 5.4). This may mean that more AREs are required to assemble co-
activator complexes than are required for the assembly of co-repressor complexes. 
Further studies are required to determine if the putative AREs identified in this study 
are functional because in silico based methods can identify the presence of transcription 
factors associated with genes but do not test functio ality (Wasserman 2004). 
 
PC3, LNCaP and BPH45 cells were treated with TNF. TNF treatment down-regulated 
the expression of ADAMTS-15 in LNCaP and BPH45 cells. TNF also down-regulated 
TIMP-3 expression in BPH45 cells, but ADAMTS-1 expression was not modulated by 
TNF in any of the cell lines tested. TNF is a pro-inflammatory cytokine that may also be 
playing a role in prostate cancer progression. A study by Mizikami et al showed that 
malignant prostate epithelial cells strongly expressed TNF compared to normal 
epithelial cells (Mizokami 2000). This suggests that in addition to TNF produced by 
TAMs, tumour cells express TNF. Another study showed that TNF at a treatment dose 
of 200U/ml (equivalent of 12ng/ml) down-regulated AR, PSA and Epidermal Growth 
Factor receptor (EGFR) expression and up-regulated th  expression of HLA Class I 
antigen in LNCaP cells (Sokoloff 1996). PC3 cells trea ed with TNF had down-
regulated expression of MMP-2 (Gelatinase A), basic Fibroblast Growth Factor (bFGF) 
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and P-Cadherin. TNF treatment inhibited proliferation of LNCaP cells, but not PC3 
cells (Sokoloff 1996).  
Mozokami et al also showed that TNF treatment at a dose of 30ng/ml reduced the 
sensitivity of LNCaP cells to androgen stimulation by down-regulating AR expression, 
with the resulting cells forming new androgen-insensitive cell populations (Mizokami 
2000). However, long term (> 3 months) treatment with 50ng/ml TNF produced LNCaP 
derived cells that had a greater rate of proliferation in response to DHT treatment 
compared to the parental LNCaP cells (Harada 2001). Results in this chapter showed 
that the effects of TNF were seen at doses of 100pg/ml and 10ng/ml (Figures 5.9 and 
5.10). In vivo studies in the literature have produced mixed results, with TNF treatment 
having partial or no anti-tumour effect on prostate cancer xenografts (van Moorselaar 
1991; van Moorselaar 1991). Clinical studies have shown that patients with advanced 
prostate cancer have elevated serum levels of TNF (Pfitzenmaier 2003; Michalaki 
2004). 
It is known that TNF could play either a pro- or anti-tumour role, depending on the site 
and stage of the cancer (Balkwill 2009). The body of evidence seems to suggest that 
TNF has anti-tumour activity in sarcomas, but minimal anti-tumour and sometimes pro-
tumour activity in epithelial tumours like prostate cancer (Balkwill 2009).  
It is not known with certainty the consequence of dwn-regulation of ADAMTS-15 and 
TIMP-3 in the TME. Evidence from breast cancer (Porter 2006) and colorectal cancer 
(Viloria 2009) suggests that ADAMTS-15 plays an anti-tumour role. TIMP-3 is an 
inhibitor of several MMPs, ADAMs and ADAMTSs, many of which degrade the ECM 
and promote prostate cancer cell invasion and metastase  (Nemeth 2002; Udayakumar 
2003; Aalinkeel 2004). ADAM-17 (TNF converting enzyme) is a metalloproteinase 
which sheds membrane-bound TNF into the ECM (Black 1997; Moss 1997). Down-
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regulation of TIMP-3 by TNF could lead to an increas  in ADAM-17 activity and 
initiate a vicious cycle creating a positive feed-back loop.  
Down-regulation of TIMP-3 would lead to increased activity of ECM degrading MMPs 
and favour cancer cell invasion and metastasis. Decreased TIMP-3 expression would 
also lead to attenuation of its anti-angiogenic effect (Qi 2003) and favour metastasis. 
With these findings put together, the implication of the down-regulation of ADAMTS-
15 and TIMP-3 by TNF in the TME is that TNF is likely playing a pro-tumour role in 


























































KNOCK-DOWN OF ADAMTS-1 & -15 
EXPRESSION & EFFECT ON 
PROLIFERATION, MIGRATION & 






















CHAPTER 6:  
 
KNOCK-DOWN OF ADAMTS-1 AND -15 EXPRESSION AND EFFECT ON 
PROLIFERATION, MIGRATION AND INVASIVE POTENTIAL OF PC3 
CELLS 
 
6.1 Introduction  
 
Previous chapters in this thesis have reported on the expression of ADAMTS-1 and -15 
in prostate cells and the effect of androgen and cytokine treatment on expression levels. 
In this chapter, results from functional assays following knock-down of ADAMTS-1 
and -15 expression are presented. PC3 prostate cancr cells were used for the functional 
assays because of their high clonogenic and invasive properties. PC3 cells have proven 
metastatic potential and are representative of an advanced, poorly differentiated prostate 
adenocarcinoma (Kaighn 1979). PC3 cells express ADAMTS-1 and -15 (Cross 2005), 
and hence provided a good model system to determine the ffects of ADAMTS-1 and -
15 in prostate cancer progression. 
Morbidity and mortality from prostate cancer is usually a consequence of local 
progression and metastasis of the primary tumour (Khafagy 2007). The cancer cells can 
invade locally; infiltrating surrounding tissues like the urethra, bladder and ureters, and 
eventually metastasize (Ware 1987). Metastatic spread could also occur to para-aortic 
lymph nodes lying adjacent to the ureters (Long 1999). Tumour infiltration of these 
structures could cause obstruction in the flow of urine, leading to renal failure and death 
(Mazur 1991; Paul 1994; Khafagy 2007). Prostate cancer also has a predilection to 
metastasize to bone, causing pain, pathologic fractu es and spinal cord compression in 
the vertebrae. Metastases to the lungs and the liver could lead to respiratory and hepatic 
failure respectively (Long 1999; Khafagy 2007). Understanding the mechanisms by 
which cancer cells infiltrate surrounding tissue and metastasize is therefore of utmost 
importance. 
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The role of ADAMTS-1 and -15 in proliferation, migration and invasion were 
evaluated, as these are three important processes involved in tumour progression (Ware 
1987; Arya 2006).  
 
6.2 ADAMTS-1 and -15 Knock-down in PC3 Cells 
A number of techniques have been used for transfection in mammalian cells. These 
include calcium phosphate co-precipitation (Graham 1973), lipid based transfection 
reagents (Chesnoy 2000) and electroporation (Chu 1987). These methods were 
evaluated to select the most suitable for introducing siRNA into PC3 cells to knock-
down ADAMTS-1 and -15 expression. 
6.2.1 Transient Knock-down 
Transient knock-down can be achieved by transfecting s RNA targeted against the gene 
of interest into cells. 
6.2.1.1 Metafectene Pro, Dharmafect 2 and Calcium Phosphate 
PC3 cells were transfected according to the supplier’s protocols as described in Section 
2.18.3.1 for Metafectene Pro, Section 2.18.3.2 for Dharmafect 2 and Section 2.18.2 for 
calcium phosphate using the Profection kit (Promega) with the siGENOME 
(Dharmacon, Thermo Fisher) transient siRNA knock-down system (Section 2.19). 
According to the product data sheets, Metafectene Pro (Biontex) and Dharmafect 2 
(Dharmacon, Thermo Fisher) are lipid based transfection reagents.  
Knock-down of target siRNA was analysed by real-time RT-PCR at 72 hours post-
transfection. ADAMTS-1 and -15 expression in non-targeting knock-down (NTC) PC3 
cells was compared with expression in knock-down and WT cells. To monitor 
transfection efficiency, siGLO Red was transfected into separate cells using each of the 
transfection reagents. Transfection using each method was done in triplicate. 
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Using the expression of siGLO Red as an indicator, 72 hours was the approximate time 
that the effect of transfection peaked. Expression of siGLO Red was greatest in the cells 
that were transfected with Metafectene Pro, and least in the cells transfected with 
Dharmafect 2 (Figure 6.1). However, the cells transfected with Metafectene Pro did not 
appear healthy. They were rounded and remained loosely attached to the bottom of the 





Figure 6.1: PC3 cells transfected with siGLO Red using Metafectene Pro, Dharmafect 2 
and calcium phosphate transfection reagents as indicated on each photo-slide. Photo-
Ca Phosph at 24 hrs Ca Phosph at 72 hrs 
Metafectene at 24 hrs Metafectene at 72 hrs 





micrographs images were captured at 24 hours post-transfection and 72 hours post-
transfection. 
 
At 72 hours post-transfection, cells were lysed andsamples prepared for real-time RT-
PCR to determine expression levels of ADAMTS-1 and -15 mRNA. The results of 
transfection with these three agents were compared (Figure 6.2). The transfection 
process up-regulated ADAMTS-1 and -15 mRNA expression, evident by the higher 
expression of ADAMTS-1 and -15 in the non-targeting knock-down (NTC) cells 
compared to WT. Comparing the NTC with the knock-down cells, the highest 
transfection efficiency was seen with Metafectene Pro, followed by calcium phosphate. 
This was in keeping with the pattern of expression of siGLO Red seen in Figure 6.1. 
Transfection using Dharmafect 2 led to higher expression in the knock-down cells in 
one of the replicates of ADAMTS-1 knock-down (ATS1) and two replicates of 
ADAMTS-15 knock-down (ATS15). Transfection using Dharmafect 2 had previously 
produced as low as 80% knock-down of target genes i previous experiments (Sections 















Figure 6.2: Transient transfection of PC3 cells with siRNA against ADAMTS-1 (A), and 
ADAMTS-15 (B). Knock-down of target siRNA was analysed by real-time RT-PCR at 72 
hours post-transfection. Transfections were perfomed in triplicate. ADAMTS-1 
expression (A) and ADAMTS-15 expression (B) were compared in non-targeting knock-
down (NTC), ADAMTS-1 knock-down (ATS1), ADAMTS-15 knock-down (ATS15) and 






PC3 cells were transfected by electroporation using the Nucleofector II (Amaxa, Lonza) 
Kit-V which was optimised for PC3 cells by the supplier as described in Section 2.18.1 
using the siGENOME (Dharmacon, Thermo Fisher) transient siRNA knock-down 
system (Section 2.19). Separate cells were also transfected with a non-targeting siRNA 
sequence (NTC). Knock-down of target siRNA was analysed by real-time RT-PCR at 
72 hours post-transfection. 
Cell attrition was not observed when cells were examined under the microscope at 24, 
48, and 72 hours post-transfection. Electroporation resulted in knock-down of 
ADAMTS-1 and -15 mRNA in PC3 cells, with approximately 80% knock-down, as 
determined by real-time RT-PCR at 72 hours post-transfection (Figure 6.2). 
6.2.2 Stable Knock-down 
DNA coding for two shRNA sequences against ADAMTS-1 mRNA designated ATS1a 
and ATS1b were designed as described in Section 2.20. The oligonucleotides were 
annealed and inserted into the p-Silencer 4.1 CMV vector system (Invitrogen) using the 
supplier’s protocol and used to transform TOP-10 competent E.coli. PC3 cells were 
transfected with DNA for either ATS1a or ATS1b by electroporation with the 
Nucleofector II kit (Amaxa, Lonza) as described in Section 2.18.1.  An empty neomycin 
resistance vector (NTC) was transfected to be used a  control. Successfully transfected 
cells were selected by growing in complete medium containing 12.5µg/ml puromycin 
(Invitrogen) for ATS1a or complete medium containing 500µg/ml geneticin for ATS1b 
in 100mm tissue culture dishes. These optimal concentrations of selection antibiotics 
were determined by a ‘death curve’. WT PC3 cells were grown in wells containing 
increasing doses of the respective antibiotic. The lowest concentration of antibiotic that 
caused massive cell death of WT cells was selected. The antibiotic selection media 
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killed off cells that were not successfully expressing the puromycin or neomycin 
resistance genes, leaving scattered colonies of surviving cells in the dish. Clones were 
selected from the surviving cells using 3mm cloning discs (Sigma). The cell colonies 
were washed twice in PBS and trypsin-soaked cloning d scs were placed on the each 
colony with sterile forceps for 5 minutes. The disks were picked up and placed into 
individual T25 flasks and the clones were left to pr liferate, expanding into T75 flasks. 
The clones were kept under antibiotic selection pressure. Expression levels of 
ADAMTS-1 in the clones was analysed by real-time RT-PCR. 
ATS1a and ATS1b knock-down cells produced viable clones that were expanded in 
culture. The NTC cells did not survive when grown in antibiotic selection media, 
suggesting that the neomycin resistance DNA was not being incorporated into the 
cellular DNA. WT PC3 cells were cloned in a similar manner as the transfected cells. 
Three clones were generated.  
The ATS1a construct produced eight clones, while the ATS1b produced two. One of the 
WT clones was designated as the control, and the expression of ADAMTS-1 mRNA 
was determined in the other two WT clones and the ATS1a and ATS1b clones relative 
to the control. The most important finding was that the cloning process revealed that 
there was a wide range of expression between WT cells that were cloned from the same 
cell population (Figure 6.3). This made interpretation of the knock-down results 
difficult, as it was not possible to ascertain whether the differences in expression in the 
knock-down cells was due to a specific knock-down effect, or due to inherent 
differences in expression levels between clonal populations.  Also, the difficulty in 
generating a non-targeting knock-down clone of cells to use as controls meant that the 
ATS1a and ATS1b clones could not be used in experiments to study the biological 
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functions of ADAMTS-1 in PC3 cells. For the same reasons, this knock-down system 
was not used for down-regulation of ADAMTS-15. 



















































































Figure 6.3: Expression levels of ADAMTS-1 mRNA in PC3 stable knock-down clones 
(ATS1a and ATS1b) relative to a WT PC3 cell clone (WT1). Stable transfection of DNA 
coding for short hairpin RNA (shRNA) against ADAMTS-1 was transfected into PC3 
cells by electroporation. Following electroporation, the cells were plated in 100mm 
tissue culture dishes in complete medium for 24 hours. Medium was changed to 
antibiotic selection media and clones were selected an  expanded from surviving 
colonies. Knock-down of target siRNA was analysed by real-time RT-PCR. Expression 
in two other WT clones (WT2 and WT3) was also determined. Results are from one 
experiment which is representative of 2 experiments. 
 
6.3 Functional Assays 
ADAMTS-1 and -15 expression was knocked down separately in PC3 cells using the 
transient siRNA knock-down procedure as described in Section 6.2.1.2. At 72 hours 
post transfection, levels of ADAMTS-1 and ADAMTS-15 expression in the ADAMTS-
1 knock-down (ATS1kd) and ADAMTS-15 knock-down (ATS15kd) cells respectively 
was analysed relative to non-targeting control (NTC) cells using real-time RT-PCR. A 
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minimum of 70% knock-down was arbitrarily set for cells to be used in all of the 
functional assays reported below. Functional assays were commenced on Day 5 post-
transfection, as previous experiments (Section 4.3.5) had shown that ADAMTS-15 
protein expression was down-regulated at Day-5 post-transfection. 
6.3.1 Proliferation 
ADAMTSs are involved in ECM remodelling by cleaving proteoglycans (Jones 2005). 
The ECM acts as a reservoir for growth factors hence ECM degradation increases the 
bio-availability of growth factors sequestered in the ECM (Ruoslahti 1991; Schultz 
2009). Down regulation of ADAMTS-1 and -15 could alter the rate of ECM proteolysis 
and cell proliferation. 
6.3.1.1 Haemocytometer Cell Counts 
Proliferation of PC3 ATS1kd and ATS15kd cells were compared to NTC cells by using 
direct cell counts to produce a growth curve (Jones, H.E. 1997; Wiepz 2006). Fifty 
thousand cells/well were plated in 12-well plates in quadruplicate in serum-free 
medium. Serum-free medium was used as there was no certainty that serum added to the 
media would not contain high enough concentrations f ADAMTS-1 or ADAMTS-15 
to attenuate the effect of knock-down. At 24, 48, and 60 hours, cells were washed twice 
with phosphate buffered saline (PBS) and detached using trypsin-EDTA and counted 
using an Improved Neubauer haemocytometer (Hawksley). After each count, the cells 
were re-plated and incubated until the next time point. 
The growth curve showed a progressive attrition of cells in all the ATS1kd, ATS15kd 
and NTC cells (Figure 6.4), suggesting that this method was not suitable for studying 
proliferation under the conditions used in our experim nts. Possible reasons for the 
attrition of the cells were the effect of repeated trypsinisation on the cell membranes that 
had possibly not recovered from electroporation, and the use of serum-free medium for 
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the proliferation assay, which did not neutralise th rypsin when the cells were re-
plated after each count.  
 
Figure 6.4: Cell proliferation assay comparing rate of proliferation in ADAMTS-1 
knock-down (ATS1kd), ADAMTS-15 knock-down (ATS15kd) an  non-targeting knock-
down (NTC) PC3 cells using the haemocytometer count method. Knock-down levels 
were analysed by real-time RT-PCR at 72 hours post-transfection. At Day 5 post-
transfection, 50,000 cells/well of each cell type wre placed in 12-well plates in 
quadruplicate in serum-free medium. At 24, and 48 hours, cells were detached using 
trypsin-EDTA and counted using a haemocytometer. After each count, the cells were re-
plated and incubated until the next time point. Mean (±) SEM is displayed. The assay 
was terminated at Day 2 due to the large attrition of cells. 
 
 
6.3.1.2 MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) Assay 
Proliferation of ATS1kd and ATS15kd cells were compared to NTC cells using an MTT 
assay (Sigma) as described in Section 2.23.2. Mitochondrial dehydrogenases of viable 
cells cleave the tetrazolium ring of MTT forming formazan crystals which change the 
colour of the solution from yellow to purple (Vistica 1991). Compared to direct cell 
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counts, the MTT assay is less labour intensive and voids repeated trypsinisation 
(Wiepz 2006). Fifty thousand cells/well were plated in 12-well plates in triplicate. For 
each experiment, 4 sets of cells were plated, 1 set each to be counted on day 0, day 1, 
day 2 and day 5 of the experiment. The experiment was done three times (n=3). 
Results from each experiment were plotted in the form f growth curves (Figure 6.5). 
There were no significant differences in the rate of pr liferation between ADAMTS-1 
knock-down cells, ADAMTS-15 knock-down cells and non-targeting knock-down cells. 
The experiment was not carried on beyond 5 days becaus  using a transient knock-down 







Figure 6.5: Cell proliferation assay comparing rate of proliferation in ADAMTS-1 
knock-down (ATS1kd), ADAMTS-15 knock-down (ATS15kd) an  non-targeting knock-
down (NTC) PC3 cells using the MTT method. Knock-down levels were analysed by 
real-time RT-PCR at 72 hours post-transfection to ensure a minimum of 70% knock-
down. At Day 5 post-transfection, 50,000 cells/well of each cell type were placed in 12-
well plates in quadruplicate in serum-free medium. For each experiment, 4 sets of cells 
were plated, to be analysed on day 0, day 1, day 2 nd day 5 of the experiment. At the 
designated time point, absorbance was measured using the protocol for the MTT assay. 
Absorbance was plotted against time. Mean (±) SEM is shown. 
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Table 6.1: P values of proliferation assays done using the MTT method comparing 
ADAMTS-1 knock-down (ATS1kd) and ADAMTS-15 knock-down (ATS15kd) with non-
targeting knock-down (NTC) PC3 cells. P values were calculated using the two-tailed 
unpaired t-test. P values for individual time points in each experiment are shown. Data 
from all three experiments were pooled and the resulting P values displayed. 
 
6.3.2 Migration 
For the purpose of this thesis, migration was defined as the movement of living cells in 
contact with a biologic or synthetic scaffold, from one position to another, with no 
physical barrier between the two positions. Motility of cancer cells is essential for 
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invasion and metastasis (Wolf 2003). Cell migration s a complex process requiring 
anterior protrusion and attachment to the ECM, localised ECM degradation and 
posterior detachment and retraction (Lauffenburger 1996). Gon-1, a homologue of 
ADAMTSs in Caenorhabditis elegans, mediates cell migration during gonadogenesis 
(Blelloch 1999). The proteoglycanase activity of ADMTS-1 implies that it could be 
playing a role in ECM remodelling during migration. Also, ECM degradation could be 
releasing chemotactic factors that influence cell motility. ADAMTS-15 is predicted to 
be a proteoglycanase (Cal 2002) but its role in the ECM is not clear. The effect of 
ADAMTS-1 and -15 knock-down on migration was analysed using two methods, the 
wound healing (scratch) assay, and a modified Boyden chamber assay. 
6.3.2.1 Migration using Scratch Assays 
The scratch assay (O'Toole 1997; Cao 2006; Liang 2007) was used with some 
modifications as described in Section 2.24.1. One hundred thousand cells were plated in 
12-well plates that had been pre-coated with Matrigel to act as a biological scaffold for 
the migrating cells. Assays were run for 24 hours. Six experiments were perfomed, four 
comparing ADAMTS-1 and -15 knock down cells with non-targeting knock-down cells, 
and two experiments each comparing either ADAMTS-1 or ADAMTS-15 knock-down 
cells with non-targeting knock-down cells. Each experiment was done in triplicate. 
Distance migrated was calculated by subtracting the width of the start gap from the 
width of the end gap as illustrated in Figure 2.7. The results of each experiment were 
plotted graphically (Figure 6.6) and the relative-fold difference in migration between the 
non-targeting knock-down and the ADAMTS knock-down cells was calculated by 
normalising the mean distance migrated in the non-targeting knock-down cells to 1. The 
relative-fold changes from Experiments 1 to 6 were pooled together and the two-tailed 
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paired t-test was used to analyse the results for significant differences in migration 
between the ADAMTS knock-down cells and the non-targeting knock-down cells.  
Analysis of the pooled data from all six experiments showed no change in the migration 











Figure 6.6: Cell migration assay comparing rate of migration in ADAMTS-1 knock-
down (ATS1kd), ADAMTS-15 knock-down (ATS15kd) and no -targeting knock-down 
(NTC) PC3 cells using the scratch method. Six experiments were carried out, four 
comparing ADAMTS-1 and -15 knock down cells with non-targeting knock-down cells, 
and two experiments each comparing either ADAMTS-1 or ADAMTS-15 knock-down 
cells with non-targeting knock-down cells. Each experiment was done in triplicate. 
Distance migrated was plotted and the rate of migrat on of the knock-down cells 
relative to control in each experiment was calculated by normalising the distance 
migrated by the non-targeting knock-down cells to 1. Results of all six experiments were 
pooled to show relative-fold changes in migration (large graph at the bottom). The two-
tailed paired t-test was used to analyse the results for significant differences in the 
relative migration of the ADAMTS knock-down cells compared to the non-targeting 
knock-down cells. Mean (± SEM) is shown. 
 
6.3.2.2 Migration using Boyden Chamber Assays 
The modified Boyden chamber was adapted for use in migration assays (Albini 1987; 
Taniguchi 1989; Szpaderska 2001) as described in Section 2.24.2. Based on results of 
chemo-attraction assays reported in Section 3.5, 48 hour conditioned medium from 
prostatic stromal cells was placed in the lower chamber as a chemo-attractant as 
described in Figure 2.6. Seven-day conditioned medium was not used as there was 
evidence of nutritional depletion of the conditioned medium at 7 days. Assays were run 
for 6 hours.  
Nine experiments were performed, six comparing ATS1kd cells and ATS15kd cells 
with NTC cells, two comparing ATS1kd cells with NTC cells and one comparing 
ATS15kd cells with NTC cells. Each experiment was done in triplicate. The results of 
 209 
each experiment were plotted graphically (Figure 6.7). The relative difference in 
migration between the non-targeting knock-down and the ADAMTS knock-down cells 
was calculated by normalising the mean number of non-targeting knock-down cells to 1. 
Data from individual experiments were pooled and the two-tailed paired t-test was used 
to analyse the results for significant differences in the relative-fold changes in migration 
between the ADAMTS knock-down cells and the non-targeting knock-down cells.  
Analysis of the pooled data from all nine experiments showed no change in the 







Figure 6.7: Cell migration assays comparing rate of migration in ADAMTS-1 knock-
down (ATS1kd), ADAMTS-15 knock-down (ATS15kd) and no -targeting knock-down 
(NTC) PC3 cells using the modified Boyden chamber mthod. The number of cells 
migrating to the lower surface of the filter was counted at x20 magnification.  Nine 
experiments were perfomed, six comparing ATS1kd cells and ATS15kd cells with NTC 
cells, two comparing ATS1kd cells with NTC cells and o e comparing ATS15kd cells 
with NTC cells. Each experiment was done in triplicate. Number of cells migrating per 
high power field was plotted and the number of migrating knock-down cells relative to 
control in each experiment was calculated by normalising the number of migrating NTC 
cells to 1. Results of all the experiments were pooled to show relative changes in 
migration. The two-tailed paired t-test was used to analyse the results for significant 
differences in the relative migration of the ADAMTS knock-down cells compared to the 




In addition to their ability to migrate, cancer cells require the ability to degrade the 
ECM proteins and proteoglycans that form structural barriers between tissue 
Pooled Data 
 212 
compartments (Liotta 1986; Mareel 2003). For the purpose of this thesis, invasion refers 
to the movement of living cells in contact with a biological or synthetic scaffold, from 
one point to another, with a biological barrier separating the two points. Cancer cells of 
epithelial origin, like prostate cancer, have to breach the basement membrane 
underlying the epithelium on order to reach the stroma. They also have to penetrate the 
basement membrane encasing the endothelial cells in the vasculature in order to enter 
the circulation and metastasize to distant sites (Rowe 2008). Basement membranes are 
composed mainly of laminin and type IV collagen forming polymeric networks in a 
sheet-like structure (Kalluri 2003). Metalloproteinases have been implicated in the 
process of ECM and basement membrane degradation (Rowe 2009). The 
proteoglycanase properties of ADAMTS-1, and possibly ADAMTS-15, make them 
candidate proteinases for investigation into the mechanism of prostate cancer cell 
invasion.  
6.3.3.1 Invasion using Boyden Chambers Assays  
Invasion assays were adapted for modified Boyden chambers (Boyden 1962; Albini 
1987; Taniguchi 1989; Szpaderska 2001; Albini 2007) as described in Section 2.25 
using Transwell permeable polycarbonate 13mm filter wells with 8µm pore size 
(Corning, Fisher Scientific) coated with Matrigel as a biological barrier to cell 
migration. This experimental model mimics the process of invasion of the basement 
membrane. Two important variables of the invasion assay are the amount of Matrigel 
used to coat the filters, and the optimal length of time to run the assay. A novel method 
was devised to determine the assay duration for PC3cells by allowing detection of 
invading cells in real-time. The polycarbonate filters were coated with 20µg of 
Matrigel. Some filters were also coated on the under-surface with Matrigel containing 
50µg/ml of DQ-Gelatin. Based on results of chemo-attraction assays reported in Section 
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3.5, 48 hour conditioned medium from prostatic stromal cells was placed in the lower 
chamber as a chemo-attractant as described in Figure 2.6. Seven-day conditioned 
medium (Figure 2.8) was not used as there was evidence of nutritional depletion of the 
conditioned medium at 7 days.  For the wells with the under-coating of DQ-Gelatin 
containing Matrigel, invading cells were detected by counting fluorescent spots as the 
invading cells proteolytically cleaved the DQ-Gelatin on the under-surface of the filter 
(Figure 2.8). For the wells with no DQ-Gelatin, the number of invading cells was 
counted either by staining the filters with haematoxylin and eosin (H&E), or with 4% 
(w/v) crystal violet in 95% (v/v) ethanol as described in Section 2.25. 
Using the fluorescence method, the filters were examined under a fluorescence 
microscope every six hours. Fluorescent spots were first detected at 24 hours. The assay 
was continued and terminated at 48 hours. Figure 6.8 shows the appearance of the filter 
at 48 hours. In white light (Figure 6.8 A), it was not possible to tell which cells were 
above or below the polycarbonate filter. Under blue ight (Figure 6.8 B), green 
fluorescent spots were seen which correspond to focal areas of proteolysis by invading 
cells. Figure 6.9 shows the appearance of invading cells on the polycarbonate filter after 
H&E staining.  
 
    
 
Figure 6.8: Counting invading cells after 48 hours u ing the fluorescence method at x 




the polycarbonate filter is viewed under white light in A. In blue light in B, the 
fluorescent spots (white arrows) emitted by the invading cells as DQ-Gelatin on the 




    
 
 
Figure 6.9: Counting invading PC3 cells after 24 hours using the H&E staining 
method. A, polycarbonate filter viewed at x 20 magnification and B, at x 40 
magnification. Cells (C) can be differentiated from the 8µm filter pores (P). 
 
To compare the fluorescence method with the conventional method of staining the 
filters before counting, invasion assays were set up as described above with triplicate 
wells for each counting method. The assay was run for 24 hours using 20µg of Matrigel 
to coat the filters. The results in Figure 6.10 showed that the there was no significant 
difference in number of invading cells counted between the two methods using the 
unpaired t-test (p=0.1704). This implies that the fluorescent spots counted are due to 







Figure 6.10: Modified Boyden chamber invasion assay comparing the fluorescence 
counting method with the H&E staining method. Six polycarbonate filters were coated 
with 20µg of Matrigel. Three of the filters were also coated on the under-surface with 
Matrigel containing 50µg/ml of DQ-Gelatin. The assay was stopped at 24 hours and the 
number of cells invading the Matrigel barrier was counted. The number of distinct 
fluorescent spots viewed under the microscope per high power field (hpf) was compared 
to the number of invading cells seen on the filters after staining with haematoxylin-eosin 
(H&E). Mean (± SEM) is shown. 
 
 
The fluorescence method had shown evidence of proteolytic activity at the lower 
surface of the filters at 24 hours. Based on those re ults, the invasion assays were run 
for a duration of 24 hours. Polycarbonate filters were coated with 20µg Matrigel. Two 
hundred thousand PC3 cells were plated in the upper chamber of the transwell inserts in 
serum-free medium. Forty-eight hour conditioned medium from prostatic stromal cells 
was used as a chemo-attractant. The number of invading cells was counted either by 
staining the filters with haematoxylin and eosin (H&E), or with 4% (w/v) crystal violet 
in 95% (v/v) ethanol as described in Section 2.25. Four high power fields (hpf) were 
counted at magnification of x 20 and the mean was calculated. 
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Seven experiments were perfomed, five comparing ATS1kd cells and ATS15kd cells 
with NTC cells, one comparing ATS1kd cells with NTC cells and one comparing 
ATS15kd cells with NTC cells. Each experiment was done in triplicate. The results of 
each experiment were plotted graphically (Figure 6.11). The relative difference in 
migration between the non-targeting knock-down and ADAMTS the knock-down cells 
was calculated by normalising the mean number of non-targeting knock-down cells to 1. 
The relative changes were pooled together and the two-tailed, paired t-test was used to 
analyse the results for significant differences in the relative changes in migration 
between the ADAMTS knock-down cells and the non-targeting knock-down cells.  
Analysis of the pooled data from all seven experiments showed no change in the 











Figure 6.11: Invasion assays comparing invasive potential of ADAMTS-1 knock-down 
(ATS1kd), ADAMTS-15 knock-down (ATS15kd) and non-targeting knock-down (NTC) 
PC3 cells using the modified Boyden chamber method. The filters were coated with 
20µg of Matrigel. Seven experiments were perfomed, five comparing ATS1kd cells and 
ATS15kd cells with NTC cells, one comparing ATS1kd cells with NTC cells and one 
comparing ATS15kd cells with NTC cells. Each experim nt was done in triplicate. 
Number of cells invading per high power field was plotted and the number of invading 
knock-down cells relative to control in each experiment was calculated by normalising 
the number of invading NTC cells to 1. Results of all the experiments were pooled to 
show relative changes in invasion. The two-tailed paired t-test was used to analyse the 
results for significant differences in the relative invasion of the ADAMTS knock-down 
cells compared to the non-targeting knock-down cells. Mean (± SEM) is shown. 
 
6.4 Discussion 
This chapter described the use of calcium phosphate, lipid-based transfection reagents 
and electroporation for introducing siRNA and DNA into PC3 prostate cancer cells., 
and functional assays to analyse phenotypic changes.  
Pooled Data 
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siRNA against ADAMTS-1 and ADAMTS-15 were used to transiently knock-down 
expression in PC3 cells, and DNA coding an shRNA sequence against ADAMTS-1 was 
used in an attempt to produce stable knock-down cells.   
Comparison of the transfection methods showed that the levels of knock-down achieved 
was variable between experiments. Metafectene Pro, a lipid-based reagent, produced the 
greatest knock-down effect but attrition of cells was high. Dharmafect 2, also lipid-
based, produced inconsistent knock-down results but had no obvious effect on cell 
viability. Calcium phosphate transfection produced intermediate results and also did not 
have an obvious effect on cell viability. The Dharmfect 2 protocol utilised the greatest 
amount of siRNA (2.5µg for Dharmafect 2 compared with 0.5µg for Metafectene Pro 
and 0.4µg for calcium phosphate) per 30,000 cells transfected. The electroporation 
protocol required 2µg of siRNA for 1 x 106 PC3 cells, and produced high levels of 
knock-down, making it the best method to use when pla ning to perform experiments 
that required large cell numbers. For each of the transfection methods, comparing 
expression levels in WT and non-targeting knock-down cells suggested that the 
transfection process may have induced expression of ADAMTS-1 and -15 (Figure 6.2). 
The electroporation method produced the least of this non-specific effect. Based on 
these results, the electroporation method was chosen for knock-down of ADAMTS-1 
and -15 for functional assays. 
Stable knock-down of gene expression is preferable for functional studies because it 
allows for experiments to be optimised and repeated without performing transfection 
before each experiment. Attempts to produce stable knock-down of ADAMTS-1 in PC3 
cells were unsuccessful. The protocol for the pSilencer 4.1-CMV knock-down system 
(Invitrogen) involved selecting clones of cells successfully expressing the selected 
antibiotic resistance gene. This created unexpected onfounding factor in results 
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because WT PC3 cells hade a wide range of ADAMTS-1 expression (Figure 6.4), for 
reasons not understood. Differences in expression between transfected cells and controls 
due to the variability could be mistaken for a specific knock-down effect. Presumably, if 
there is an inherent variability in ADAMTS-1 expression, there is likely to be variability 
in the expression of other proteins and molecules which could be influencing cell 
phenotype. Hence, differences in migration or invasion may not necessarily be due to 
ADAMTS-1 expression levels. This was coupled with the fact that cells transfected with 
the DNA for the control vector did not survive after ransfection. It is unclear why the 
cells did not survive. The plans for producing stable knock-down PC3 cells were 
therefore abandoned in favour of a transient knock-down system. 
Functional studies analysing the effect of ADAMTS-1 and ADAMTS-15 knock-down 
on PC3 cell proliferation, migration and invasion were perfomed using the siGENOME 
transient transfection system (Dharmacon, Thermo Fisher) with the electroporation 
method. The disadvantage of transient knock-down is that transfection of the cells with 
siRNA had to be done before each batch of experiments. Duration of knock-down was 
variable but up to 50% knock-down was seen at Day 14 post transfection in some 
experiments. Functional assays were started at Day 5, as western blotting showed 
attenuation of ADAMTS-15 protein expression at that time point (Section 4.3.5). The 
Boyden migration assay lasted 6 hours, the scratch migration assay and the Boyden 
invasion assay lasted 24 hours, and the proliferation assay lasted 5 days. Thus all the 
functional assays were completed within 10 days post transfection.  The results of the 
functional studies showed that there was no effect of ADAMTS-1 or ADAMTS-15 
knock-down on proliferation, migration and invasion f PC3 cells. A simple explanation 
for this would be that these biological functions are not dependent on ADAMTS-1 or -
15 activity. However, it is possible that ADAMTS-1 and -15 activity are not manifested 
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in in vitro settings, but requires the complex interaction betwe n cancer and stromal 
cells that can only be studied using i  vivo models. In fact, a study on BZR lung cancer 
cells showed that ADAMTS-1 over-expression had no effect on proliferation, migration 
and invasion in vitro, but promoted tumour growth in mouse xenografts (Rocks 2008). 
The in vitro assays used by the authors were similar to those used in this study. 
ADAMTS-1 over-expression also induced a stromal reaction characterised by 
recruitment of α smooth muscle actin (α-SMA) positive cells and higher collagen, 
fibronectin, interleukin 1β (IL-1β), transforming growth factor β (TGF-β) and MMP-13 
production (Rocks 2008). These findings provide furthe  evidence of tumour-stromal 
interactions in cancer progression. It may be that knock-down or over-expression 
studies on ADAMTS-1 and -15 in prostate cancer cells using in vivo models could 
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CHAPTER 7:  
GENERAL DISCUSSION, LIMITATIONS, FUTURE WORK AND 
CONCLUSIONS 
 
7.1 General Discussion and Limitations  
The aim of this work was to demonstrate proteolytic activity in prostate cancer and 
stromal cells and to investigate the role of ADAMTS-1 and -15 proteinases in prostate 
cancer progression. ADAMTS-1 and -15 are the most highly expressed of the 
ADAMTSs proteins in prostate cell lines (Cross 2005). Due to the multi-domain 
structure of the ADAMTSs, these proteinases could be playing a number of roles. 
ADAMTS-1 has been more extensively studied than ADAMTS-15. The role of 
ADAMTS-1 as a proteolytic enzyme led to the hypothesis that ADAMTS-1 promotes 
prostate cancer progression by cleaving ECM components, releasing sequestered 
growth factors, and degrading the ECM to facilitate cancer cell migration and invasion. 
The function of ADAMTS-15 is not yet known. It is homologous with ADAMTS-1 
(Cal 2002), which suggests that it may have proteoglycanase activity. However, reports 
have provided evidence that ADAMTS-15 is more likely p aying an anti-tumour role in 
breast and colorectal cancers (Porter 2006; Viloria 2009). This led to the hypothesis that 
ADAMTS-15 has an inhibitory effect on prostate cancer progression by attenuating 
cancer cell proliferation, migration and invasion.  
Experiments in this study were designed firstly to sh w evidence of proteolytic activity 
in prostate cancer cells; secondly, to determine whther ADAMTS-1 and -15 expression 
is regulated by DHT and TNF; and thirdly, analyse th  effect of ADAMTS-1 and -15 on 
prostate cancer cell proliferation, migration and ivasion. 
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7.1.1 Proteolytic Activity of Prostate Cells  
Imaging of multicellular tumour spheroids of prostate cancer and stromal cells showed 
evidence of proteolytic activity by invading and non-invading cells. Stromal cells 
emitted brighter fluorescence than cancer cells, indicating that stromal cells are active 
players in ECM remodelling. Co-cultures of cancer and stromal cells and chemotaxis 
assays showed that stromal cells released soluble chemotactic factors that attracted 
cancer cells to the stromal cells. The cross-talk between cancer and stromal cells is 
proving to be important in cancer progression. Although not analysed in this study, 
proteolysis is greatly enhanced in cancer cells co-cultured with stromal cells (Sameni 
2003; Sloane 2005; Sloane 2006; Sameni 2009). Stromal cells have been shown to 
migrate and invade collectively with cancer cells and were found to be at the leading 
edge of the invading cell cluster (Gaggioli 2007; Gaggioli 2008). It is likely that stromal 
cells have a higher capacity for synthesis of ECM degrading proteinases, and cancer 
cells possibly are able to drive stromal cells to expr ss higher levels of pro-tumour 
proteinases that facilitate tumour progression. Alternatively, prostate stromal cells may 
have the ability to alter cancer cell phenotype, and facilitate the progression of tumours 
by regulating the tumourigenic, migratory and invasi e potential of cancer cells 
(Thalmann 2010). The relative contribution of prostate cancer and stromal cells to ECM 
degradation warrants further study. 
7.1.2 Detection of ADAMTS-1 and -15 Protein 
Analysing protein expression of ADAMTS-1 and -15 presented a challenge during this 
study. Antibodies that were commercially available at the time of the study had not been 
validated in published reports to my knowledge. Generation of custom antibodies was 
considered to be beyond the scope of this study.  
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Because of the multi-domain structure of the ADAMTSs, the antibodies commercially 
available were raised against peptide sequences spanning a part of or a whole domain, 
or multiple domains. The propeptide domain of ADAMTSs is usually cleaved early in 
the Golgi apparatus before secretion (Bergeron 2000; Wang 2004), hence probing for 
the propeptide domain is a surrogate indicator of expr ssion of the active proteinase. 
The catalytic domain, as the name implies, executes the proteolytic programme. Probing 
for this domain would give a more direct indication f the amount of active proteinase 
present. However other actions, for example anti-ang ogenic activity as a result of 
VEGF binding, is effected by the thrombospondin and spacer domains in the C-
terminus. The C-terminal domains are processed and cleaved off in the ECM 
(Rodriguez-Manzaneque 2000), and so probing for the C-t rminal fragments would give 
only limited information on the expression levels and localisation of the catalytic 
domain.  
The main aims of this study included the determinatio  of the effect of androgen and 
cytokine stimulation on ADAMTS-1 and -15 expression, a d to analyse the effect of 
knock-down on prostate cancer cell phenotype. Thus, the ideal antibody for these 
purposes would be a polyclonal antibody able to detect he full length protein, with 
bands of sufficient intensity to enable analyses of changes in expression due to 
treatment or knock-down. A search through the major ntibody suppliers did not yield 
any anti-ADAMTS-1 or -15 antibodies with these desir d specifications. Four 
antibodies were selected (two against ADAMTS-1 and two against ADAMTS-15). The 
anti-C-Terminal ADAMTS-1 antibody detected multiple bands, and the anti-catalytic 
domain antibody detected a band of approximately 50kDa, which was not attenuated 
with knock-down of ADAMTS-1 mRNA.  
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A considerable amount of effort was put into detection of ADAMTS-15 protein 
expression by western blotting using the anti-ADAMTS-15 antibody raised against the 
cysteine-rich domain. Techniques used included sample preparation by cell lysis, 
immunoprecipitation of cell lysate and conditioned medium, and heparin-agarose 
precipitation of cell lysate and conditioned medium. The bands detected using 
immunoprecipitation were found to be due to a protein from the protein A-agarose 
beads, most likely protein A. This was a source of error that precluded further 
immunoprecipitation experiments. No bands were detect d with heparin-sepharose 
precipitation using this antibody. The anti-ADAMTS-15 propeptide antibody 
consistently detected a 50kDa band on western blots, which was attenuated by 
ADAMTS-15 knock-down. Fluorescence immunocytochemistry using this antibody 
showed decreased fluorescence in ADAMTS-15 knock-down cells.  
The anti-ADAMTS-15 propeptide antibody was predicted by the supplier to detect 
ADAMTS-15 at a relative mass of 103kDa on western blotting. Western blot 
experiments detected bands of 50kDa which is about half the relative mass expected for 
the full length ADAMTS-15 protein, and twice the relative mass of the propeptide 
domain, which is approximately 22kDa. This suggests that ADAMTS-15 was processed 
post-translationally by proteolytic cleavage yielding an N-terminal fragment of 50kDa, 
implying that a cleavage site lies within the disintegrin-like domain of ADAMTS-15 
(Figure 7.1c). The sequence homology of ADAMTS-15 and ADAMTS-1 (Cal 2002) 
suggests that the ADAMTS-15 disintegrin-like domain, where we predict a cleavage 
site lies, is a cysteine-rich domain with no disintegrin activity (Gerhardt 2007).  
ADAMTS proteinases are known to be C-terminally processed (Rodriguez-Manzaneque 
2000; Kashiwagi 2004), and it is likely that the form of ADAMTS-15 detected as 
50kDa has lost its C-terminal ancillary domains but retains the propeptide and catalytic 
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domains. The propeptide domain is thought to maintain he latency of the catalytic 
domain, and activation of the catalytic domain is mediated by cleavage by proprotein 
convertases such as furin (Bergeron 2000; Wang 2004). Retention of the propeptide 
implies that the catalytic domain of ADAMTS-15 remains inactive and thus proteolytic 
activity is muted. The full length ADAMTS-1 and the C-terminal region of ADAMTS-1 
are reported to display pro and anti-metastatic properties respectively (Kuno 2004; Liu 
2006). The C-terminal region containing three thromb spondin repeats and a spacer 
(Figure 7.1) is responsible for the anti-angiogenic properties of ADAMTS-1 (Kuno 
2004). This region of ADAMTS-1 is very similar to the ADAMTS-15 C-terminal 
cleavage product that is predicted in this study (Figure 7.1), leaving propeptide and 
catalytic domains of 50kDa which was detected on the western blots. It is conceivable 
that the potential proteolytic activity of ADAMTS-15 is muted because the propeptide 
remains bound to the catalytic domain, and the C-terminal half of the molecule is 
released to function as an inhibitor of angiogenesis in the TME. It is generally accepted 
that prostate cancer angiogenesis correlates with disease severity (Weidner 1993; 





Figure 7.1: Domain structure of ADAMTS-15 and similarity of predicted cleavage 
products with ADAMTS-1. (a) is a schematic diagram of the domains of the full-length 
ADAMTS-15, (b) shows the furin cleavage site and the products that would result. 
Western blots did not detect a propeptide fragment of 22kDa as would be expected from 
cleavage at this site, (c) shows the approximate position of the predicted cleavage site 
that would produce a 50kDa propeptide fragment detect d on western blots, and the 
structure of the C-terminal region that would be claved off. (d) Is a schematic diagram 
of the C-terminal region that is responsible for the anti-angiogenic activity of 
 229 
ADAMTS-1. The predicted C-terminal cleavage product from ADAMTS-15 (c) is similar 
in structure to the anti-angiogenic region of ADAMTS-1.  
 
Somatic mutations of ADAMTS15 have been identified in breast and colorectal cancer 
cells (Sjoblom 2006; Wood 2007; Viloria 2009). ADAMTS15 mutations in colorectal 
cancer cells predict that shortened, mutant forms of ADAMTS -15 are produced 
(Viloria 2009). No mutations of ADAMTS-15 have been reported in prostate cancer 
cells, but this could be a possible alternative explanation for the detection of a 50kDa 
ADAMTS-15 protein. Splice variants of ADAMTS-9, -13, -18 and -20 have been 
detected, which predict expression of proteins of varying lengths (Nicholson 2005). No 
such splice variants have been reported for ADAMTS-15, but alternative splicing could 
also explain the detection of a 50kDa form of ADAMTS-15. 
7.1.3 Androgen Regulation of ADAMTS-15 and TIMP-3 
The AR axis is important in prostate cancer pathophysiology. Normal prostate epithelial 
cells depend on androgen for growth stimulation (Sandberg 1980). Prostate cancer cells 
are initially dependent on androgen and regress when androgen stimulation is 
withdrawn (Huggins 1942; Lee, E.C. 2004). When hormone refractory cells evolve, AR 
signalling is still found to be active (Schroder 2008).  
Hormone refractory progression is thought to be through one or a combination of the 
following mechanisms. 1.) Up-regulation of AR or co-regulator expression, causing 
increased sensitivity to the low concentrations of circulating androgen (Koivisto 1997; 
Gregory 2001; Linja 2001). 2.) Mutations in the AR, leading to ligand promiscuity and 
aberrant signalling by other steroid hormones, growth factors and antagonists such as 
Flutamide (Veldscholte 1990; Culig 1996; Taplin 1999; Zhao 2000; Hu 2009). 3.) 
Mutations in the AR causing the AR to be constitutively ‘switched on’ in a ligand-
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independent manner (Hu 2009) 4.) Up-regulation of genes converting adrenal steroids 
to testosterone or de novo synthesis of testosterone by cancer cells and autocrine 
stimulation (Titus 2005; Stanbrough 2006; Mostaghel 2007; Locke 2008). The 
realisation that prostate cancer tumours progressing despite ADT, either in the form of 
medical or surgical castration, actually remain androgen dependent has led to a gradual 
change in terminology from ‘hormone-refractory prostate cancer’ (HRPC) to 
‘castration-resistant prostate cancer’ (CRPC).  
Because of the importance of AR signalling in prostate cancer progression, the effect of 
DHT on ADAMTS-1 and -15 was analysed. ADAMTS-15, but not ADAMTS-1 was 
regulated by DHT in LNCaP cells. DHT significantly down-regulated the expression of 
ADAMTS-15 approximately five-fold, with the maximal down-regulation at a 
concentration of 1nM. This concentration has been rported in previous studies to be the 
optimal concentration for DHT stimulated growth in LNCaP cells(Lee 1995; Okamoto 
1997; Sherwood 1998).  Thus the expression of ADAMTS-15 is lowest at a 
concentration of DHT that stimulates maximal proliferation. The implication of this is 
not clear but it suggests that low ADAMTS-15 expression is associated with increased 
LNCaP cell proliferation. TIMP-3 expression was also down-regulated by DHT, 
implying that DHT attenuates the inhibitory effect of TIMP-3 on metalloproteinases.  
Long term management of prostate cancer usually involves androgen deprivation. 
Control of tumour growth at the cellular level may be partly due to higher expression of 
ADAMTS-15 and TIMP-3 expression in the androgen-deprived state. Androgen 
deprivation treatment causes depletion of circulating androgens, a situation which could 
increase ADAMTS-15 and TIMP-3 expression. This would conceivably result in down-
regulation of proteolytic activity in the ECM and favour maintenance of normal prostate 
tissue architecture. The effect of flutamide was not i  keeping with its function as an 
 231 
AR antagonist (Peets 1974), as it did not reverse the effect of DHT. LNCaP cells have a 
mutation in the AR ligand binding domain in which threonine is changed to alanine at 
position 868 (T868A), leading to AR activation by flutamide (Veldscholte 1990; Culig 
2001). The T877A mutation identified by Suzuki et al in AR from prostate cancer 
tumours was found to be identical to the T868A mutation in LNCaP cells (Suzuki 
1996). Other AR mutations have been identified in tumours of patients with prostate 
cancer (Taplin 1995). Up to 68% of prostate cancer patients with disease progression 
while on treatment with flutamide experience disease remission when flutamide is 
withdrawn (Dupont 1993; Scher 1993; Herrada 1996; Sartor 2008). This phenomenon is 
known as the ‘Anti-androgen Withdrawal Syndrome,’ and provides clinical evidence 
that mutations in the AR of prostate cancer cells could lead to aberrant activation by 
flutamide. 
Using an in silico method, the genes for ADAMTS-1 and ADAMTS-15 were screened 
for the presence of putative AREs. This revealed one ARE in the ADAMTS-15 gene 
promoter and 12 in the gene sequence. The presence of AREs provides a mechanism for 
the regulation of ADAMTS15 expression by androgen. However, the effect of androgen 
could also occur via the action of intermediary androgen-regulated proteins that are 
involved in regulation of ADAMTS15 transcription. Another possible explanation for the
down-regulation by DHT of ADAMTS-15 and TIMP-3 mRNA expression could be that 
the action of DHT may be mediated through pathways that are independent of the AR, 
hence the inability of flutamide to antagonise this effect. Testosterone and DHT induce 
rapid increases in intracellular calcium in prostate cancer cells through non-genomic 
mechanisms (Lyng 2000; Sun 2006). Testosterone also induces rapid vasodilation that 
is not inhibited by flutamide (Yue 1995; Jones 2002; Tep-areenan 2002). This suggests 
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the possibility that calcium influx into LNCaP cells treated with DHT may be an 
alternative mechanism of ADAMTS-15 and TIMP-3 regulation.  
7.1.4 TNF Regulation of ADAMTS-15 and TIMP-3 
Cancer-related inflammation has been of interest to researchers for many years, dating 
back to Virchow in 1863 (Balkwill 2001). Virchow first identified the presence of 
inflammatory cells within tumours. TAMs secrete cyteine proteinases, MMPs, and an 
assorted array of cytokines including TNF, interleukins and interferons (Wahl 1998; 
Kuper 2000). TAM density in prostate tumours has been shown to predict disease 
progression in patients treated with hormone therapy (Nonomura 2011). The activity of 
TAMs could either be pro or anti-tumour. TAMs may be cytotoxic following activation 
(Brigati 2002; Tsung 2002), but on the other hand may produce angiogenic and 
lymphangiogenic proteinases and cytokines which promote tumour progression 
(Schoppmann 2002). Taking TNF as an example, binding a d activation of the TNF 
receptor 1 (TNFR1) could induce pathways that lead to inflammation and cell survival 
via TNF receptor-associated factor 2 (TRAF2) pathway, or could induce apoptosis via 
the FAS-associated death domain (FADD) pathway (Balkwill 2009). The role of TNF in 
prostate cancer progression is not clear. Even thoug  the name ‘tumour necrosis factor’ 
suggests anti-tumour activity, some studies have shown that the serum level of TNF 
required to cause decline in tumour growth could also be toxic to the patient (Balkwill 
1992), and TNF may even promote tumour growth in certain situations (Malik 1992; 
Szlosarek 2006). Macrophages infiltrating the tumour site release cytokines locally as 
part of the inflammatory reaction to the presence of the tumour (Coussens 2002). This 
could explain the elevated levels of TNF in patients with advanced prostate cancer 
(Michalaki 2004). 
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Treatment of PC3, LNCaP and BPH45 cells with TNF showed that ADAMTS-15 
mRNA expression was down-regulated by TNF in LNCaP and BPH45 cells, and TIMP-
3 mRNA was down-regulated in BPH45 cells. It is notclear what pathway mediates the 
regulation of ADAMTS-15 and TIMP-3 but it is possibly via the action of nuclear 
factor-κB (NF-κB), a transcription factor that regulates the transcription of numerous 
genes including many proteinases (Hoffmann 2006). The online transcription factor tool 
CONSITE (www.phylofoot.org/consite) (Lenhard 2003) identified three NF-κB binding 
sites in the ADAMTS1 promoter, four in the ADAMTS15 promoter, and four in the 
TIMP3 promoter. ADAMTS-1 was not regulated by TNF, even though it has been 
regarded as an inflammation related proteinase (Kuno 1997).  
Kuno et al found that ADAMTS-1 expression was up-regulated by IL-1 in colon 
carcinoma cells in vitro and by LPS in heart and kidney tissue in vivo (Kuno 1997). 
ADAMTS-1 expression was also up-regulated by IL-1β in human uterine decidual 
stromal cells (Ng 2006) and by TNF in ARPE-19 retinal pigment epithelial cells (Bevitt 
2003). Regulation of ADAMTS-1 by cytokines in prostate cancer cells has not been 
reported. It could be that ADAMTS-1 is regulated by cytokines other than TNF in the 
prostate cancer TME. 
7.1.5 ADAMTS-1 and -15 Gene Silencing and Functional Assays 
Silencing of gene expression using RNA interference is a valuable method of studying 
the function of specific proteins. RNA interference in the study of gene function began 
with the use of antisense RNA to knock-down gene expression (Izant 1984). Double-
stranded RNA was later found to be more potent thansingle stranded antisense RNA at 
silencing gene expression (Fire 1998; Montgomery 1998), and has been adapted to the 
systems currently available (Sandy 2005). siRNA is introduced into the cell either 
directly by transfecting ready-made siRNA (transient transfection), or by transfecting 
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DNA coding for the desired siRNA sequence, which is incorporated into the nucleus 
and constitutively expresses the desired siRNA (stable transfection) (See Figure 2.4). 
Both systems have advantages and disadvantages. The main advantage of transient 
transfection is that it is relatively quick to set up, with the protocol involving fewer 
steps than are required for stable transfection. The disadvantage is that the effect of 
knock-down is progressively lost with each successive mitotic event due to dilution and 
degradation. This leaves a relatively short window f r studying phenotypic changes due 
to gene silencing.  
Stable knock-down generates clones of cells that constitutively express the desired 
siRNA along with resistance to a selected toxin and passes the trait to successive 
generations of daughter cells. Constant selection pressure has to be maintained using the 
toxin, usually an antibiotic. The constitutive expression of the siRNA enables long-term 
gene silencing, allowing in vitro and in vivo experiments to be performed over weeks 
and months. The protocol for stable transfection is longer, as more steps are required. 
Stable knock-down of ADAMTS-1 in PC3 cells was achieved in this study, but a source 
of error was detected.  
Knock-down using the p-silencer system involved a cloning step after the cells were 
transfected and selected with antibiotics. Sub-clones of PC3 cells had wide variations in 
their expression levels for ADAMTS-1. Other proteins for example, osteoprotegerin 
(OPG), also show wide variations in expression even without any attempts being made 
to modulate expression (Dr Neil Cross, pers commun). Under these circumstances, 
experiments done with PC3 cells after any process of cloning is likely to be subject to 
error since there will not be certainty as to whether t e differences in expression of the 
protein of interest is inherent to the cells as a result of being from different sub-clones, 
or as a result of modulation of expression. If the difference in expression is inherent, it 
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could be assumed that there may be inherent differenc s in expression of other proteins 
too. As such, any differences in phenotype may not be attributed solely to the activity of 
the silenced gene. 
In this study, ADAMTS-1 and -15 expression was transie tly down-regulated in PC3 
cells using double-stranded siRNA. The in vitro assays used did not identify a role for 
ADAMTS-1 or -15 in proliferation, migration and invasion. It is possible that these 
results truly represent the situation in prostate cancer tumours in vivo. However, there 
are a number of alternative explanations for this. It i  possible that in vitro assays do not 
sufficiently replicate the TME, and the presence of stromal cells, endothelial cells and 
inflammatory cells is required for activity of ADAMTS-1 and 15 to be manifested. 
Rocks et al found that ADAMTS-1 over-expression in BZR bronchial carcinoma cells 
had no effect on cell proliferation, migration and i vasion using in vitro assays (Rocks 
2008). In vivo assays in severe combined immunodeficiency (SCID) mice showed 
increased tumour sizes in ADAMTS-1 over-expressing BZR tumour xenografts and 
infiltration of host stromal cells. This implies that ADAMTS-1 activity in tumours is 
effected via recruitment of stromal cells, and explains why no effects were seen using 
monoculture in vitro assays.  In contrast to these findings, ADAMTS-1 over-expression 
in SCP20 breast cancer cells (a derivative of the MBA-MD-231 cell line) did not lead to 
an increase in cell proliferation i vivo in nude mice (Lu 2009). No in vivo assays were 
perfomed in this study due to the fact that stable knock-down did not yield desirable 
results as explained earlier. Another possible explanation is that the sequence homology 
between ADAMTS-1 and -15 (Cal 2002) and the fact that both proteins evolved from 
the same ancestral ADAMTS protein could mean that tey play mutually redundant 
roles in prostate cancer cells. Hence down-regulation of one or the other would lead to 
no phenotypic changes. Functional redundancy between other homologous ADAMTS 
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enzymes for example ADAMTS-4 and -5 in arthritis ha not been demonstrated because 
Adamts5 but not Adamts1 or Adamts4 knock-out mice are protected from developing 
arthritis (Glasson 2004; Glasson 2005; Little 2005; Stanton 2005), but redundancy 
between ADAMTS-1 and -15 has not been investigated. ADAMTS-1 and -15 are the 
most abundantly expressed ADAMTSs in prostate cells (Cross 2005), and so 
simultaneous knock-down may be required to reveal ch nges in phenotype.  
7.1.6 Relevance of ADAMTS-15 Cleavage Products  
Western blot experiments revealed what may well be a possible role for ADAMTS-15. 
If, as is predicted, ADAMTS-15 has a cleavage site at Pro460 – Cys470, the C-terminal 
fragment would be similar to the anti-angiogenic C-terminal of ADAMTS-1. Protein 
sequence alignment of Cys470 - Cys950 of ADAMTS-15 and His559 – Ser967 of 
ADAMTS-1 showed that 47% identity of 436 residues overlapped, with conservation of 




Figure 7.2: Protein sequence alignment of the C-terminal half of ADAMTS-15 and 
ADAMTS-1 showing the similarity between the predict C-terminal cleavage product 
and the anti-angiogenic C-Terminal fragment of ADAMTS-1. The protein sequences 
were obtained from the Ensembl website (www.ensembl.org) and the sequences aligned 
using the online sequence alignment tool, SIM (www.expasy.ch/tools/sim-prot.html). 
The conserved cysteine residues are highlighted in grey. 
 
The role of ADAMTS-15 in angiogenesis has not been investigated. ADAMTS-1 is 
known to be anti-angiogenic. Gustavsson et al have studied the expression of 
ADAMTS-1 in prostate cancer and the correlation with markers of angiogenesis and 
found that decreased ADAMTS-1 expression correlates with increased micro-vascular 
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density (MVD) (Gustavsson 2009). The role of ADAMTS-15 in angiogenesis in 
endothelial and prostate cancer cells deserves further study. 
 
7.2 Future Work 
The results from the experiments carried out during this study have answered some 
important questions. However some lines of investigation could not be pursued during 
the limited time period. 
Given the chemotactic effect of stromal cell conditioned media on prostate cancer cells, 
and the reported role of epithelial-stromal cell interactions in cancer progression, an 
analysis of the changes in expression of ADAMTS-1 and -15 with stromal cell 
conditioned media would provide important information about possible mechanisms of 
regulation of ADAMTS expression. Three dimensional cu ture models more closely 
represent the in vivo environment than monolayer culture on plastic. The scratch 
migration assays and the Boyden chamber invasion assays used in this study employed 
the use of ECM gels to provide a biological scaffold and barrier respectively. Three 
dimensional models for functional assays could be further developed and validated for 
use in experiments in which monolayer culture would be inadequate. 
 
The work in this thesis did not include an investigation of the role of ADAMTS-1 and -
15 in angiogenesis, and also did not study the effect of simultaneous knock-down of 
ADAMTS-1 and -15.  In vivo models were not used to study the effect of ADAMTS-1 
and -15 knock-down on tumour progression. Future work should be directed towards 
the following goals. 1.) To analyse the effect of simultaneous knock-down of 
ADAMTS-1 and -15 on proliferation, migration and invasion and angiogenesis using  
vitro and in vivo assays. 2.) To further characterise the cleavage products of ADAMTS-
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15 to determine where the cleavage sites lie. 3.) Given the possibility that the cleavage 
products of ADAMTS-15 may have anti-angiogenic properties, the role of the 
fragments in angiogenesis should be investigated using in vitro and in vivo assays. A 
number of assays have been described for measuring angiogenesis and the effect of ant-
angiogenic molecules (Staton 2004). 
 
ADAMTS-15 was expressed in relatively small amounts i  the PC3 and LNCaP cell 
lines used in this study. Real-time RT-PCR experiments yielded ∆CT values of 
approximately 11 for ADAMTS-15 when normalised with GAPDH, and in western 
blotting experiments 100µg of protein was loaded in each lane for ADAMTS-15 bands 
to be detected. Therefore future functional assays could include an investigation of the 
effects of ADAMTS-15 over-expression on the phenotype of prostate cancer cells.  
The Gleason score remains the most accurate predictor of prognosis in prostate cancer 
(Albertsen 1998; Buhmeida 2006). ADAMTS-1 expression s reported to have no 
correlation with Gleason score (Gustavsson 2009). Analysis of ADAMTS-1 and -15 
expression in clinical samples was not undertaken during this study, due initially to 
difficulties encountered with validation of the ADAMTS-1 and -15 antibodies, and then 
because of time constraints. Immunohistochemistry fo  localisation and quantification 
of ADAMTS-15 would be a logical experimental step using the Abcam ab45047 
antibody. Analysis of the correlation between ADAMTS-15 expression and Gleason 
score in prostate cancer tissue would determine whether this proteinase is a promising 
candidate diagnostic or prognostic marker. The use of fluorescence in-situ hybridisation  
can be explored for large through-put expression analyses, in conjunction with real-time 




This thesis presents work aimed at analysing the role of ADAMTS-1 and -15 in prostate 
cancer progression. Prostate cancer and stromal cells execute proteolysis of ECM 
components as tumours grow, migrate and invade the surrounding ECM. Expression of 
ADAMTS-1 is not regulated by the prostate growth factor, DHT, in androgen sensitive 
LNCaP prostate cancer cells. Expression of ADAMTS-15 and the metalloproteinase 
inhibitor, TIMP-3 are down-regulated by DHT. This suggests that ADAMTS-15 and 
TMP-3 expression do not favour prostate cancer progression. The action of DHT is 
possibly via binding of activated AR to AREs associated with the ADAMTS15 and 
TIMP3 genes. The cytokine, TNF, down-regulates ADAMTS-15 expression in LNCaP 
and stromal cells and TIMP-3 expression in stromal cells. ADAMTS-1 expression was 
not regulated by TNF. This implies that inflammation in the TME would down-regulate 
the expression of ADAMTS-15 and the metalloproteinase inhibitor, TIMP-3. These 
findings suggest an anti-tumour role for ADAMTS-15. However, knock-down of 
ADAMTS-1 and -15 expression in PC3 cells had no effect on proliferation, migration 
and invasion using in vitro assays, suggesting that cancer-stromal cell interactions may 
be required for effects of knock-down to be observed. Detection of a 50kDa pro-peptide  
containing fragment of ADAMTS-15 suggests the release of a C-terminal fragment with 
anti-angiogenic properties. These findings indicate that ADAMTS-15 may have an anti-
tumour role for ADAMTS-15. This warrants further study of ADAMTS-15 in in vivo 
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